

**Grants and Contracts Office** 

# Funding Opportunities Monthly Edition July 2024 Due Dates

#### Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in July 2024. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
117828	RFA-CA-23-029 Cancer Immuno Projects (UG3/UH3 Clinical Trials N	prevention Network (CIP-Net) ?Research Not Allowed)	National Cancer Institute/NIH/DHHS	RFA- CA-23- 03- 029	-Jul-2024	2,500,000 USD
	Contact Name	Altaf Mohammed, Ph.D.				
	Contact Telephone	240-276-6028				
	Contact Email	CIP-Net@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	03-Jul-2024				
	Synopsis	discover novel immunoprevention strate of cancer immunoprevention researcher pathways, targets, immunoprevention m immunomodulatory agents. Applicants re single application. Achievement of the U	s. The UG3/UH3 research projects will e echanisms, or investigate the efficacy a esponding to this NOFO must apply for	nable de nov nd potential both the UG3	vo discovery of imp side effects of nev 3 and UH3 phases	mune v vaccines or together in a
110367	Research Projects in Physical Scier	nces-Oncology (U01 Clinical Trial Optional	) National Cancer Institute/NIH/DHHS	PAR- 22-147 01-	-Jul-2024	2,000,000 USD
	Contact Name	Eric M. Johnson Chavarria, Ph.D.				
	Contact Telephone	240-276-7416				
	Contact Email	eric.johnsonchavarria@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2024 , 01-Nov-2024				
	Synopsis	This Funding Opportunity Announcemen Oncology Projects (PS-OP). The goal of the physical sciences approaches and perspection oncology by forming transdisciplinary tea physical scientists may include engineers	e Physical Sciences-Oncology Network ctives with cancer research to advance ams of physical scientists and cancer bio	(PS-ON) is to our understa ologists/physi	foster the conver- anding of cancer b ician scientists. Ex	gence of ology and amples of

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	support transdisciplinary research that: (2) facilitates team science and field co	fork along with other PS-OPs and the Phy (1) establishes a physical sciences persp nvergence at the intersection of physical d experimental and theoretical concepts acer research.	ective within sciences and	the cancer resear cancer research; a	ch community; and (3)
110473 Research Opportunities in Establis (U01 Clinical Trial Not Allowed)	shed Cancer Epidemiology Cohort Studie	<u>S</u> National Cancer Institute/NIH/DHHS	PAR- 22-162 29-	Jul-2024	Not Specified
Contact Name	Joanne Elena, PhD, MPH				
Contact Telephone	240-276-6818				
Contact Email	joanne.elena@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	29-Jul-2024 , 28-Feb-2025				
Synopsis	support research in established cancer planned recruitment goal. Applications and are expected to include support for	ouncement (FOA), the National Cancer In epidemiology cohort studies, defined as must include hypothesis-based research cohort maintenance, continued follow- ns across the cancer control continuum.	studies that h using data fro up, and sharir	ave achieved thei om an established	r initial cohort study
121826 Revision Applications for Validation	on of Biomarker Assays Developed Throu R01 Clinical Trial Not Allowed)	gh National Cancer Institute/NIH/DHHS	PAR- 24-047 09-	Jul-2024	450,000 USD
Contact Name	Sumana Dey, Ph.D.				
Contact Telephone	240-276-5748				
Contact Email	<u>sumana.dey@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 08-Oct-2024 , 14-Feb-202	5 , 11-Jul-2025 , 14-Oct-2025 , 13-Feb-20	26 , 10-Jul-20	26 , 13-Oct-2026	
Synopsis	Through this Notice of Funding Opportu (formerly called "competing revisions")	inity (NOFO), the National Cancer Institu from currently funded NCI R01 research	te (NCI) enco projects. The	urages revision ap applicants should	plications I propose

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		as "assays") to the clinic. Specifically, th and clinical validation of molecular/celle diagnosis, prognosis, monitoring, and pi control. Applications may support the a observational cohorts/consortia for the this NOFO encourage multidisciplinary i and clinical laboratory staff. Clinical labor parts of the application. This NOFO is no	e the pace of translation of NCI-supported e focus of applications submitted in resp ular/imaging markers (referred to as "ma rediction of response in treatment, as we cquisition of well-annotated specimens f purpose of clinical validation of the assa nteraction among scientific investigators pratory scientist(s) and statistical experts of intended to support early-stage develo ad validation of assays to the point where	onse to this N Irkers" or "bio ell as markers rom NCI-supp y. Research p s, assay develo are highly er opment of teo	NOFO should be of pmarkers") for car for cancer prever ported or other cli projects proposed opers, clinicians, s ncouraged to com chnology or the co	n the adaption acer detection, ntion and nical trials or in response to tatisticians, prise integral nduct of
106261 🛓	Basic Research in Cancer Health D	Disparities (R01 Clinical Trial Not Allowed	National Cancer Institute/NIH/DHHS	PAR- 21-322 05-	Jun-2024	Not Specified
	Contact Name	e Anu Sharman, Ph.D.				
	Contact Telephone	240-276-6250				
	Contact Emai	l <u>sharmananu@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	) 05-Jun-2024 , 05-Jul-2024				
	Synopsis	into the biological/genetic causes of car studies designed to investigate biologic factors associated with cancer disparities strategies, (2) the development and tes also designed to aid and facilitate the gu in cancer health disparities research wh	rowth of a nationwide cohort of scientist o can expand available resources and too y to conduct basic research in cancer hea	oject grants ( ch as (1) mech rch in cancer and (3) secon s with a high ols, such as bi	R01) will support hanistic studies of biology or cancer dary data analyse level of basic rese iospecimens, patie	innovative biological prevention s. This FOA is arch expertise ent derived
1116787	Mechanisms that Impact Cancer I Frial Optional)	Risk after Bariatric Surgery (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR- 21-331 05-	Jun-2024	2,500,000 USD

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Name	Edward R. Sauter, M.D., Ph.D.			
Contact Telephone	240-276-7657			
Contact Email	edward.sauter@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	05-Jun-2024 , 05-Jul-2024			
Synopsis	of investigator-initiated studies address	uncement (FOA), the National Cancer Institute ing mechanisms by which bariatric surgery imp urgery to investigate its effects on cancer, rath	bacts cancer risk, and see	eks to draw in
105645 Integration of Imaging and Fluid-E (R01 Clinical Trial Optional)	Based Tumor Monitoring in Cancer Thera	PAR- National Cancer Institute/NIH/DHHS 21-29	(1)/-1/(2)/-2(1)/4	499,999 USD
Contact Name	Shane Woodward			
Contact Telephone	240-276-6624			
Contact Email	woodwars@mail.nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 05-Jul-202	4 , 07-Sep-2024 , 05-Oct-2024 , 07-Jan-2025		
Synopsis	monitoring (liquid biopsy) assays during	applications for research projects that integrat cancer therapy in patients to determine the o d/or emergence of resistance. This FOA will us	ptimal use of those mod	lalities in the
113232 Bioengineering Research Grants (I	BRG) (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS 22-24	07-May-2024	Not Specified
Contact Name	Rao Divi, Ph.D.			
Contact Telephone	240-276-6913			
Contact Email	divir@mail.nih.gov			
Sponsor Website				
Leahn School of Medicine at	NIH Funding Opport	unities Due: July 2024		6

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	ink to program URL			
		7-May-2024 , 05-Jun-2024 , 05-Jul-2024 025 , 07-May-2025 , 05-Jun-2025 , 05-Ju	، 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 0 ul-2025 , 07-Sep-2025	07-Jan-2025 , 05-Feb-20	25 , 05-Mar-
	tl o Synopsis e d a	nat: 1) apply a multidisciplinary bioengi ptimize, validate, translate or accelerat nd address specific research or clinical p nhancing our understanding of health a esign-directed, developmental, discove	announcement is to encourage collaborations neering approach to the solution of a biomedia e adoption of promising tools, methods and te problem in basic, translational, and/or clinical and disease, and/or c) improve practice of med ry-driven, or hypothesis-driven research, and ease our understanding of and solve problems	cal problem; and 2) deve echniques: a) that fulfill science and practice, b) licine. Applications may this FOA is appropriate	elop, integrate, an unmet need capable of propose for small teams
113233 Bioenginee	ring Research Grants (BR	G) (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS 22-24	07-May-2024	Not Specified
	Contact Name R	ao Divi, Ph.D.			
	Contact Telephone 2	40-276-6913			
	Contact Email <u>d</u>	ivir@mail.nih.gov			
	Sponsor Website				
	Program URL <mark>L</mark>	ink to program URL			
		7-May-2024 , 05-Jun-2024 , 05-Jul-2024 025 , 07-May-2025 , 05-Jun-2025 , 05-Ju	، 07-Sep-2024 , 05-Oct-2024 , 05-Nov-2024 , 0 ul-2025 , 07-Sep-2025	07-Jan-2025 , 05-Feb-20	25 , 05-Mar-
	tl v Synopsis a si c a a	hat: 1) apply a multidisciplinary bioengi alidate, translate or otherwise accelera r clinical problem in basic, translational evelopmental, discovery-driven, or hyp pproach to increase our understanding upport clinical trials that test functional onventional clinical trials that lack trans	announcement is to encourage collaborations neering approach to the solution of a biomedia te the adoption of promising tools, methods, a , or clinical science and practice. An applicatio othesis-driven research and is appropriate for of and solve problems in biological, clinical, or ity or validate performance in the chosen sett slation as the primary motivation. Applications nd will not be supported through this FOA. Thi	cal problem; and 2) inte and techniques for a spe n may propose design-d small teams applying an translational science. ing. This FOA is not inter that propose phase III o	grate, optimize cific research irected, n integrative This FOA will nded to support linical trials in

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
112442 NCI Clinical and Translational Expl Clinical Trial Optional)	oratory/Developmental Studies (R21	National Cancer Institute/NIH/DHHS 22-216	12-Jun-2024	275,000 USD
Contact Name	William C. Timmer, Ph.D			
Contact Telephone	240-276-6130			
Contact Email	william.timmer@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	12-Jun-2024 , 01-Jul-2024 , 10-Oct-2024	, 01-Nov-2024 , 13-Feb-2025 , 01-Mar-2025 , 12-J	un-2025 , 01-Jul-202	.5
Synopsis	management, or reduction of cancer dis following: new molecular agents or biolo treatment-related toxicity; cancer screer approaches; predictive and prognostic bi- vitro tumor models (including genetically lines); and strategies to address theraper new treatment strategies may involve re- on established mechanisms of action. Co- health disparities are encouraged to exp resistance to therapeutic interventions. I diagnosis of human disease are supporter (such as studies of cancer-related pathw risk assessment studies, epidemiological not responsive to this FOA and will not b responsive for this FOA). The R21 mecha	is in cancer treatment, diagnosis, prevention, comparities. This includes (but is not limited to) developing of cancer treatment; management strategies ing or diagnostic tools, such as imaging technique iomarkers for patient selection or stratification; clay engineered mouse models, patient-derived xence utic outcome disparities among underserved pope purposed agents or novel combinations of intervelopmarative correlative studies in cancer patients velore mechanisms underlying their differential resp. Comparative oncology studies in dogs investigating as well. This FOA does not support research that ays, molecular mechanisms, or mechanisms of mechanisms of the reviewed (see below for a more detailed description is intended to encourage exploratory and detailed to encourage exploratory and the encourage exploratory explores ex	opment and testing of s for cancer-related es; cancer preventive inically relevant in v ograft models, organ ulations. In addition entions (including ra- vith age, gender, rac oonses (efficacy and g strategies for trea- it focuses on basic ca etastasis), late-stage ese applications wil otion of studies that evelopmental resear v involve considerab	of the symptoms or e agents or ivo or in oids, and cell to novel agents, diation), based ial/ethnic, or toxicity) and tment and ancer biology clinical trials, I be deemed are not ch projects by le risk but may

106264 Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)	National Cancer Institute /NULL/DULLS	PAR-	16 Jun 2024	400,000
100204 Basic Research in Cancer Health Dispanties (R21 Clinical That Not Allowed)		21-323	10-Juli-2024	USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Anu Sharman, Ph.D.			
	Contact Telephone	240-276-6250			
	Contact Email	<u>sharmananu@nih.gov</u>			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Jul-2024			
	Synopsis	National Cancer Institute (NCI) invites a into the biological/genetic causes of car studies designed to investigate biological factors associated with cancer disparities strategies, (2) the development and tess also designed to aid and facilitate the gr in cancer health disparities research wh models, and methods that are necessar	ncer health disparities. These research p al/genetic bases of cancer disparities, su es, including those related to basic resea ting of new methodologies and models, rowth of a nationwide cohort of scientis to can expand available resources and to	project grants (R01) will suppor uch as (1) mechanistic studies arch in cancer biology or cance and (3) secondary data analys its with a high level of basic re pols, such as biospecimens, pa	rt innovative of biological er prevention ses. This FOA is search expertis
106265 [	Basic Research in Cancer Health D	visparities (R03 Clinical Trial Not Allowed	) National Cancer Institute/NIH/DHHS	PAR- 21-324 16-Jun-2024	100,000 USD
	Contact Name	Anu Sharman, Ph.D.			
	Contact Telephone	240-276-6250			
	Contact Email	<u>sharmananu@nih.gov</u>			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Jun-2024 , 16-Jul-2024			
	Synopsis	This Funding Opportunity Announceme basic, mechanistic research into the bio will support projects on cancer health d projects should propose innovative stud mechanistic studies of biological factors	logical/genetic causes of cancer health lisparities that can be carried out in a sh dies designed to investigate biological/g	disparities. These small resear ort period of time with limited enetic bases of cancer disparit	rch grants (RO3) d resources. The ties, such as (1)

biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
106283	Mechanisms that Impact Cancer R Trial Not Allowed)	Risk after Bariatric Surgery (R21 Clinical	National Cancer Institute/NIH/DHHS	PAR- 21-332 16-	-Jun-2024	550,000 USD
	Contact Name	Edward R. Sauter, M.D., Ph.D.				
	Contact Telephone	240-276-7657				
	Contact Email	edward.sauter@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2024 , 16-Jul-2024				
	Synopsis	of investigator-initiated studies address	uncement (FOA), the National Cancer Ins ing mechanisms by which bariatric surge urgery to investigate its effects on cance	ry impacts ca	ancer risk, and see	ks to draw in
	Notice of Special Interest (NOSI):	Utilization of Cohorts and Prospective		NOT-		Not
113746	Study Designs for Liquid Biopsy As Cancers	say Validation for Early Detection of	National Cancer Institute/NIH/DHHS	CA-23- 07- 004	-May-2024	Specified
	Contact Name	Matthew Young, Ph.D.				
	Contact Telephone	•				
	Contact Email	matthew.young@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		07-May-2024 , 05-Jun-2024 , 11-Jun-202 2024 , 10-Oct-2024 , 11-Oct-2024 , 05-Ja May-2025 , 05-Jun-2025 , 12-Jun-2025 ,		•		
	Synopsis	biomarker technology developers with a and biorepository researchers. Proposal	ered retrospective cohorts and/or throug	pulation-bas ssay develop	ed researchers, in oment, verificatior	cluding cohort , qualification,
125493	RFA-CA-24-022 SBIR Phase IIB B	ridge Awards to Accelerate the	National Cancer Institute/NIH/DHHS	RFA- 21-	-Jul-2024	4,500,000

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Development of Cancer-Relevant (R44 Clinical Trial Optional)	Technologies Toward Commercialization		CA-24- [O 022 Ap	ptional][LOI/Pre- pp]	USD
	Contact Name	Jonathan Franca-Koh, PhD, MBA				
	Contact Telephone	240-618-0984				
	Contact Email	francakohjc@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Jul-2024 [Optional][LOI/Pre-App], 21-	Aug-2024			
	Synopsis	Through this Notice of Funding Opportur Research (SBIR) applications from small & development for cancer-relevant project agency. The purpose of this NOFO is to fa stage. This NOFO is expected to promote party investors and/or strategic partners commercialize new products and service any independent third-party investor fun Award project period. It is expected that NCI funds being requested throughout th and/or clinical stages of technology deve	business concerns (SBCs) that seek addit is that were previously funded under SB acilitate the transition of SBIR or STTR PH e partnerships between Federally-funded to facilitate and accelerate the capital-i s. Applicants must submit a Commercial adding that has already been secured or is the level of this independent third-part one Phase IIB Bridge Award project period	ional fundir IR or STTR P nase II proje d SBIR or ST ntensive ste ization Plan s anticipated y funding wi l. Proposed	ng to support the ne hase II awards from octs to the commerce TR Phase II awarde eps that are require by which should incl during the Phase ill be equal to or gro projects may addre	ext stage of n any Federal cialization es and third- d to ude details on IB Bridge eater than the ess preclinical
125528	Study of the Diverse Aspects of Ut	Administrative Supplements for the the tee termine Serous Carcinoma (Clinical Trial Not	National Cancer Institute/NIH/DHHS		-Jul-2024	125,000 USD
	Allowed)	1		044		
	Contact Name	Toby T. Hecht, Ph.D.				
	Contact Telephone	240-276-5683				
	Contact Email	<u>hechtt@mail.nih.gov</u>				
	Sponsor Website					
	•	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2024				
	Synopsis	The Office of the Director (OD) at the Na	tional Cancer Institute (NCI) announces	this notice c	of special interest (	NOSI) to

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	encourage current grant or cooperative a carcinoma (USC). To be eligible for these (2) TP53 aberrant tumors; (3) serous ovar health disparities. The overall goal of the (including the tumor microenvironment), disparity issues of USC that would lead to	supplemental funds, parent grants must rian cancer; (4) development of in vitro an ese administrative supplements is to adva prevention, diagnosis, early detection, tr	currently foo nd in vivo mo ance knowleo reatment, ris	cus on (1) endom odel systems; or dge in the tumor	etrial cancer; (5) cancer biology
123152 Feasibility Clinical Trials of Mind a Priority Research Topics (R34 Clin	nd Body Interventions for NCCIH High ical Trial Required)	National Center for Complementary F and Integrative Health/NIH/DHHS 2	PAR- 24-084 20-J	un-2024	450,000 USD
Contact Name	Jennifer N. Baumgartner, Ph.D.				
Contact Telephone	301-402-4084				
Contact Email	jennifer.baumgartner@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	20-Jun-2024 , 15-Jul-2024 , 21-Oct-2024 , , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-20	. 13-Nov-2024 , 20-Feb-2025 , 10-Mar-202 26 , 22-Jun-2026 , 13-Jul-2026 , 20-Oct-20			5 , 20-Oct-2025
Synopsis	The goal of this notice of funding opportu approaches with physical and/or psychol- that have been identified by NCCIH as hig clinical trials that provide new informatio clinical efficacy or effectiveness study, pr NCCIH expects that applications to this N the proposed (R34) research is scientifica Under this R34, the data collected should scale clinical trial, including, but not limite published data; tailoring or adapting the refining the intervention to determine th retention, and data collection procedures interventions; or examining acceptability have the potential to make a significant in encouraged to contact the appropriate N application. This NOFO requires a Plan for	ogical therapeutic inputs (often called mi gh-priority research topics. This funding o on that are scientifically necessary for the agmatic trial, or dissemination and imple OFO will describe the planned future clin illy necessary to design or plan the subsect be used to fill gaps in scientific knowledge ed to the following: examining feasibility content or structure of an intervention to e most appropriate frequency or duration s; refining and assessing the feasibility of and adherence of control conditions. The mpact on public health. Prior to submitt CCIH Scientific/Research contact person	ind and body opportunity is planning an mentation tr ical trial and quent compo ge necessary and accepta o a specific p n; determini protocolized e subsequen ing to this N for the scien	y interventions) for s intended to sup ind conduct of a sup rial within NCCIH l in so doing demo etitive full-scale of y to develop a con ability of intervent opulation, modal ng feasibility of re d multi-component t full-scale clinicat OFO, applicants a nee area of the pla	or conditions port feasibility ubsequent 's mission. onstrate that linical trial. mpetitive full- tions lacking lity, or setting; ecruitment, nt I trial should are anned

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		scientific and technical peer review evalu be withdrawn. Applicants are strongly en guidance material.				•
123153		ls of Complementary and Integrative / or via mHealth (R01 Clinical Trial	National Center for Complementary and Integrative Health/NIH/DHHS	PAR- 24-086 20-	Jun-2024	Not Specified
	Contact Name	Beda Jean-Francois, Ph.D.				
	Contact Telephone	202-313-2144				
	Contact Emai	l <u>beda.jean-francois@nih.govr01</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2024 , 15-Jul-2024 , 21-Oct-2024 , , 17-Nov-2025 , 20-Feb-2026 , 17-Mar-20				5, 20-Oct-2025
	Synopsis	This Notice of Funding Opportunity (NOF conducted clinical trials to assess the effi NCCIH- designated areas of high research remotely delivered and conducted fully p participants and may utilize mHealth too approach and provide preliminary data o intervention has promise of clinical bene Scientific/Research contact for the area o to this NOFO. This NOFO requires a Plan scientific and technical peer review evalu be withdrawn. Applicants are strongly en guidance material.	cacy or effectiveness of complementary opriority. Applications submitted under owered clinical trial with no in-person of ls or technologies. Applicants must prov n the feasibility and safety of the appro- fit. Applicants are encouraged to conta- of science for which they are planning to for Enhancing Diverse Perspectives (PE ation. Applications that fail to include a	and integrat this NOFO at contact betw vide justificat ach, along w act the appro develop an DP), which w a PEDP will be	tive health interve re expected to pro een research staff ion for the remote ith evidence that to priate NCCIH application prior to vill be assessed as e considered incor	entions in opose a and study ely delivered the o submitting part of the mplete and will
1/314/	NCCIH Multi-Site Feasibility Clinic (R01 Clinical Trial Required)	al Trials of Mind and Body Interventions	National Center for Complementary and Integrative Health/NIH/DHHS	PAR- 24-083 20-	Jun-2024	Not Specified
	Contact Name Contact Telephone	Pete Murray, Ph.D. 301-496-4054				

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) , 20-Feb- This noti integrati interven propose and cone trial with so doing powered including demonst adheren the feasi preparat expected publishe competi submitti the scier be asses consider	rogram URL 024 , 15-Jul-2024 , 21-Oct-2024 , 2026 , 17-Mar-2026 , 22-Jun-202 ce of funding opportunity (NOFC ve health approaches with physi tions) in NCCIH-designated areas a multisite feasibility clinical tria duct of a subsequent clinical effic in NCCIH's mission. NCCIH expect demonstrate that the proposed l, full-scale clinical trial. Under the g, but not limited to the following grating feasibility of recruitment, ce to the intervention, as well as bility of protocolized multimodal ion for a future fully powered, m d to be justified by sufficient prel d literature. The data collected s tive fully powered multisite clinic ng to this NOFO, applicants are e area of the planned applications sed as part of the scientific and t	, 13-Nov-2024 , 20-Feb-2025 , 20-Jun-2025 , 15-Jul-2 26 , 14-Jul-2026 , 20-Oct-2026 , 17-Nov-2026 D) invites applications for investigator-initiated clinic cal and/or psychological therapeutic inputs (often ca s of high research priority. Applications submitted un I that will provide new information that is scientifica- cacy or effectiveness study, pragmatic trial, or disser cts that applications to this NOFO will describe the p (R01) research is scientifically necessary to design o is R01, the data collected should be used to fill gaps g: assessing whether the intervention can be deliver accrual, and randomization of participants across si retention of participants throughout the study acro I interventions, and/or demonstrating feasibility of co bultisite efficacy or effectiveness trial. The need for r iminary data from previous single site feasibility or a hould be used to fill gaps in scientific knowledge and cal trial that has the potential to make a significant in encouraged to contact the appropriate NCCIH Scient on. This NOFO requires a Plan for Enhancing Diverse echnical peer review evaluation. Applications that f rawn. Applicants are strongly encouraged to read th aterial.	al trials of complete alled mind and boo nder this NOFO are ally necessary for t mination and imple olanned future clin or plan the subseque in scientific know ed with fidelity act tes; demonstrating adata collection acro multisite feasibility acceptability trial(s d be necessary to a mpact on public he ific/Research cont e Perspectives (PEI fail to include a PEI	mentary and dy e expected to he planning ementation ical trial and in uent fully ledge, ross sites; g participant nd assessing oss sites in r trials is s) or the develop a ealth. Prior to act person for DP), which will DP will be
123160 🤇	Clinical Coordinating Center for NCCIH Mul Clinical Trials of Mind and Body Interventic Clinical Trial Required)		National Center for Complementary PAR- and Integrative Health/NIH/DHHS 24-090	-Jun-2024	Not Specified
	Contact Name Elizabetl Contact Telephone 301-827				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email Sponsor Website	elizabeth.ginexi@nih.gov			
		Link to program URL			
	Deadline Dates (ALL)	20-lup-2024 15-lul-2024 20-Eeb-2025	, 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-F	eb-2026 , 17-Mar-20	26 , 22-Jun-2026
	Synopsis	collaborating Data Coordinating Center (I (Phase III and beyond) application submit companion Clinical Coordinating Center ( comprehensive plan that provides overal support for the proposed clinical trial. Bo simultaneously for consideration by NCCI NCCIH and considered a high priority by t research priorities of NCCIH, applicants a are encouraged to contact the appropria develop an application prior to submittin (PEDP), which will be assessed as part of	D), utilizing the U24 grant funding mechanism, e DCC) application that accompanies an investigat tted under companion PAR-24-090. The DCC application. The objective of the DCC application and administrative, data th a DCC application and a corresponding CCC a IH. Trials for which this NOFO applies must be r the Center. For additional information about the re encouraged to consult the NCCIH website (h te Scientific/Research contact for the area of sci g to this NOFO. This NOFO requires a Plan for I the scientific and technical peer review evaluati will be withdrawn. Applicants are strongly enco dance material.	cor-initiated multi site plication must be spec- ication is to propose a management, and big pplication need to be elevant to the research e mission, strategic vis ttp://www.nccih.nih.g ience for which they a Enhancing Diverse Per on. Applications that	clinical trial cific to the ostatistical submitted ch mission of sion, and gov). Applicants are planning to rspectives fail to include a
123155 1		CIH Multi-Site Investigator-Initiated Clinical Cions (Collaborative U24 Clinical Trial	National Center for Complementary PAR- and Integrative Health/NIH/DHHS 24-087	20-Jun-2024	Not Specified
	Contact Name	Elizabeth Ginexi, Ph.D.			
	Contact Telephone	301-827-0160			
	Contact Email	elizabeth.ginexi@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , , 13-Jul-2026	, 10-Mar-2025 , 20-Jun-2025 , 14-Jul-2025 , 20-F	eb-2026 , 17-Mar-202	26 , 22-Jun-2026
	Synopsis	This notice of funding opportunity (NOFC	), utilizing the U24 grant funding mechanism, e	ncourages applicatior	ns for a

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		(Phase III and beyond) application submit companion Clinical Coordinating Center ( comprehensive plan that provides overal support for the proposed clinical trial. Bo simultaneously for consideration by NCC NCCIH and considered a high priority by t research priorities of NCCIH, applicants a are encouraged to contact the appropria develop an application prior to submittin (PEDP), which will be assessed as part of	DCC) application that accompanies an investigato tted under companion PAR-24-090. The DCC appl (CCC) application. The objective of the DCC applica Il project coordination, and administrative, data month a DCC application and a corresponding CCC applies. The DCC application and a corresponding CCC applies. The Center. For additional information about the month are encouraged to consult the NCCIH website (htt ate Scientific/Research contact for the area of scienting the scientific and technical peer review evaluatio will be withdrawn. Applicants are strongly encour- idance material.	ication must be spec ation is to propose a nanagement, and bic plication need to be evant to the researc mission, strategic vis p://www.nccih.nih.g nce for which they a nhancing Diverse Per n. Applications that	tific to the statistical submitted h mission of ion, and gov). Applicants re planning to spectives fail to include a
123823		CCIH Multi-Site Investigator-Initiated (Collaborative UG3/UH3 Clinical Trial	National Center for Complementary PAR- and Integrative Health/NIH/DHHS 24-123	21-Jun-2024	Not Specified
	Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.			
	Contact Telephone	301-402-1272			
	Contact Email	<u>weberwj@mail.nih.gov</u>			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , , 14-Jul-2026	, 10-Mar-2025 , 23-Jun-2025 , 17-Jul-2025 , 23-Fe	o-2026 , 17-Mar-202	e , 22-Jun-2026 ,
	Synopsis	multi-site, clinical trials (Phase III and bey research priority. Applicants should desc multi-site clinical trial. The objective of th comprehensive scientific and operationa responsible for project management, par conduct, and dissemination of results. Cli	It (FOA) encourages cooperative agreement applic yond) to study the effects of natural products in N ribe plans for a Clinical Coordinating Center to de he Clinical Coordinating Center is to provide the d I plan for the clinical trial. The Clinical Coordinatin rticipant recruitment and retention strategies, per inical Coordinating Center applications submitted reement (UG3/UH3) funding mechanism. In additi	CCIH designated are velop and implemen esign scientific ration g Center is expected formance milestone under this FOA will	eas of high t the proposed hale and a t to be es, scientific utilize a two-

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Coordinating Center application, submitted clinical project is required. Both a Clinical (DCC) application need to be submitted s	Coordinating Center application and a	correspon	-	-
	<u>ition: Research Resource for Natural</u> ance Data (R24 Clinical Trial Not Allowed)	National Center for Complementary and Integrative Health/NIH/DHHS	AT-24- [	L0-Jun-2024 Optional][LOI/Pre- \pp]	Not Specified
Contact Name	Patrick C. Still, Ph.D.				
Contact Telephone					
Contact Email	patrick.still@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Jun-2024 [Optional][LOI/Pre-App], 08-	-Jul-2024			
Synopsis	The National Center for Complementary a applications for continuation of an establ meta-data from natural products ranging store, search and analyze raw NMR data. wider community inclusiveness of the est of the Consortium Advancing Research or Program include the RFA-OD-24-014 Bota 008Leveraging Big Data to Understand Na	ished nuclear magnetic resonance (NM from crude extracts to purified substan The purpose of this limited competitio ablished NMR research resource. This in Botanicals and Other Natural Product anical Dietary Supplements Translation	R) researcl nces; with t n is to pror notice of fu s (CARBON al Research	h resource consisting the capacity to uploa mote sustainability, s unding opportunity ( I) Program. Other ele n Teams (RM1) and R	g of raw and ad, download, ccaling and NOFO) is part ements of this
123858 <u>Natural Product Multi-Site Clinica</u> (Collaborative U24 Clinical Trial R		National Center for Complementary and Integrative Health/NIH/DHHS	PAR- 24-125 2	21-Jun-2024	Not Specified
Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.				
Contact Telephone	301-402-1272				
Contact Email	weberwj@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	21-Jun-2024 , 15-Jul-2024 , 20-Feb-2025 , , 14-Jul-2026	10-Mar-2025 , 23-Jun-2025 , 15-Jul-20	25 , 20-Feb	o-2026 , 17-Mar-202	6 , 22-Jun-2026

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This Notice of Funding Opportunity (NOF collaborating Data Coordinating Center (I (Phase III and beyond) application submit Clinical Coordinating Center (CCC) applicat provides overall project coordination, and clinical trial. Both a DCC application and a consideration by NCCIH. Trials for which considered a high priority by the Center. of the NCCIH, applicants are encouraged	DCC) application that accompanies an i sted under PAR-24-123. The DCC applica- ation. The objective of the DCC applicat d administrative, data management, ar a corresponding CCC application need t this NOFO applies must be relevant to For additional information about the m	nvestigator-in ation must be tion is to prop nd biostatistic to be submitte the research nission, strate	nitiated multi-site e specific to the co lose a comprehens al support for the ed simultaneously mission of the NCC gic vision, and res	clinical trial Ilaborating sive plan that proposed for CIH and
108576		ct Definition for Small Molecules and and Series Identification (R33 - Clinical Tria	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-23- 22- 012	Jul-2024	700,000 USD
	Contact Name	Mike Pieck, Ph.D.				
	Contact Telephone	301-827-7986				
	Contact Email	nhlbi_catalyze@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	22-Jul-2024 , 19-Aug-2024 , 21-Nov-2024	, 20-Dec-2024			
	Synopsis	This Catalyze Product Definition Funding needed to develop and test device proto- develop research tools for use in the trea of a suite of Catalyze innovation grants to Catalyze Preclinical program or attract in preclinical product optimization and char	type designs, identify diagnostic diseas atment of heart, lung, blood and sleep ( advance projects to the point where the point where the support from the supp	e targets and (HLBS) disease they can mee	develop associate es and disorders. T t the entry criteria	d assays, and his FOA is part for the NHLBI
108577	and Testing, Diagnostic Disease Ta	<u>ct Definition – Device Prototype Design</u> arget Identification and Assay Development (R61/R33 - Clinical Trial Not	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-23- 22- 013	Jul-2024	750,000 USD
_	Contact Name Contact Telephone	Mike Pieck, Ph.D. 301-827-7986				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Link Deadline Dates (ALL) 22-J This nee Synopsis	ul-2024, 19-Aug-2024, 21-Nov-2024 Catalyze Product Definition Funding ded to develop and test device proto elop research tools for use in the trea	, 20-Dec-2024 Opportunity Announcement (FOA) wil type designs, identify diagnostic diseas atment of heart, lung, blood and sleep o advance projects to the point where	e targets and (HLBS) disease	develop associate es and disorders. T	d assays, and his FOA is part
	Cata	alyze Preclinical program or attract in clinical product optimization and char finition – Device Prototype Testing sease Target Assay Development and	dependent development support from racterization.		l or private partne	
	Clinical Trials Not Allowed) Contact Name Mik Contact Telephone 301					
	Contact Email <u>nhlt</u> Sponsor Website Program URL <u>Link</u>	i catalyze@nih.gov				
	Deadline Dates (ALL) 22-J This test Synopsis grar attr	ul-2024, 19-Aug-2024, 21-Nov-2024 Funding Opportunity Announcemen ing/design modification, assay develo treatment of heart, lung, blood, and its to advance projects to the point w	4, 20-Dec-2024 t (FOA) will provide the early stage transported by the provide the early stage transported by the provided	and developm nis FOA is part for the NHLBI	nent of research to of a suite of Catal Catalyze Preclinica	ols for use in yze innovation Il program or
108575	RFA-HL-23-011 Catalyze: Product De Biologics - Target Identification and Va Product/Lead Series Identification (R6	lidation, and Preliminary	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-23- 22- 011	Jul-2024	1,050,000 USD

SPIN ID Progra Title	am	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Mike	Pieck, Ph.D.				
	Contact Telephone 301-8	27-7986				
	Contact Email <u>nhlbi</u>	<u>_catalyze@nih.gov</u>				
	Sponsor Website					
	Program URL <u>Link t</u>	o program URL				
	Deadline Dates (ALL) 22-Ju	-2024 , 19-Aug-2024 , 21-Nov-2024	4 , 20-Dec-2024			
	chara Synopsis disea: can m	cterize potential therapeutic candi- ses and disorders. This FOA is part of neet the entry criteria for the NHLB	nt (FOA) will provide the early stage tra dates (compound and lead series) to the of a suite of Catalyze innovation grants I Catalyze Preclinical program or attract clinical optimization and development	reat heart, lung to advance pr ct independent	g, blood, and sleep ojects to the poin development sup	o (HLBS) t where they
	23-010 Catalyze: Enabling Tec is for HLBS Research (R33 - Clini		National Heart, Lung, and Blood Institute/NIH/DHHS	RFA- HL-23- 22- 010	Jul-2024	600,000 USD
	Contact Name Mike	Pieck, Ph.D.				
	Contact Telephone 301-8	27-7986				
	Contact Email <u>nhlbi</u>	catalyze@nih.gov				
	Sponsor Website					
	Program URL <u>Link t</u>	o program URL				
	Deadline Dates (ALL) 22-Ju	-2024 , 19-Aug-2024 , 21-Nov-2024	4 , 20-Dec-2024			
	transi blood enabl Synopsis data, adopt scree assoc	ormative platforms to catalyze new , and sleep (HLBS)-related disorder ing technology or transformative p but still requires further developm ion. Well-suited applications must ning, model development, clinical d iated with HLBS-related diseases ar	nt (FOA) solicits grant applications to funct st-generation predictive, diagnostic an rs and diseases. This FOA solicits R33 a platform have already been overcome, ent and rigorous validation to encoura offer the potential to accelerate and/or diagnosis, treatment, control, preventi and disorders. Projects proposing applic al target/question being pursued are n	d therapeutic p pplications who as demonstrat ge downstrear or transform th on or epidemic ation of existin	products to address ere major feasibili ed with supportive n demonstration, he areas of early de plogy, while addre ng technologies wh	ss heart, lung, ty gaps for the e preliminary utilization and etection and ssing issues here the

SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date	Funding Amount
		•		l not be reviewed. This FOA is part of a can meet the entry criteria for the NH			
108514	RFA-HG-22-004 Genome Resear Undergraduates into Genomic Fie Not Allowed)			National Human Genome Research Institute/NIH/DHHS	HG-22-	01-Jun-2024 [Optional][LOI/Pre- App]	1,750,000 USD
	Contact Name	Tina Gatlin, Ph.D.					
	Contact Telephone	301-480-2280					
	Contact Email	gatlincl@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jun-2024 [Optional][LOI/I	Pre-App], 01-	Jul-2024			
	Synopsis	overarching goal of this R25 backgrounds, including those studies or careers in research mission areas of the NIH. The undergraduates from diverse pursue further training and c accomplish the stated over-a Research Experiences Course into the Genomic Field to Pro provide research education p Development Award (IDeA)-	program is to e from group n The NIH Re e overarching background careers in the arching goal, es for Skills D pomote Divers programs for eligible instit	5) supports research education activities o support educational activities that en as underrepresented in the biomedical esearch Education Program (R25) support g goal of this NHGRI R25 program is to socientific, medical, ethical, social and/ this FOA will support creative education evelopment This Genome Research Ex sity (GREAT) Program will support colla undergraduates enrolled at minority-sutions. A partnership will include a MS ations with a suitable research base for	icourage in and behav orts resea support ed epresente for legal an onal activit periences borative in serving ins I or IDeA-e	ndividuals from divers vioral sciences, to purs rch education activities ducational activities th d in the biomedical w reas of genomics resea ies with a primary foc to Attract Talented U institutional partnersh titutions (MSIs) or Inst eligible institution, and	e sue further s in the nat encourage orkforce, to arch. To us on: ndergraduate ips that titutional d one or more
177387 -	RFA-HG-23-048 Advancing Geno Not Allowed)	omic Medicine Research (R03	<u>Clinical Trial</u>	National Human Genome Research Institute/NIH/DHHS	RFA- HG-23- 048	08-Jul-2024	750,000 USD

Contact Name Christine Chang, MPH

048

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	240-552-1208				
Contact Email	<u>changcq@mail.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	08-Jul-2024 , 11-Feb-2025				
Synopsis	This NOFO solicits proposals that stimula implement the use and sharing of genom racial/ethnic background or socioeconom	nic information and technologies in cli	-		
109790 NIAID Research Education Program	n (R25 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 22-134 25-	-Jul-2024	1,755,000 USD
Contact Name					
Contact Telephone					
Contact Email	<u>AlTrainingHelpDesk@niaid.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	25-Jul-2024 , 09-Oct-2024				
Synopsis	The NIH Research Education Program (R overarching goal of this R25 program is t workforce to meet the nation's biomedic goal, this FOA will support creative educa Experiences Mentoring Activities	o support educational activities that c cal, behavioral and clinical research ne	omplement an eds. To accom	d/or enhance the plish the stated ov	training of a /er-arching
113395 <u>NIAID Research Opportunities for Promote Workforce Diversity (R01</u>		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 22-241 07-	-May-2024	Not Specified
Contact Name	Diane Adger-Johnson, MPH				
Contact Telephone					
Contact Email	<u>AlTrainingHelpDesk@niaid.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 05-Jul-2024 2025 , 07-May-2025 , 05-Jun-2025 , 05-Ju		r-2024 , 07-Jaı	า-2025 , 05-Feb-202	25 , 05-Mar-
Synopsis	The purpose of this funding opportunity mission. This FOA seeks to support either successfully for substantial, independent support as a PD/PI on a substantial independent award in the current fiscal year, will have backgrounds, including those from groups	(a) a New Investigator (NI), an individ funding from NIH, or (b) are an 'At-Ri endent research award and unless su no substantial research grant funding	dual who has sk' investigato ccessful in seo g in the follow	not previously com or, an individual wh curing a substantial	peted o had prior research grant
125210 RFA-AI-24-013 Cell and Gene Th Pipeline (P01 Clinical Trial Not Allo	erapies for HIV Cure: Developing a owed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	24-013	)-Jun-2024 )ptional][LOI/Pre- op]	11,000,000 USD
Contact Name	Betty Poon, Ph.D.				
Contact Telephone	240-669-5024				
Contact Email	poonb@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-	Jul-2024			
Synopsis	The purpose of this notice of funding op development, characterization, and advar elimination of HIV. Applications are expect as test-of-concept studies in animal mode participate in their program.	ncement of gene- and cell-based app ted to include basic science discover	roaches to acl y as well as pr	hieve long-term rer eclinical research a	nission or ctivities such
125057 RFA-AI-24-020 Immunobiology ( Not Allowed)	of Xenotransplantation (U19 Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-020 [C	)-Jul-2024 )ptional][LOI/Pre- )p]	Not Specified
Contact Name	Nasrin Nabavi, Ph.D.				
Contact Telephone	240-627-3538				
Contact Email	nnabavi@niaid.nih.gov				
Sponsor Website					

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Jul-2024 [Optional][LOI/Pre-App], 09-	Aug-2024			
	The purpose of this notice of funding opp Xenotransplantation Cooperative Resear physiologic barriers to safe and efficacion decedent models of pancreatic islet, kidn	ch Program (IXCRP), a multi-center pr us xenotransplantation using preclinic	ogram dedio al pig to nor	cated to resolving im	nunologic an
125056 RFA-AI-24-019 Immunobiology of Not Allowed)	of Xenotransplantation (U01 Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-019	10-Jul-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Nasrin Nabavi, Ph.D.				
Contact Telephone	240-627-3538				
Contact Email	nnabavi@niaid.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	10-Jul-2024 [Optional][LOI/Pre-App], 09-	Aug-2024			
Synopsis	The purpose of this notice of funding opp Xenotransplantation Cooperative Resear physiologic barriers to safe and efficaciou decedent models of pancreatic islet, kidn	ch Program (IXCRP), a multi-center pr us xenotransplantation using preclinic	ogram dedio al pig to nor	cated to resolving im	nunologic ar
124850 RFA-RM-24-007 Technologies ar INDs (U01, Clinical Trial Not Allow	nd Assays for Therapeutic Genome Editing ed)	g National Institute of Allergy and Infectious Diseases/NIH/DHHS	RM-24-	26-Jun-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Betty Poon, Ph.D.				
Contact Telephone	240-669-5024				
Contact Email	poonb@mail.nih.gov				
Sponsor Website					
	United and an and UDI				
Program URL	Link to program URL				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity characterization of technologies and assa genome editing therapeutics. This Fundir https://commonfund.nih.gov/) through (https://dpcpsi.nih.gov/). All NIH Institut by the National Institute of Allergy and In	ays with the potential for utilization and ng Opportunity Announcement (FOA) is the NIH Office of the NIH Director, Offi ces and Centers participate in Common	d adoption in s developed a ce of Strategi Fund initiativ	regulatory submiss is a Common Fund ic Coordination	sions of initiative
124966 <mark>0</mark> R	of Transmission and Treatment of	n Targeted Epidemiology: Epidemiology HV Among People Who Are at Increased ica (LITE-LA) (UG3/UH3 Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS		-Jun-2024 ptional][LOI/Pre- p]	Not Specified
	Contact Name	Gerald B. Sharp, Dr.P.H.				
	Contact Telephone	240-627-3217				
	Contact Email	<u>GSharp@niaid.nih.gov</u>				
	Sponsor Website					
	Program URL	ink to program URL				
	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-	-Jul-2024			
	Synopsis	The purpose of this notice of funding opp generated cohorts in Latin America of HIN who inject drugs (PWID), and/or female s follow-up of those persons who acquire H shese groups and comparisons of particip defined areas of high HIV incidence as we participants who seroconvert and compa evels to those whose virus remains deter will allow digital trials to determine optim prevention and treatment interventions to	V-negative men who have sex with mer sex-workers and follow them to study to HIV will be required to study the epider bants by seroconversion status will pro- ell as on both personal and structural v risons of those becoming rapidly engage ctable will inform on the treatment of nal study approaches, or to pilot evider	n (MSM), trar he epidemiol miology of vir vide informat ulnerabilities ged in care ar HIV in Latin A nce-based dig	nsgender women (1 ogy of HIV incident al suppression. Des ion on geographic to HIV infection. St nd who reach non-c merican countries. gital (mHealth and c	GW), people ce. Continued scriptions of and socially cudies of letectable HIV This NOFO
1 // 468 -	RFA-AI-24-018 Interaction betwe Coinfections (R01 Clinical Trial Opti	en ARVs and Hormones in HIV and onal)	National Institute of Allergy and Infectious Diseases/NIH/DHHS		-Jun-2024 ptional][LOI/Pre- p]	Not Specified

Contact Name Cherlynn Mathias

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	240-292-4791				
	Contact Email	<u>cmathias@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-	-Jul-2024			
	Synopsis	The purpose of this Notice of Funding Op between hormone therapy and antiretro	portunity (NOFO) is to support resear viral drugs (ARVs) used for treatment	ch to identif and prevent	y and characterize t ion of HIV and co-in	he interaction fections.
124822 <u>R</u>	RFA-AI-24-011 HIV/AIDS Clinica	I Trials Units (UM1 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-011	0-Jun-2024 Optional][LOI/Pre- .pp]	2,000,000 USD
	Contact Name	Leia Novak, Ph.D.				
	Contact Telephone	301-761-7825				
	Contact Email	Leia.novak@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-	Jul-2024			
	Synopsis	The purpose of this Notice of Funding Op will enable future clinical trials to determ tailored to the participants. The ultimate development and prioritization of more k NOFO will support multidisciplinary team intact, rebound-competent HIV reservoir combinations of HIV curative approaches	ine whether combinations of HIV cure goal is for the results of such proof-or proad-based curative strategies that w s to conduct coordinated basic and pr s and immunologic backgrounds and p	e strategies of f-concept clir vill be effectiv re-clinical res use that info	an be effective when nical studies to infor ve in all people livin search to profile par rmation to develop	n optimally m the g with HIV. This ticipants'
	RFA-AI-24-008 Strategies for Co I) (R01 Clinical Trial Not Allowed)	ntrolled Release of HIV Vaccines (SCORE-	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-008	0-Jun-2024 Optional][LOI/Pre- .pp]	Not Specified
	Contact Name Contact Telephone	Angela Malaspina, Ph.D. 301-825-3859				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	angela.malaspina@nih.gov				
	Sponsor Website					
	-	Link to program URL				
		30-Jun-2024 [Optional][LOI/Pre-App], 30-				
		The purpose of this Notice of Funding Op release vaccine strategies to improve imr single-shot vaccination formulations. Tim	nune responses for HIV prevention, tr	eatment, ar		
125059		the Development of Tools to Advance Intibiotic-Resistant Gram-Negative Dwed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 24-021	21-Jul-2024 Optional][LOI/Pre- App]	750,000 USD
-	Contact Name	Zuoyu Xu, Ph.D.				
	Contact Telephone	240-627-3394				
	Contact Email	xuzuoyu@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Jul-2024 [Optional][LOI/Pre-App], 20-/	Aug-2024			
	Synopsis	The purpose of this Notice of Funding Op utilizing novel predictive models, assays, facilitate therapeutic discovery for select carbapenem-resistant Enterobacterales (	tools, and/or platforms based on pene Gram-negative bacterial pathogens: c	etration and arbapenem	l efflux of small mole -resistant Acinetobac	cules to
125479	RFA-AI-24-017 Human Leukocyt mmunoglobulin-like Receptor (KII Diseases (U01 Clinical Trial Not All	R) Region Genomics in Immune-Mediated	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI- 2 24-017	21-Jul-2024 [LOI/Pre- App]	2,000,000 USD
	Contact Name	Shilpa Kulkarni, Ph.D.				
	Contact Telephone	240-747-7365				
	Contact Email	shilpa.kulkarni@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
	Deadline Dates (ALL)	21-Jul-2024 [LOI/Pre-App], 20-Aug-2024 The purpose of this notice of funding opp		•				
	Synopsis	variations in human leukocyte antigen (H mediated diseases, 2) elucidates mechan opportunities, and/or 3) validates associa NOFO requires a Plan for Enhancing Diver peer review evaluation. Applications that withdrawn. Applicants are strongly encou guidance material.	isms underlying these associations with ation data in order to improve the pre- rse Perspectives (PEDP), which will be fail to include a PEDP will be consider	th the goal of a dictive power assessed as pa red incomplete	advancing therape of clinical disease art of the scientific and will be	eutic screening. This c and technical		
	Exploratory Clinical Trial Grants in Diseases (R61 Clinical Trial Require	Arthritis and Musculoskeletal and Skin ed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR- 24-035 02-	Jul-2024	600,000 USD		
	Contact Name	Yan Wang, M.D., Ph.D.						
	Contact Telephone	301-594-5032						
	Contact Email	wangy1@mail.nih.gov						
	Sponsor Website							
	Program URL	L <u>Link to program URL</u> ) 02-Jul-2024 , 01-Nov-2024 , 04-Mar-2025 , 02-Jul-2025 , 04-Nov-2025 , 04-Mar-2026 , 02-Jul-2026 , 02-Nov-2026						
	Deadline Dates (ALL)							
	Synopsis	This Notice of Funding Opportunity (NOF frame. A broad range of types of explorat questions related to the mission and goal surgical, dietary, behavioral or rehabilitat	tory studies may be submitted to this Is of the NIAMS and may evaluate inte	NOFO. The tria	als must address r	esearch		
177361	Clinical Observational (CO) Studie Diseases (R01 Clinical Trial Not All	<u>s in Musculoskeletal, Rheumatic, and Skin</u> lowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR- 02- 24-036	Jul-2024	475,000 USD		
	Contact Name	Yan Wang, M.D., Ph.D.						
	Contact Telephone	301-594-5032						
	Contact Email	wangy1@mail.nih.gov						
	Sponsor Website							

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	-	Link to program URL				
		02-Jul-2024, 01-Nov-2024, 04-Mar-2025 The purpose of this Notice of Funding Op				
	Synopsis	pursue clinical observational (CO) studies rheumatic, or skin diseases or conditions clinical study design by providing essentia comorbid conditions; availability of poter can facilitate efforts to develop and/or va clinical study. A future clinical study may encouraged to propose studies that addr determining the appropriate primary or s patients are most likely to respond to an	. Research data from observational stu al information about disease symptom ntial research participants; and outcom alidate objective biomarkers or subject include a clinical trial or an observatio ess significant obstacles or questions i secondary outcome measures or identi	idies suppo s, stages, an nes that are ive outcom nal study. A n the desigr fying the st	orted by this NOFO ca nd timing of disease e important to patient ne measures for use in Applicants to this NOF n of a clinical project, tages of disease durin	n enhance progression; ts. They also n a future O are such as g which
1,51,77	RFA-HD-25-001 Medical Rehabil Trial Optional)	itation Research Resource (P50 Clinical	National Institute of Child Health and Human Development/NIH/DHHS	HD-25- [	30-Jun-2024 [Optional][LOI/Pre- App]	3,750,000 USD
	Contact Name	Joe Bonner, PhD				
	Contact Telephone	301-827-8303				
	Contact Email	joe.bonner@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	30-Jun-2024 [Optional][LOI/Pre-App], 30-	-Jul-2024			
	Synopsis	This Notice of Funding Opportunity (NOF Medical Rehabilitation Research Center. 7 research project supported by 3 cores. Th Together, the cores will support: adminis community engagement and outreach. T research infrastructure by developing and the goal of enhancing the capability of m develop therapeutic strategies, identify c include a plan for inclusion of People with	The centers will have a specific rehabil he 3 cores will have functions within the trative functions (including an optional he Medical Rehabilitation Research Ce d disseminating techniques, data, theo edical rehabilitation investigators to un linical care gaps, and improve the lives	itation rese le center as l pilot prog nters will co ries, resear nderstand r s of people	earch theme and be c s well as functions nat ram), resource sharin ontribute to medical rch programs, and ex mechanisms of functi with disabilities. App	omprised of a tionwide. ng, and rehabilitation pertise with onal recovery lications must

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	1	theme of the center and increases the <sub>l</sub>	potential impact of the center.			
	RFA-HD-25-004Optimizing Health Perinatal HIV Exposure (U19 Clinica		National Institute of Child Health and Human Development/NIH/DHHS	HD-25-	30-Jun-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Telephone Contact Email Sponsor Website	Allahna Esber, PhD 301-827-4560 <u>allahna.esber@nih.gov</u> Link to program URL				
	Deadline Dates (ALL) Synopsis	30-Jun-2024 [Optional][LOI/Pre-App], 3 This Notice of Funding Opportunity (NC to support the Optimizing Health of Chi NOFO is to generate information neede term effects of in utero/perinatal expos but uninfected (IHEU). Investigators wit IHEUs are encouraged to apply. A multi R01 or U01. The applications should an IHEUs. Proposed projects should 1) hav	0-Jul-2024 DFO) invites applications to participate in Idren and Adolescents with Perinatal HI ed to develop and to test interventions f sure to antiretroviral therapy (ART) and/ th innovative thinking and new approac -program project grant is proposed to a swer important fundamental questions e a scope that is well matched to the re ement one another, be synergistic, and	V Exposure or the early or HIV amo hes to addro nswer ques related to lo sources and	e Initiative. The object y detection and reduc ong individuals who a ress the public health stions not easily addre ong-term health outo d the research object	tive of this tion of long- re HIV exposed issues facing essed in an comes for ives, 2) be
III/hXK	Continuation or Revision of NIDCR Agreement (UH3 Clinical Trial Requ	Clinical Trial Implementation Cooperat uired)	ive National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR- 22-068	08-Jul-2024	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	Link to sponsor website Link to program URL	4 08 lan 2025			
	. ,	08-Jul-2024 , 06-Sep-2024 , 07-Nov-202 This Funding Opportunity Announceme	4, 08-Jan-2025 nt (FOA) will accept applications for cor	npeting ren	newal or competitive	revision of

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	ongoing clinical trials supported by the N ongoing clinical trial through a competin complete the trial or when an extended revisions will be supported when there i Applicants are strongly encouraged to co which they are planning a competing ref	ng renewal application will be supported period of follow-up is well justified to a s compelling justification for modifying pontact the appropriate Scientific/Resea	d when there assess longer the scope o rch contact f	e is need for additio term outcomes. Co f the ongoing clinica or the ongoing clini	nal time to ompetitive Il trial. cal trial for
124379 RFA-DK-25-013 Impact of Com Reservoirs (R01 Clinical Trial Not	orbidities and Co-Infections on HIV Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	DK-25- [(	0-May-2024 Optional][LOI/Pre- pp]	Not Specified
Contact Name	e Peter J. Perrin, Ph.D.				
Contact Telephone	e 301-451-3759				
Contact Ema	il <u>Peter.Perrin@nih.gov</u>				
Sponsor Website	e				
Program UR	L Link to program URL				
Deadline Dates (ALL	) 30-May-2024 [Optional][LOI/Pre-App], 3	30-Jul-2024			
Synopsi	This Notice of Funding Opportunity (NO and co-infections within the missions of strategies aimed at either sustained vira interrogate the impact of inflammation, these comorbidities or co-infections on reservoir biology in ways that are likely t	NIDDK and NIAID interact with viral results of an one of the second seco	servoirs, pote body. These t hophysiologic by of these co	entially confounding eams will mechanis cal processes associa	g cure tically ated with
113279 Limited Competition: Small Gran Recipients (R03 Clinical Trial Opti	t Program for NIDDK K01/K08/K23/K25 ional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR- 22-129	7-May-2024	150,000 USD
Contact Name	e Lisa M. Spain, Ph.D.				
Contact Telephon	e 301-451-9871				
Contact Ema	il <u>SpainL@niddk.nih.gov</u>				
Sponsor Website	e				
Program UR	L Link to program URL				
		unities Due: July 2024			

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 16-Jul-2024 2025 , 07-May-2025 , 16-Jun-2025 , 16-Ju	, 07-Sep-2024 , 16-Oct-2024 , 16-Nov- Il-2025 , 07-Sep-2025	2024 , 07-Ja	n-2025 , 25-Feb-202	5 , 16-Mar-
	The National Institute of Diabetes and Di supported K01, K08, K23, and K25 recipie the award period of their K award. Throu K01, K08, K23, and K25 award recipients investigator status. The R03 grant mecha secondary analysis of existing data; small development of new research technolog out in a short period of time with limited equivalent, application.	ents the opportunity to apply for Small gh the use of this mechanism, the NID to conduct research as they complete nism supports different types of projec , self-contained research projects; dev y. The R03 is, therefore, intended to su	Grant (RO3) DK is seeking their transiti cts, including elopment of pport resear	support during the g to enhance the ca on to fully independ g pilot and feasibility research methodol rch projects that ca	latter years of pability of its lent v studies; ogy; and n be carried
125058 RFA-DK-24-002 Adaptation of D Adults with T1D (R01 Clinical Trial	iabetes Control Technologies for Older Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	DK-24- [C	7-Jun-2024 )ptional][LOI/Pre- pp]	500,000 USD
Contact Name	Guillermo Arreaza-Rubín, M.D.				
Contact Telephone	301-594-4724				
Contact Email	arreazag@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	17-Jun-2024 [Optional][LOI/Pre-App], 17	-Jul-2024			
Synopsis	The main objective of this NOFO is to fos older adults (aged 65 years or older) with increased vulnerability to hypoglycemia, benefits of these technologies in this pop adapt and test existing technologies. It is among older adults with T1D will improve hypoglycemia unawareness) while enhan- quality of life for these individuals and th	n T1D to improve diabetes management cognitive impairment and/or multiple pulation. Projects will be funded to a) d expected that aging-adaptive diabetes e usability, adoption and adherence de poing glycemic control, facilitating bette	t and quality co-morbiditi evelop and t technologie creasing the	y of life. Older adult es which may affect test new technologi es that address barr e risk of hypoglycem	s may have the risks and es and b) to fers for use ia (and
1/5/15/1	ly Type 1 Diabetes Disease Processes in In the second	National Institute of Diabetes and Digestive and Kidney		D-Jun-2024 Dptional][LOI/Pre-	2,200,000 USD

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
(CBDS)] (U01 Clinical Trial Not Allowed)		Diseases/NIH/DHHS	007 A	vpp]	
Contact Name Olivier	Blondel, Ph.D.				
Contact Telephone 301-26	3-4342				
Contact Email <mark>blonde</mark>	lol@niddk.nih.gov				
Sponsor Website					
Program URL Link to	program URL				
Deadline Dates (ALL) 10-Jun-	2024 [Optional][LOI/Pre-App], 0	9-Jul-2024			
compar of T1D, staging therape Consor Synopsis stress a cell ma CBDS is whose	rtment for the discovery of speci the discovery of early biomarke of early T1D in at-risk or recentle eutic targets for the developmen tium on Beta Cell Death and Surv and destruction central to the de ss in T1D patients as early as pos part of a collaborative research overall mission is to support inno	FO) requests applications to explore hu fic signaling or processing pathways that rs of T1D pathogenesis, the development y-diagnosed individuals, and/or the ident t of preventative or early treatment stru- vival (CBDS), whose mission is to better velopment of T1D in humans, with- the sible in the disease process, and of preventative and collaborative translational r	It may contri Int of diagnost Intification ar ategies. Succ define and d long-term go venting the p Network (HIF esearch to u	ibute to the asympto stic tools for the detend biological validation cessful applicants wi detect the mechanismo oal of protecting the progression to autoin RN, https://hirnetwo understand how hum	omatic phase action and on of I join the ns of beta cell residual beta nmunity. The rk.org/),
only su	pport studies with a primary focu	trategies to protect and replace function us on increasing our understanding of h ot accept applications proposing a clinic	uman diseas		s NOFO will
only su	pport studies with a primary focunity not a primary focunity of a	us on increasing our understanding of h	uman diseas al trial. RFA- 1 DK-25- [0		s NOFO will
125481 RFA-DK-25-010 Cystic Fibrosis Research Clinical Trial Optional)	pport studies with a primary focunity not a primary focunity of a	us on increasing our understanding of h ot accept applications proposing a clinic National Institute of Diabetes and Digestive and Kidney	uman diseas al trial. RFA- 1 DK-25- [0	se biology (as oppose .7-Jun-2024 Optional][LOI/Pre-	s NOFO will ed to rodent o 3,750,000
125481 RFA-DK-25-010 Cystic Fibrosis Research Clinical Trial Optional)	pport studies with a primary focu nimal models). This NOFO will no and Translation Centers (P30 s Eggerman, MD, Ph. D.	us on increasing our understanding of h ot accept applications proposing a clinic National Institute of Diabetes and Digestive and Kidney	uman diseas al trial. RFA- 1 DK-25- [0	se biology (as oppose .7-Jun-2024 Optional][LOI/Pre-	s NOFO will ed to rodent o 3,750,000
125481     RFA-DK-25-010 Cystic Fibrosis Research Clinical Trial Optional)       Contact Name     Thoma	pport studies with a primary focu nimal models). This NOFO will no and Translation Centers (P30 s Eggerman, MD, Ph. D. 4-8813	us on increasing our understanding of h ot accept applications proposing a clinic National Institute of Diabetes and Digestive and Kidney	uman diseas al trial. RFA- 1 DK-25- [0	se biology (as oppose .7-Jun-2024 Optional][LOI/Pre-	s NOFO will ed to rodent o 3,750,000
125481       RFA-DK-25-010 Cystic Fibrosis Research Clinical Trial Optional)         Contact Name Contact Telephone       Thoma 301-59	pport studies with a primary focu nimal models). This NOFO will no and Translation Centers (P30 s Eggerman, MD, Ph. D. 4-8813	us on increasing our understanding of h ot accept applications proposing a clinic National Institute of Diabetes and Digestive and Kidney	uman diseas al trial. RFA- 1 DK-25- [0	se biology (as oppose .7-Jun-2024 Optional][LOI/Pre-	s NOFO will ed to rodent o 3,750,000
125481       RFA-DK-25-010 Cystic Fibrosis Research Clinical Trial Optional)         Contact Name       Thoma         Contact Telephone       301-59         Contact Email       eggerm         Sponsor Website       Program URL         Link to       1000000000000000000000000000000000000	pport studies with a primary focu nimal models). This NOFO will no and Translation Centers (P30 s Eggerman, MD, Ph. D. 4-8813 mant@mail.nih.gov	us on increasing our understanding of h ot accept applications proposing a clinic National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	uman diseas al trial. RFA- 1 DK-25- [0	se biology (as oppose .7-Jun-2024 Optional][LOI/Pre-	s NOFO will ed to rodent o 3,750,000



( F F Synopsis ¢ V	This Notice of Funding Opportunity (NOF CF Research and Translation Core Centers Research and Translation Core Centers su Feasibility program; and an Administrativ support research to develop and test new existing research base in CF. The NIDDK c with documented programs of research e CF Research and Translation Centers may	s are designed to support both basic an upport three primary research-related a re Core with an enrichment program. Co v therapies for CF and to foster collabou urrently supports seven CF Research ar excellence in basic and clinical CF Resea	nd clinical res activities: Re ore Centers rations amor nd Translatio rch. Informa	earch on Cystic Fib search Core service provide shared resc ng institutions with n Centers located a tion about the curr	rosis. CF s; a Pilot and ources to a strong at institutions
	programs/cystic-fibrosis-research-transla	tion-centers or https://www.cysticfibro		-	
125706 RFA-ES-24-001 Hazardous Materi (U45 Clinical Trials Not Allowed)	ials Worker Health and Safety Training	National Institute of Environmental Health Sciences/NIH/DHHS		-Jun-2024 ptional][LOI/Pre- p]	700,000 USD
Contact Name S	Sharon Beard				
Contact Telephone	984-287-3237				
Contact Email <u>t</u>	<u>beard1@niehs.nih.gov</u>				
Sponsor Website					
	Link to program URL				
	08-Jun-2024 [Optional][LOI/Pre-App], 08-				
t G Synopsis f a s u	NIEHS invites applications for cooperative training and education of workers engage containment, transportation, and emerge health training to prevent and reduce wo on how best to identify and protect them during hazardous waste operations, haza facilities, and emergency response. A vari action, and transportation-related emerg surrounding communities. These sites con uncontrolled. A major goal of the Worker development and delivery of model train	ed in activities related to hazardous ma ency response. This funding opportunity rk-related harm. The training programs iselves and their communities from exp rdous materials transportation, enviror iety of industry sites, such as those invo ency response may pose severe health ntain many hazardous substances, som Training Program (WTP) is to support i	terials and w y announcer s will provide posure to haz nmental rest plved with ha and safety c etimes unkn	vaste generation, re nent aims to use sa skills and knowled ardous materials e oration of contamin azardous waste clea concerns to workers own, and a site ma	emoval, ifety and lge to workers ncountered nated anup, remedial s and the tybe



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
<u> </u>	Healthcare and Community Settir	ngs (R34 Clinical Trial Required)	Health/NIH/DHHS	MH- 25-120	[Optional][LOI/Pre- App]	USD
	Contact Name	Stephen O'Connor, Ph.D.				
	Contact Telephone	301-480-8366				
	Contact Email	stephen.o'connor2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2024 [Optional][LOI/Pre-App]	, 15-Jul-2024 , 23-Jan-2025			
	Synopsis	attempts and death. Yet, the field is community settings. Pilot effectivene change mechanisms, and inform dec provide preliminary evidence on the safety (e.g., number/percent of firea pilot phase of effectiveness research and potential effectiveness of the ap is/are presumed to underlie the inter	eling into their programming have bee lacking strong evidence on the effectiv ess research will advance knowledge re isions about whether further effective extent to which lethal means safety in rms safely stored, overdose injury cod , the trial should be designed to evalua proach; to address whether the interv rvention effects; and to obtain prelimi rative effectiveness study, practical tria	eness of these egarding optin ness testing is terventions m es for an indiv ate the feasibi ention engage nary data nee	e strategies tested in h nization strategies, the warranted. The resear ore optimally lead to i idual) and lower suicid lity, tolerability, accept es the target(s)/mechar ded as a pre-requisite t o definitively test the ef	ealthcare ar rapeutic och will mproved e risk. In th ability, safe nisms(s) tha to a larger-
1 7/1257	Developmental AIDS Research Ce Clinical Trial Optional)	nters on Mental Health and HIV/AIDS	(P30 National Institute of Mental Health/NIH/DHHS	PAR- 24-164	27-Jul-2024 [Optional][LOI/Pre- App]	3,000,00 USD
	Contact Name	Christopher Gordon, PhD				
	Contact Telephone	240-627-3867				
		cgordon1@mail.nih.gov				
	Sponsor Website					
	Program LIPI	Link to program LIPI				

Program URL Link to program URL



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
Deadline Dates (ALL)	27-Jul-2024 [Optional][LOI/Pre-App], 26-, [Optional][LOI/Pre-App], 25-Aug-2026	Aug-2024 , 26-Jul-2025 [Optional][LOI/	′Pre-App], 2	5-Aug-2025 , 26-Jul-2	2026	
Synopsis	The National Institute of Mental Health (I grants (P30) to support Developmental H support that facilitates the development mission. This Funding Opportunity Annou areas, including basic, NeuroHIV, behavio implementation science. The intent of D- successfully for a full NIMH AIDS Research	IV/AIDS Research Centers (D-ARC). The of high impact science in HIV/AIDS and incement (FOA) intends to support inn oral and social, integrated biobehaviora ARC support is that the proposed core	e D-ARC is in d mental he ovative, int al, applied, activities w	ntended to provide ir alth that is relevant t erdisciplinary researc clinical, translational,	nfrastructure o the NIMH ch in several and	
124853 <u>NIMH AIDS Research Center on M</u> Trial Optional)	ental Health and HIV/AIDS (P30 Clinical	National Institute of Mental Health/NIH/DHHS	PAR- 24-165	27-Jul-2024 Optional][LOI/Pre- App]	7,500,000 USD	
Contact Name	Christopher Gordon, PhD					
Contact Telephone	240-627-3867					
Contact Email	cgordon1@mail.nih.gov					
Sponsor Website						
Program URL	Link to program URL					
Deadline Dates (ALL)	27-Jul-2024 [Optional][LOI/Pre-App], 26-/ [Optional][LOI/Pre-App], 25-Aug-2026	Aug-2024 , 26-Jul-2025 [Optional][LOI/	'Pre-App], 2	5-Aug-2025 , 26-Jul-2	2026	
The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support HIV/AIDS Research Centers (ARC). The ARC is intended to provide infrastructure support that facilitates the development of high impact science in HIV/AIDS and mental health that is relevant to the NIMH mission. Thi Funding Opportunity Announcement (FOA) intends to support innovative, interdisciplinary research in several areas, including basic, NeuroHIV, behavioral and social, integrated biobehavioral, applied, clinical, translational, and implementat science.						
125607 RFA-MH-25-185Advancing HIV S Pharmacists (R01 Clinical Trial Opt	ervice Delivery Through Pharmacies and cional)	National Institute of Mental Health/NIH/DHHS		.3-Jul-2024 Optional][LOI/Pre- App]	Not Specified	

Contact Name Michael J. Stirratt, PhD



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	240-627-3875				
Contact Emai	l <u>stirrattm@nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	) 13-Jul-2024 [Optional][LOI/Pre-App], 13-/	Aug-2024			
Synopsis	the delivery of HIV testing, prevention, ar This includes the advancement of training systems to deliver the spectrum of needer mechanism, while RFA-MH-25-186 uses t novel intervention may be most appropri large-scale clinical trials or longitudinal ar	g curricula to enable pharmacy studen ed HIV services with ease, equity, and e he R21 mechanism. Projects that lack ate for the R21 mechanism. Applicatio	ts, pharmage ffectivenes preliminary ons with pre	cists, pharmacies, and ss. This NOFO uses the data or that propose eliminary data and the	d pharmacy e R01 grant e to pilot a
125608 RFA-MH-25-186Advancing HIV S Pharmacists (R21 Clinical Trial Op	Service Delivery Through Pharmacies and htional)	National Institute of Mental Health/NIH/DHHS		13-Jul-2024 [Optional][LOI/Pre- App]	400,000 USD
Contact Name	Michael J. Stirratt, PhD				
Contact Telephone	240-627-3875				
Contact Emai	l <u>stirrattm@nih.gov</u>				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL)	) 13-Jul-2024 [Optional][LOI/Pre-App], 13-/	Aug-2024			
Synopsis	The purpose of this Notice of Funding Op the delivery of HIV testing, prevention, ar This includes the advancement of training systems to deliver the spectrum of neede mechanism, while RFA-MH-25-185 uses t novel intervention may be most appropri large-scale clinical trials or longitudinal ar	nd care services through pharmacists a g curricula to enable pharmacy studen ed HIV services with ease, equity, and e he R01 mechanism. Projects that lack ate for the R21 mechanism. Applicatio	and pharma ts, pharma effectivenes preliminary ons with pre	icies in US and/or glo cists, pharmacies, and ss. This NOFO uses th data or that propose eliminary data and th	bal settings. d pharmacy e R21 grant e to pilot a
110192 RFA-NS-22-038 Research Progra	am Award (R35 Clinical Trial Optional)	National Institute of Neurological	RFA- 1	15-Jun-2024	6,000,000

Icahn School of Medicine at Mount Sinai

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
			Disorders and Stroke/NIH/DHHS	-	Optional][LOI/Pre- App]	USD
	Contact Name	Alisa Schaefer, Ph.D.				
	Contact Telephone					
	Contact Email	alisa.schaefer@nih.gov				
	Sponsor Website					
	Program URL I	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2024 [Optional][LOI/Pre-App]	, 15-Jul-2024			
	i i s synopsis i i i i i i i i i i i i i i i i i i	administrative burden of writing and investigators at most career stages the research opportunities, and mentor so will support the overall research proge PD/PI's recent NINDS support (Part 2, security, allowing them to undertake breaks new ground. Research activitie Center, will not be considered throug facilitating the pursuit of longer-term opportunities as they arise, not tied t grant awards, allowing investigators to mentor and foster a diverse workforce ensure it reflects our commitment to supported scientific workforce, include global competitiveness, contributes to Interest in Diversity). NINDS will work areas, approaches, regions, institutio maximizing the ideas explored and the accepts clinical trials, only applicatior	(Principal Investigators (PIs), to allow ther managing multiple grant applications and he opportunity to advance their long-term students and postdoctorates, which suppor grams of NINDS-funded investigators for u , Section II). This greater funding stability research projects that require a longer time es outside of the NINDS mission, or tradition that program. Benefits of the RPA include research goals; Flexible funding, enabling to specific aims; Reduced time spent writing to spend more time conducting and oversise in their laboratories. The RPA is a unique enhancing the diversity and inclusiveness ding individuals from underrepresented give o robust learning environments, and impli- to to ensure that it maintains a broad and cons, and individuals. Such diversity will opt the chances for important breakthroughs. If and proposing "mechanistic clinical trials or information on the types of clinical trial the portunity Description, below.	I towards en research go ort and align p to 8 years, will provide meframe or f onally suppo de: A more st g investigato ng grant app eeing resear roups, foster roups, foster roves the qua diverse resea imize return Note that, wi studies" or b	gaging in the lab. The pals, rigorously explo- with the mission of , at a level commens eligible investigators to embark upon rese orted by another NIH table funding enviro rs to pursue researc lications and manag rch; More time for P or NINDS, as such NH oscience workforce. Is scientific innovation ality of the research arch portfolio in term s on the Institute's i hile this funding opp basic experimental s	is RPA affords re exciting NINDS. RPAs surate with a s increased earch that I Institute or nment, h ing multiple Ds/PIs to NDS strives to A diverse NIH- on, enhances (see NIH's ns of scientific nvestments by portunity also tudies with

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
121161 RFA-NR-24-001 Firearm Injury P Settings (R01 Clinical Trial Optiona	revention in Community Healthcare al)	National Institute of Nursing Research/NIH/DHHS	RFA- NR-24- 001	26-Jul-2024	500,000 USD
Contact Name	Karen Huss, PhD, RN, ANP-BC, FAAN, FAA	ΑΑΑΙ, ΓΑΗΑ			
Contact Telephone	301-594-5970				
Contact Email	hussk@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	26-Jul-2024				
Synopsis	The purpose of this initiative is to advance evaluation of firearm injury primary prevare a Plan for Enhancing Diverse Perspective evaluation. Applications that fail to inclu	vention interventions leveraging comm s (PEDP), which will be assessed as par	unity hea t of the so	thcare settings. This N ientific and technical p	OFO requires
122306 <u>RFA-NR-24-002 Short Courses in</u> <u>Allowed</u>	n Social Determinants of Health for search (R25 Independent Clinical Trial No	National Institute of Nursing Research/NIH/DHHS	RFA- NR-24- 002	01-Jun-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Liz Perruccio, MS, PhD				
Contact Telephone	301-402-8084				
Contact Email	liz.perruccio@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Jun-2024 [Optional][LOI/Pre-App], 01	-Jul-2024			
	The NIH Research Education Program (R2 overarching goal of this R25 program is t		omplemer	it and/or enhance the t	training of a

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		fail to include a PEDP will be considered NOFO instructions carefully and view the	•	opplicants are stro	ongly encouraged	l to read the
	NINR Areas of Emphasis for Resea Health Equity (R01 Clinical Trial O	arch to Optimize Health and Advance ptional)	National Institute of Nursing Research/NIH/DHHS	PAR- 22-230 07-N	May-2024	Not Specified
	Contact Name	David L. Tilley, MPH, MS, CPH				
	Contact Telephone	• • • • •				
		david.tilley@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 05-Jul-2024 2025 , 07-May-2025	4 , 07-Sep-2024 , 05-Oct-2024 , 05-No	ov-2024 , 07-Jan-2	2025 , 05-Feb-202	25 , 05-Mar-
	Synopsis	This funding announcement solicits R01 with the scientific framework detailed in research will be rooted in nursing's holis nation's most pressing and persistent he study designs to inform practice and pol	the 2022-2026 National Institute of tic, contextualized approach to unde alth challenges with a solutions orier	Nursing Research rstanding people	NINR) Strategie and their health	: Plan. This , address the
112758 -	NINR Areas of Emphasis for Resea Health Equity (R21 Clinical Trial O	arch to Optimize Health and Advance ptional)	National Institute of Nursing Research/NIH/DHHS	PAR- 22-231 07-N	May-2024	200,000 USD
	Contact Name	David L. Tilley, MPH, MS, CPH				
	Contact Telephone	301-827-6014				
	Contact Email	david.tilley@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 16-Jul-2024 2025 , 07-May-2025	، 07-Sep-2024 , 16-Oct-2024 , 16-Nc	ov-2024 , 07-Jan-2	2025 , 16-Feb-20	25 , 16-Mar-
	Synopsis	This funding announcement solicits R21 are consistent with the research framew Plan. This research will be rooted in nurs	ork detailed in the 2022-2026 Nation	nal Institute of Nu	ursing Research (	NINR) Strategi

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		address the nation's most pressing and p rigorous study designs to inform practice	-	tions orient	ation, and employ ir	novative and
125561		the Intersection of Social Inequities to th Disparities: The Axes Initiative (R01	National Institute of Nursing Research/NIH/DHHS	NR-24- [(	6-Jun-2024 Optional][LOI/Pre- .pp]	2,500,000 USD
	Contact Name	Shalanda A. Bynum, PhD, MPH				
	Contact Telephone	301-755-4355				
	Contact Email	<u>shalanda.bynum@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Jun-2024 [Optional][LOI/Pre-App], 05 2025	-Jul-2024 , 29-Jul-2024 , 15-Jan-2025 [(	Optional][LC	0I/Pre-App], 14-Feb-	2025 <i>,</i> 10-Mar-
	Synopsis	Research shows that intersecting system health. The Axes Initiative will support re ethnicity, socioeconomic status, sexual o of health. This NOFO requires a Plan for I and technical peer review evaluation. Ap withdrawn. Applicants are strongly encou- material.	search to understand health at the int rientation, and ability, by examining co Enhancing Diverse Perspectives (PEDP) plications that fail to include a PEDP w	ersections o ontributions , which will vill be consid	f social statuses suc of social and other be assessed as part ered incomplete and	h as race, determinants of the scientific d will be
123977	NIA Career Transition Award (K22	Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR- 24-120 1	2-Jun-2024	Not Specified
	Contact Name	Jamie Lahvic, Ph.D.				
	Contact Telephone					
	Contact Email	NIATraining@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2024 , 12-Jul-2024 , 12-Oct-2024 , 12-Nov-2025	, 12-Nov-2024 , 12-Feb-2025 , 12-Mar-	2025 , 12-Ju	n-2025 , 12-Jul-2025	5 , 12-Oct-2025

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The purpose of the NIA Career Transition tenure-track or equivalent faculty positio provide postdoctoral phase funding; ther faculty positions within 12 months after of position at an extramural institution/orga salary and research support. This Notice of research that does not involve leading an	ns conducting research that advances refore, candidates should be prepared confirmation of a positive funding decis anization, the award will provide three of Funding Opportunity (NOFO) is desig	the mission to transitic sion. After years of pr gned specif	n of NIA. This award o on to tenure-track or e transition to an appro rotected research tim fically for candidates p	loes not equivalent oved faculty e through proposing
124215 RFA-AG-25-002 Consortium for Lifespan (U54 Clinical Trial Option	Palliative Care Research Across the al)	National Institute on Aging/NIH/DHHS	AG-25-	31-May-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Alexis Bakos, PhD, MPH, RN				
Contact Telephone	301-921-5970				
Contact Email	NIAPalliativeCareResearch@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	31-May-2024 [Optional][LOI/Pre-App], 02	2-Jul-2024			
Synopsis	This Notice of Funding Opportunity (NOF Henceforth, the center will be referred to expertise, and coordination to advance in illnesses across the lifespan. The research (ADRD), cancer, and other serious illnesse (ICOs). NIH currently funds many palliative infrastructure to leverage synergies, coor field. An important focus will be research services for health disparities populations overall goals of the Consortium are the foc care approaches across the lifespan and a mid-career investigators pursuing research care research, with a goal of diversifying that provides resources and expertise to range of populations and serious illnesse	b as the "Consortium." The aim of the C nnovative, high-quality research on pal in infrastructure will encompass Alzhein es and populations relevant to NIH's par ve care research projects across its ICO rdinate efforts, develop the scientific w in to understand and address disparities is (as defined by the NIA Health Disparit collowing: Create new scientific knowled across a range of populations and serio ch careers in palliative care as well as e and expanding the palliative care resear facilitate high-quality research on palli	Consortium liative care ner's disea artnering Ir s, and ther vorkforce, a in access, ties Frame dge on deli- bus illnesse established arch workfo ative care a	n will be to provide re- e for those living with se (AD) and AD-relate nstitutes, Centers, and e is a need for a resea and address remaining quality, and use of pa work priority populati very and outcomes of s. Foster developmen investigators shifting orce. Serve as a nation across the lifespan an	sources, serious d dementias d Offices arch g gaps in the lliative care ons). The <sup>5</sup> palliative t of early- and to palliative nal platform d across a

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		research. Engage healthcare systems, in and other community partners, to inforr clinical trials. Disseminate research findi practices, toolkits, and other impactful r	n the design and conduct of palliative ngs and their implications for clinical p	care research s ractice, metho	studies, including p dologic approach	pragmatic es, best
108315		Dementia Care Workforce for Those Livin neimer's Disease-Related Dementias	<sup>g</sup> National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 049	Jul-2024	Not Specified
	Contact Name	John W. R. Phillips, Ph.D.				
	Contact Telephone	301-496-3136				
	Contact Email	john.phillips@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
	Synopsis	This Notice of Special Interest (NOSI) is i and the impact of workforce factors on a dementia (AD/ADRD) and their families. provide care may cite NOT-AG-21-046, a cite NOT-AG-21-047 in the Agency Routi be considered a high priority for this NO whether PAR-21-307 Dementia Care and 308 Pragmatic Trials for Dementia Care a appropriate.	outcomes for persons living with Alzhe Applications focused on care of perso and applications focused solely on unpa ng Identifier field (box 4B). PLEASE NO SI. Studies proposing dementia care in Caregiver Support intervention Resea	imer's disease ons living with o aid dementia c TE: Application tervention res orch (R01 – Clir	or Alzheimer's dis dementia and the are partners/care ns proposing clinic earch are encoura iical Trial Requirec	ease-related systems that givers may al trials will no ged to explore I) or PAR-21-
108305	Notice of Special Interest (NOSI): I Studying Clinical Alzheimer's Disea	Novel Approaches to Diagnosing and ase and Related Dementias	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 036	Jul-2024	Not Specified
	Contact Name	John Hsiao, M.D.				
	Contact Telephone	301-496-9350				
	Contact Email	jhsiao@mail.nih.gov				
	Sponsor Website					

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL)	Link to program URL 09-Jul-2024 , 12-Nov-2024 The goal of this NOSI is to encourage the	development of novel approaches to	characterizing	diagnosing and	predicting
Synopsis	outcomes in AD and ADRD.				in called ing
108284 Notice of Special Interest (NOSI): Services for Persons with Dement	Dementia Care Research: Programs and ia	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 046	Jul-2024	Not Specified
Contact Name	Elena Fazio, Ph.D.				
Contact Telephone	301-496-3136				
Contact Email	<u>elena.fazio@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
Synopsis	This NOSI invites applications on high-pric as set forth by the National Institute on A discussions from the NIH 2020 Dementia on AD/ADRD, and is aligned with AD/ADR	ging's Division of Behavioral and Soci Care Summit, the NASEM Decadal Su	al Research. Th rvey of Behavio	ne NOSI is based o	n expert
108321 Notice of Special Interest (NOSI): Genetic Variants	Human Cell Biology of Alzheimer's Disease	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 052	Jul-2024	Not Specified
Contact Name	Bradley Wise, Ph.D.				
Contact Telephone	301-496-9350				
Contact Email	wiseb@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
Synopsis	The goal of this Notice of Special Interest and other age- and disease-modifying fac	(NOSI) is to encourage research that tors contributing to AD using human	assesses the fu cell reprogram	unction of AD gene ming (e.g., iPSCs a	etic variants Ind iNeurons)

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		and genomic editing approaches.				
108313	Notice of Special Interest (NOSI): I Monitoring of Alzheimer's Disease	Digital Technology for Early Detection and and Related Dementias	Aging/NIH/DHHS	NOT- AG-21- 09- 048	Jul-2024	Not Specified
	Contact Name	Yuan Luo, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	yuan.luo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
	Synopsis	This Notice of Special Interest (NOSI) end of cognitive and functional decline in per	courages research on the use of digita rsons with Alzheimer's disease (AD) ar	l technology fo nd AD-related c	r early detection a lementias (ADRD)	and monitoring
108309	Notice of Special Interest (NOSI): I Areas in Dementia Care Partner/C	Behavioral and Social Science Priority aregiver Research	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 047	Jul-2024	Not Specified
	Contact Name	Melissa S. Gerald, Ph.D.				
	Contact Telephone	301-496-3136				
	Contact Email	melissa.gerald@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
	Synopsis	This NOSI solicits high-priority Alzheimer areas as set forth by the National Institut the AD/ADRD research implementation r Summit and recommendations from the	te on Aging's Division of Behavioral an milestones and are based on expert di	d Social Resea scussions from	rch. Priority areas the NIH 2020 Der	are guided by nentia Care
108322	Notice of Special Interest (NOSI): I in Alzheimer's Disease	Role of Age-Associated Metabolic Change	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 053	Jul-2024	Not Specified

SPIN ID Program Title	Sponsor Name	Sponsor Number	D	eadline Date	Funding Amount
Contact Name	Yih-Woei Fridell, Ph.D.				
Contact Telephone	01-496-7847				
Contact Email	<u>yih-woei.fridell@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
	This Notice of Special Interest (NOSI) is a peripheral tissues or in the brain affect the second sec				c changes in
108307 Notice of Special Interest (NOSI): In Disease and Related Dementias	n vivo Synaptic Function in Alzheimer's	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09-Ju 038	l-2024	Not Specified
Contact Name	John Hsiao, M.D.				
Contact Telephone	301-496-9350				
Contact Email	jhsiao@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
Synopsis	This Notice of Special Interest (NOSI) has (AD) and Alzheimer's disease-related der vivo, in humans.				
Notice of Special Interest (NOSI): C 108282 Epidemiology of Alzheimer's Disea Dementias (AD/ADRD) and Cogniti	se and Alzheimer's Disease-Related	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09-Ju 045	I-2024	Not Specified
Contact Name	Dallas W. Anderson, Ph.D.				
Contact Telephone	301-402-6693				
Contact Empil	dallas.anderson@nih.gov				
Contact Email	danas.anderson@ini.gov				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Deadline Dates (ALL)	Link to program URL 09-Jul-2024, 12-Nov-2024 This Notice of Special Interest (NOSI) enco relevant to AD/ADRD and cognitive resilie well as gaps and opportunities identified	ence, but identifies specific areas that b	uild on curre	nt efforts support	
	Capturing Complexity in the Molecular and he Etiology of Alzheimer's Disease		NOT- AG-21- 09- 041		Not Specified
Contact Name	Austin Yang, Ph.D.				
Contact Telephone	301-496-9350				
Contact Email	yangj13@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
Synopsis	The goal of this NOSI is to support innova underlying the heterogeneity and multifa scientific paradigms. This NOSI encourage approaches to understanding the comple biology that have not been adequately ac research and analytical tools and to integ	ctorial nature of AD, with the potential es individual and/or collaborative resea x biology of AD to fill critical knowledge ddressed in the past. Applicants are enc	to create ne rch projects t gaps or to e ouraged to u	w, or to challenge that propose innov xamine critical are use or develop stat	existing, /ative eas of AD e-of-the-art
Notice of Special Interest (NOSI):108114Trafficking as a Pathological Hub iDisease-Related Dementias (AD/A)		National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 034	Jul-2024	Not Specified
Contact Telephone Contact Email Sponsor Website	millerm@nia.nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		09-Jul-2024 , 12-Nov-2024				
	Synopsis	The goals of this Notice of Special Interes cellular, and physiological processes asso dementias (ADRD). Studies funded under our understanding of how the genetic un pathophysiological changes associated w	ciated with the endosomal compartn this topic will support research into derpinnings of endosomal trafficking	nent in AD and AD/ADRD path	Alzheimer's disea ogenesis related t	se-related p enhancing
	Notice of Special Interest (NOSI): S Aging and Alzheimer's Disease	Selective Cell and Network Vulnerability in	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 040	Jul-2024	Not Specified
	Contact Name	Bradley C. Wise, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	WiseB@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
	Synopsis	The goal of this Notice of Special Interest (e.g., neurons and glia), neural activity an (or resistant) in brain aging and AD and the signatures of different types of neurons a and in different stages of AD will implicat types by physiological measures such as e networks will provide a functional index of generate sophisticated data on molecular networks. Understanding the mechanism define the disease process and to develop	In d circuits, structural and functional name mechanisms underlying such select and glial cells across the adult lifespare e cell processes and pathways media electrophysiology and connectivity are of selective vulnerability. Applicants are signatures of brain cells and on strues s underlying selective vulnerability from the selective selective vulnerability.	etworks, and b tive vulnerabili n, in AD compar ting selective v nd manipulating are encouraged cture and funct	rain regions that a ty. Genetic and m red to other deme ulnerability in AD. g neural activity in to use new appro- ion of brain circui	are vulnerable olecular ntias of aging, Defining cell circuits and aches to ts and
	Notice of Special Interest (NOSI): S Predictors of Preclinical Alzheimer	Sensory and Motor System Changes as 's Disease	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 044	Jul-2024	Not Specified

Contact Name Coryse St. Hillaire-Clarke, Ph.D.

044

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone					
	sthillaireclacn@mail.nih.gov				
Sponsor Website	Link to program URL				
-	09-Jul-2024 , 12-Nov-2024				
	The purpose of this Notice of Special Inter combination of basic and clinical studies the development and progression of Alzh	that investigate how functional change	• •		
108280 Notice of Special Interest (NOSI): Alzheimer's Disease	Deciphering the Glycosylation Code of	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 042	Jul-2024	Not Specified
Contact Name	Austin Yang, Ph.D.				
Contact Telephone	301-496-9350				
Contact Email	yangj13@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
Synopsis	The goal of this Notice of Special Interest carbohydrate analyses to understand the				
108373 Notice of Special Interest (NOSI):	Infectious Etiology of Alzheimer's Disease	National Institute on Aging/NIH/DHHS	NOT- AG-21- 09- 043	Jul-2024	Not Specified
Contact Name	Miroslaw 'Mack' Mackiewicz, Ph.D.				
Contact Telephone	301-496-9350				
Contact Email	mirolsaw.mackiewicz@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	This NOSI strongly encourages leveraging brain tissue, as well as imaging data, to a				uid (CSF), and
1 / / 5 4 / -	Aging Research Dissertation Awar Not Allowed)	ds to Promote Diversity (R36 Clinical Trial	National Institute on Aging/NIH/DHHS	PAR- 24-052	-Jun-2024	Not Specified
	Contact Name	Jamie Lahvic, Ph.D.				
	Contact Telephone					
	Contact Email	NIATraining@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2024 , 16-Jul-2024 , 16-Oct-2024 , , 16-Nov-2025 , 16-Feb-2026 , 16-Mar-20				5 , 16-Oct-202
	Synopsis	This Notice of Funding Opportunity (NOF engaged in research on aging and aging-r within NIA's strategic priorities.		•		
113465 🧧		Development of Radiotracers for Diagnosis Disease (AD) and AD-Related Dementias	S National Institute on Aging/NIH/DHHS	NOT- AG-22- 07 032	'-May-2024	Not Specified
	Contact Name	Lorenzo M. Refolo, Ph.D.				
	Contact Telephone	301-594-7576				
	Contact Email	<u>refolol@nia.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 09-Jul-2024 2025 , 05-Apr-2025 , 07-May-2025 , 05-Ju	· · · · · · · · · · · · · · · · · · ·	-2024 , 12-Nov	v-2024 , 07-Jan-202	25 , 05-Feb-
	Synopsis	This Notice of Special Interest (NOSI) invit Emission Tomography (PET) for use in Alz and/or emerging biological process or mo pathophysiology of neurodegeneration.	heimer's disease (AD) and AD-related	l dementias (A	DRD) research tar	geting new

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
121767	RFA-DA-25-011 Exploratory Studio Infection, Replication, Latency, and, Substance Use Disorders (R01 Clinic		National Institute on Drug Abuse/NIH/DHHS	RFA- DA-25- 011	14-Jul-2024 [Optional][LOI/Pre- App]	3,500,000 USD
	Contact Telephone 3 Contact Email <u>s</u> Sponsor Website	<u>tsai@nih.gov</u>				
	Deadline Dates (ALL) 1 T t Synopsis a e e	Link to program URL L4-Jul-2024 [Optional][LOI/Pre-App], 14 This notice of funding opportunity (NOF echnologies or 2) test novel hypothese pathogenesis (including neuroHIV) in the and characterization of signaling pathwa promote milestone-driven research to in established, and maintained in the CNS ize and persistence of CNS HIV reservoi	O) will support high risk high impact s s to investigate mechanistic questions e context of Substance Use Disorders ays that are involved in CNS HIV estab nvestigate the underlying molecular m and to determine how addictive subst	tudies that in HIV infe (SUDs). Thi lishment an nechanisms	1) develop or apply no oction, replication, later s initiative focuses on e nd expansion. The NOF s by which HIV infection	ncy, and/or exploration O aims to n is initiated,
	<u>RFA-DA-24-007 Avenir Award Pro</u> Substance Use Disorders (DP1- Clini	ogram for Chemistry and Pharmacology ical Trial Not Allowed)	of National Institute on Drug Abuse/NIH/DHHS	RFA- DA-24- 007	10-Jul-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name S	am Ananthan, Ph.D.				
	Contact Telephone 3					
		am.ananthan@nih.gov				
	Sponsor Website					
		<u>.ink to program URL</u> .0-Jul-2024 [Optional][LOI/Pre-App], 09	-Aug-2024 , 08-Jul-2025 [Optional][LC	0I/Pre-App]	, 07-Aug-2025	
	Synopsis a	Avenir means future in French, and this nvestigators proposing highly innovativ addiction. The purpose of this award is t equired for an R01 grant, but who prop	e research in the area of chemistry an o support those in an early stage of th	d pharmac neir career	ology of substance use who may lack the preli	disorders ar minary data

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	field.				
121296 RFA-DA-25-003 Cohort Studies Clinical Trial Not Allowed)	of HIV/AIDS and Substance Use (U01	National Institute on Drug Abuse/NIH/DHHS	RFA- DA-25- 003	16-Jul-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	e Sheba K. Dunston, EdD				
Contact Telephone	e 301-402-1526				
Contact Emai	il <u>Sheba.Dunston@nih.gov</u>				
Sponsor Website	e				
Program URI	L Link to program URL				
Deadline Dates (ALL	) 16-Jul-2024 [Optional][LOI/Pre-App], 16-	Aug-2024			
Synopsis	The National Institute on Drug Abuse (NI intersection of HIV and substance use. The clinical research on HIV and HIV-associat substance use disorders (SUDs) and to act notice of funding opportunity (NOFO) is new sites to address new emerging and/ in alignment with NIH-HIV research prior are required to report to and collaborate addressing NIDA's high priority areas. The assessed as part of the scientific and tech considered incomplete and will be withd and view the available PEDP guidance material	his program is a multidisciplinary platfo ed co-morbidities and co-infections and ddress research questions at the indivi- to support the continuation of NIDA's for high priority research on multidiscip- rities in order to inform policy or practi- e with a NIDA funded Coordinating Cer- his NOFO requires a Plan for Enhancing hnical peer review evaluation. Applicate rawn. Applicants are strongly encoura	orm to sup nong popu dual and p HIV Cohor blinary asp ice. Cohor ter, incluc g Diverse P tions that	port basic, epidemiolo lations with substance opulation level. The pu ts Program, encouragin lects of HIV/AIDS and s t sites supported under ling participating in res erspectives (PEDP), wh fail to include a PEDP w	gic, and use and urpose of this og existing and ubstance use this program earch agendas ich will be vill be
RFA-DA-25-016 Single Cell Opic 121507 (SCORCH) Program: Data Mining Allowed)	oid Responses in the Context of HIV and Functional (R01 Clinical Trial Not	National Institute on Drug Abuse/NIH/DHHS	RFA- DA-25- 016	13-Jul-2024 [Optional][LOI/Pre- App]	1,750,000 USD
Contact Name	e John Satterlee, Ph.D.				
Contact Telephone	e 301-435-1020				
Contact Emai	il <u>satterleej@nida.nih.gov</u>				
Sponsor Website	e				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Program URL	Link to program URL				
	13-Jul-2024 [Optional][LOI/Pre-App], 13-	-Aug-2024			
Synopsis	The purpose of this notice of funding op types, transcripts, enhancers, or transcri Disorder (SUD)-relevant molecular respo transcriptomic manipulation, high throu the data-mined cell types, transcripts, en NOFO requires a Plan for Enhancing Dive peer review evaluation. Applications tha withdrawn. Applicants are strongly enco guidance material.	ptional networks that play a role in HI onses, and/or to support functional val ghput secondary screening) to confirm nhancers, or transcriptional networks i erse Perspectives (PEDP), which will be t fail to include a PEDP will be conside	V/antiretrovi lidation studi n or deny a bi in HIV/ART ar assessed as red incomple	ral therapy (ART) or es (e.g. epigenomic ological role for one nd SUD molecular re part of the scientific ete and will be	Substance Use or or more of sponses. This and technical
RFA-DA-25-017 Single Cell Opio121510(SCORCH) Program: Data Mining a Allowed)	id Responses in the Context of HIV and Functional (R21 Clinical Trial Not	National Institute on Drug Abuse/NIH/DHHS	DA-25- [(	3-Jul-2024 Optional][LOI/Pre- .pp]	275,000 USD
Contact Name	John Satterlee, Ph.D.				
Contact Telephone	301-435-1020				
Contact Emai	satterleej@nida.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	13-Jul-2024 [Optional][LOI/Pre-App], 13-	-Aug-2024			
Synopsis	The purpose of this notice of funding op types, transcripts, enhancers, or transcri Disorder (SUD)-relevant molecular respo transcriptomic manipulation, high throu the data-mined cell types, transcripts, en NOFO requires a Plan for Enhancing Dive peer review evaluation. Applications tha withdrawn. Applicants are strongly enco guidance material.	ptional networks that play a role in HI onses, and/or to support functional val ghput secondary screening) to confirm nhancers, or transcriptional networks i erse Perspectives (PEDP), which will be t fail to include a PEDP will be conside	V/antiretrovi lidation studi n or deny a bi in HIV/ART ar assessed as red incomple	ral therapy (ART) or es (e.g. epigenomic ological role for one nd SUD molecular re part of the scientific ete and will be	Substance Use or or more of sponses. This and technical
120349 RFA-DA-25-001 Addressing HIV	in Highest Risk Sexual and Gender	National Institute on Drug	RFA- 1	4-Jul-2024	2,500,000



N ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Minorities (R01 Clinical Trial Op	otional)	Abuse/NIH/DHHS	DA-25- 001	[Optional][LOI/Pre- App]	USD
Contact Na	me Richard A. Jenkins, PhD				
Contact Telepho	ne 301-443-1923				
Contact Em	ail <u>jenkinsri@mail.nih.gov</u>				
Sponsor Webs	ite				
Program U	IRL Link to program URL				
Deadline Dates (A	LL) 14-Jul-2024 [Optional][LOI/Pre-A	App], 14-Aug-2024			
Synop	reduce the number of new HIV is structural health determinants a intersectional stigma are welcom sexually transmitted infections, H couples, peers, providers and/or content to existing, widely used ways of addressing substance us research is encouraged if it can is substances, as well as research t HIV outbreaks. This notice of fun	miologic, intervention, or implementat infections among sexual and gender mi and their consequences such as homeled ine and consideration should be given t hepatitis C virus, and psychiatric disord r health care systems as their primary f evidence-based HIV interventions, as v are among SGM persons. Research that inform the design of more effective fut that can inform ascertainment and inter inding opportunity (NOFO) requires a PL ientific and technical peer review evalu-	inority (SGM) perso essness, criminal ju to HIV as a syndemi der. Intervention st foci. Research is inv well as novel interv makes use of existi cure intervention ap ervention among SC lan for Enhancing D uation. Application	ons. Studies that addr stice involvement or f ic including comorbid udies can include ind rited that adds substa ention approaches th ing clinical data, include pproaches for SGM per SM persons who use s iverse Perspectives (F s that fail to include a	ess social a forms of ities such as ividuals, nce use at provide r ding modeli ersons who substances i PEDP), which PEDP will b

120351 <u>minorities (R34 Clinical Trial Requ</u>		Abuse/NIH/DHHS	DA-25- 002	[Optional][LOI/Pre- App]	430,000 USD
Contact Name	Richard A. Jenkins, PhD				
Contact Telephone	301-443-1923				
Contact Email	jenkinsri@mail.nih.gov				
Sponsor Website					

Program URL Link to program URL

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		14-Jul-2024 [Optional][LOI/Pre-App], 14- This initiative will support intervention or number of new HIV infections among sex health determinants and their consequer stigma are welcome and consideration sh transmitted infections, hepatitis C virus, and/or health care systems as their prima evidence-based HIV interventions, as wel use among SGM persons. This notice of f (PEDP), which will be assessed as part of PEDP will be considered incomplete and instructions carefully and view the availa	r implementation research that increase sual and gender minority (SGM) persons nees such as homelessness, criminal just nould be given to HIV as a syndemic incl and psychiatric disorder. Studies can in ary foci. Research is invited that adds su Il as novel intervention approaches that funding opportunity (NOFO) requires a F the scientific and technical peer review will be withdrawn. Applicants are stron	Studies the cice involver uding como clude indivi bstance use provide nev Plan for Enh evaluation.	at address social an ment or forms of informs bridities such as se duals, couples, pee content to existing w ways of addressin ancing Diverse Pers Applications that fa	d structural tersectional xually rs, providers g, widely used ng substance spectives ail to include a
123100	FDA-Qualified Drug Development	f Clinical Outcome Assessments as New Tools to Accelerate Therapeutics ulant Use Disorders (UG3/UH3 Clinical	National Institute on Drug Abuse/NIH/DHHS	DA-25- [O	9-Jun-2024 ptional][LOI/Pre- pp]	2,500,000 USD
	Contact Telephone	tanya.ramey@nih.gov				
	Program URL	Link to program URL 09-Jun-2024 [Optional][LOI/Pre-App], 09-	-Jul-2024			
	Synopsis	The purpose of this funding opportunity is Use Disorders (SUD). The COA development program. This notice of funding opportuning grant mechanism that includes two phase plan that will cover both UG3 and UH3 pl milestones to be completed by the end of determined that the UG3 phase has been additional years. The goal of this NOFO is tool (DDT) in the context of use (COI) of a	ent plan is expected to progress into the hity (NOFO) utilizes the UG3/UH3 Phase es. The applications responding to this N hases. In the first 2-year UG3 phase the f this period. Once NIDA program has en successfully completed, it transitions to to expand the armamentarium of COA	e FDA drug o d Innovation NOFO should project mus valuated the o the UH3 p that are FD	development tool q n Awards Cooperat d contain a COA dev st have a set of ope e progress of the UG hase to be funded A qualified as drug	ualification ive Agreement velopment rational G3 phase and for three development

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	SUDs. This NOFO requires a Plan for Enha and technical peer review evaluation. Ap withdrawn. Applicants are strongly encou material.	plications that fail to include a PEDP w	ill be cons	idered incomplete and	l will be
RFA-DA-25-008 Chemical Probe123166Transcription in the Context of Su Not Allowed)		National Institute on Drug Abuse/NIH/DHHS	RFA- DA-25- 008	13-Jul-2024 [Optional][LOI/Pre- App]	275,000 USD
Contact Name	e Sam Ananthan, Ph.D.				
Contact Telephone					
	l <u>sam.ananthan@nih.gov</u>				
Sponsor Website					
•	Link to program URL				
Deadline Dates (ALL	) 13-Jul-2024 [Optional][LOI/Pre-App], 13-/	•			
Synopsis	The purpose of this notice of funding opp methods, and molecular probes to identi- latency and transcriptional reactivation in novel lead compounds that suppress HIV Enhancing Diverse Perspectives (PEDP), w Applications that fail to include a PEDP w encouraged to read the NOFO instruction	fy mechanisms and signaling pathways in the central nervous system (CNS), an transcription in the context of addiction which will be assessed as part of the sci ill be considered incomplete and will be	s by which d (2) ident ve substan ientific and be withdra	addictive substances i ification and functiona ces. This NOFO require d technical peer review wn. Applicants are stre	nfluence HIV al validation of es a Plan for v evaluation.
RFA-DA-25-007 Chemical Probe123165Transcription in the Context of Su Not Allowed)		National Institute on Drug Abuse/NIH/DHHS	RFA- DA-25- 007	13-Jul-2024 [Optional][LOI/Pre- App]	2,000,000 USD
Contact Name	Sam Ananthan, Ph.D.				
Contact Telephone	9 301-435-2199				
Contact Emai	l <u>sam.ananthan@nih.gov</u>				
Sponsor Website	2				
Program URI	L Link to program URL				
6					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of this notice of funding opp methods, and molecular probes to identi latency and transcriptional reactivation in novel lead compounds that suppress HIV Enhancing Diverse Perspectives (PEDP), v Applications that fail to include a PEDP w encouraged to read the NOFO instruction	fy mechanisms and signaling pathway in the central nervous system (CNS), ar transcription in the context of addicti which will be assessed as part of the so ill be considered incomplete and will l	s by which a nd (2) Identif ve substance cientific and be withdraw	ddictive substances ication and function es. This NOFO requir technical peer review n. Applicants are str	influence HIV al validation of es a Plan for w evaluation.
110056 <mark>S</mark>	RFA-DA-23-021 - Developing Regu Solutions for Patients Affected by OUD/StUD) (R43/R44 - Clinical Tri	Opioid and/or Stimulants use Disorders	National Institute on Drug Abuse/NIH/DHHS	DA-23- [(	.4-Jul-2024 Optional][LOI/Pre- \pp]	Not Specified
	Contact Name	Leonardo Angelone, PhD				
	Contact Telephone	301-827-5946				
	Contact Email	leonardo.angelone@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Jul-2024 [Optional][LOI/Pre-App], 13-	Aug-2024 , 15-Jan-2025 [Optional][LO	I/Pre-App], 1	14-Feb-2025	
	Synopsis	This Funding Opportunity Announcement from small business concerns (SBCs) prop of novel, evidence-based, FDA-regulated disorders (OUD) and/or stimulant use dis areas, namely: (1) pharmacotherapeutics including software as a medical device. T psychostimulant emergency and offer ne devastating crisis. Small business compar for different indications and are interested the OUD/StUD space are encouraged to a	posing research projects, directed tow medical products addressing the need orders (StUD). Applications received u (small molecules and biologics) and ( his FOA strives to contribute to the eff w medical products for individuals, fa nies that developed currently markete ed in demonstrating that their FDA-reg	ards comme ds of patient under this FC 2) medical th fort against t milies, and c d technologi	ercialization, for the or s suffering from opic DA may fall within two nerapeutic and diagrathe the national opioid a ommunities affected ies or are developing	development bid use to scientific tostic devices nd d by this technologies
124184 <mark>P</mark>	RFA-DA-25-043 Transformative I Polysubstance use in Addiction (RC	Research on the Basic Mechanisms of D1 - Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	DA-23- [(	.7-Jun-2024 Optional][LOI/Pre- \pp]	1,750,000 USD
	Contact Name	Supila Nair PhD				

Contact Name Sunila Nair, PhD

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website Program URL	sunila.nair@mail.nih.gov Link to program URL 17-Jun-2024 [Optional][LOI/Pre-App], 17- This Funding Opportunity Announcement understanding of polysubstance use in ac	t (FOA) will support projects proposing ddiction. These hypothesis-based, explo	oratory proje	ects may investigate	emechanisms
RFA-DA-24-038 - Developing Regu 117771 Solutions for Patients Affected by (OUD/StUD) (R43/R44 - Clinical Tr		National Institute on Drug Abuse/NIH/DHHS		-Jul-2024 ptional][LOI/Pre- pp]	Not Specified
Contact Telephone Contact Email Sponsor Website Program URL	leonardo.angelone@nih.gov Link to program URL			1 E-k 2025	
Deadline Dates (ALL) Synopsis	14-Jul-2024 [Optional][LOI/Pre-App], 13-, This Funding Opportunity Announcement from small business concerns (SBCs) prop of novel, evidence-based, FDA-regulated disorders (OUD) and/or stimulant use dis areas, namely: (1) pharmacotherapeutics including software as a medical device. T psychostimulant emergency and offer ne devastating crisis. Small business compar for different indications and are interested the OUD/StUD space are encouraged to a	t (FOA) encourages Small Business Inno posing research projects, directed towa medical products addressing the needs orders (StUD). Applications received un (small molecules and biologics) and (2 his FOA strives to contribute to the effor w medical products for individuals, fam- nies that developed currently marketed ed in demonstrating that their FDA-regu	ovation Researds commer s of patients nder this FOA ) medical the ort against th nilies, and co I technologie	arch (SBIR) grant ap cialization, for the o suffering from opic A may fall within tw erapeutic and diagr ne national opioid a mmunities affected s or are developing	development bid use o scientific oostic devices, nd l by this s technologies
123712 <u>RFA-DA-25-032 Mechanistic Stu</u>	udies on Social Behavior in Substance Use	National Institute on Drug	RFA- 14	-Jul-2024	Not

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Disorder (R01 Clinical Trial Option	onal)	Abuse/NIH/DHHS	-	Dptional][LOI/Pre- pp]	Specified
Contact Nar	ne Mary Kautz, PhD				
Contact Telephor	ne 301-443-3206				
Contact Em	ail <u>kautzm@nida.nih.gov</u>				
Sponsor Websi	ite				
Program U	RL Link to program URL				
Deadline Dates (AI	LL) 14-Jul-2024 [Optional][LOI/Pre-App], 2	14-Aug-2024			
Synop	comorbidities. This NOFO is intended NIH clinical trials; this may include me NOFO is not intended to support studi sis in animal models. Applications in whic (BESH) should be submitted under the under the companion 'Clinical Trials N Perspectives (PEDP), which will be assi fail to include a PEDP will be considered NOFO instructions carefully and view to	chanistic clinical trials, observation ies designed to test the safety or ch all the research meets the crite e companion NOFO, RFA-DA-25-0 lot Allowed' NOFO, RFA-DA-25-0 essed as part of the scientific and ed incomplete and will be withdra	onal studies, or secor demonstrate the eff eria for Basic Experim 33. Studies involving 34. This NOFO require technical peer revie awn. Applicants are s	ndary analysis of hu icacy of an interven- nental Studies involv animals should be es a Plan for Enhance w evaluation. Appli	man data. This tion, or studies ring Humans submitted ing Diverse cations that
RFA-DA-25-053 Harnessing Ar 123707 <u>Discover Pharmacotherapeutics</u> <u>Clinical Trials Not Allowed</u> )	rtificial Intelligence and Polypharmacolog s for Substance Use Disorders (R41/R42	National Institute on Drug Abuse/NIH/DHHS	DA-25- [0	5-Jun-2024 Optional][LOI/Pre- pp]	Not Specified
Contact Nar	ne Tam Nguyen, Ph.D.				
Contact Telephor	ne 301-451-1203				
Contact Em	ail <u>tam.nguyen@nih.gov</u>				
Contact Em Sponsor Websi					
Sponsor Websi					
Sponsor Websi Program U	ite	25-Jul-2024			

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		intelligend	ce (AI), including machine learn	g research projects directed towards ing (ML), tools, and polypharmacolo treat substance use disorders (SUDs	gy to identif		
123702	FA-DA-25-054 Harnessing Artif Discover Pharmacotherapeutics fo Clinical Trials Not Allowed)			<sup>D</sup> National Institute on Drug Abuse/NIH/DHHS	RFA- DA-25- 054	25-Jun-2024 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Tam Nguy	ven, Ph.D.				
	Contact Telephone	301-451-1	.203				
	Contact Email	tam.nguy	en@nih.gov				
	Sponsor Website						
	Program URL	Link to pro	ogram URL				
	Deadline Dates (ALL)	25-Jun-20	24 [Optional][LOI/Pre-App], 25	-Jul-2024			
	Synopsis	small busi intelligend	ness concerns (SBCs) proposing ce (AI), including machine learn	<ul> <li>encourages Small Business Innova gresearch projects directed towards ing (ML), tools, and polypharmacolo treat substance use disorders (SUDs</li> </ul>	commercia gy to identif	lization to harness art	ficial

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
1/3/18	idies on Social Behavior in Substance Use Studies with Humans (BESH) Required)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA- 25-033	14-Jul-2024 [Optional][LOI/Pre-App]	Not Specified
Contact Name	Mary Kautz, PhD				
Contact Telephone	301-443-3206				
Contact Email	kautzm@nida.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	14-Jul-2024 [Optional][LOI/Pre-App], 14-A	ug-2024			
Synopsis	The purpose of this notice of funding oppo	ortunity (NOFO) is to solicit applicat	ions propos	ing studies that meet the	NIH

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	definition of Basic Experimental Studies in social behavior and its relationships with comorbidities. This NOFO is specifically so "prospective basic science studies involvin and also meet the definition of basic rese human data, or research aiming to examin Trials Optional' NOFO RFA-DA-25-032. Res Trials Not Allowed' NOFO RFA-DA-25-034. be assessed as part of the scientific and te considered incomplete and will be withdr and view the available PEDP guidance ma	the onset, trajectory, and impact o oliciting applications proposing BES ong human participants." These stud arch. Applications proposing obser one specific disease processes shoul search involving animal models sho . This NOFO requires a Plan for En echnical peer review evaluation. Ap awn. Applicants are strongly encou	f Substance Use H research, refer lies fall within th vational studies d be submitted u buld be submitte hancing Diverse oplications that fa	Disorders (SUDs) an red to in NOT-OD-1 e NIH definition of a in humans, seconda under the companio d under the compar Perspectives (PEDP) ail to include a PEDP	d 8-212 as a clinical trial ry analysis of n 'Clinical nion 'Clinical ), which will 9 will be
123719 RFA-DA-25-034 Mechanistic Stu Disorder (R01 Clinical Trials Not A	udies on Social Behavior in Substance Use Allowed)	National Institute on Drug Abuse/NIH/DHHS		Jul-2024 ptional][LOI/Pre-App	2,125,000 o] USD
Contact Name	e Mary Kautz, PhD				
Contact Telephone	301-443-3206				
Contact Email	l <u>kautzm@nida.nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	) 14-Jul-2024 [Optional][LOI/Pre-App], 14-A	Aug-2024			
Synopsis	The purpose of this notice of funding opports research in animal models that integrates complementary approaches to the study of computational model that provides mech and impact of Substance Use Disorders (S research in non-human animal models, in including studies involving human subject observational research in humans, second disease processes or evaluating clinical int DA-25-032. Applications proposing Basic E "Basic Experimental Studies with Humans Diverse Perspectives (PEDP), which will be	approaches across social/cognitive of social behavior, with the goal of anistic insights into social behavior UDs) and comorbidities. This NOF cluding secondary analysis of data is should submit under one of the c dary analysis of human subjects dat terventions should submit under th Experimental Studies involving Hun (BESH) Required" NOFO, RFA-DA-2	e neuroscience w developing a tes and its relations D is intended to from research in companion NOFC a, or research sp the companion Cli nans should be s 25-033. This NO	vith perspectives fro table conceptual or hips with the onset, support basic or tran animal models. App os. Applications with becifically aimed at s nical Trials Optional ubmitted under the FO requires a Plan for	om fields with , trajectory nslational plications studying I NOFO, RFA- companion or Enhancing

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		that fail to include a PEDP will be conside the NOFO instructions carefully and view	•	• •	nts are strongly encou	aged to read
		racterization of Genes or Variants rders (R21/R33 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-23- 041	26-Jul-2024	Not Specified
	Contact Name	John Satterlee Ph.D.				
	Contact Telephone	301-435-1020				
	Contact Email	<u>satterleej@nida.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	26-Jul-2024 , 03-Mar-2025 , 28-Jul-2025				
	Synopsis	The purpose of this initiative is to suppor substance use disorder-relevant phenoty		e and/or char	acterize genes or varia	nts involved in
104639	NIDA Animal Genomics Program (	<u> U01 – Clinical Trial Not Allowed)</u>	National Institute on Drug Abuse/NIH/DHHS	PAR-21- 244	27-Jun-2024	Not Specified
	Contact Name	Amy C. Lossie, PhD				
	Contact Telephone	301-827-6092				
	Contact Email	lossieac@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	27-Jun-2024 , 26-Jul-2024				
	Synopsis	The purpose of the NIDA Animal Genetic underlie: 1. Phenotypes associated with a disorder (SUD) trajectory (e.g. initial/acur abstinence and relapse or recovery); 2. B and other genetically-associated phenoty and behaviors linked with SUD (e.g. anxie examine any type of variant, including sin types of mobile DNA. NIDA encourages a	addictive behaviors and/or vulner, te use, escalation of use, acquisition ehaviors associated with SUD (e.g ypes); and 3. Comorbidities that do ety, stress, poor maternal care, so ngle nucleotide variants (SNVs), in	ability to distin on of toleranc . impulsivity, r emonstrate ge cial defeat, an dels, large and	nct stages along the su e, dependence, uncom novelty seeking, delaye enetic correlations with d other paradigms). Ap d small structural varia	bstance use crolled use, d discounting, phenotypes pplications may nts, and all

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	integrate multi-level 'omics data, delinea genetic or epigenetic variants. NIDA expe the discovery of targets for intervention a aspects of SUD.	cts these studies to uncover novel	mechanisms th	nat contribute to SUD	and facilitate
124329 Developing Digital Therapeutics for Clinical Trial optional)	or Substance Use Disorders (UG3/UH3	National Institute on Drug Abuse/NIH/DHHS	PAR-24- 064	.7-Jul-2024	Not Specified
Contact Telephone	aklinwm@nida.nih.gov				
Program URL	Link to program URL 17-Jul-2024 , 19-Nov-2024 , 26-Mar-2025	, 17-Jul-2025 , 19-Nov-2025 , 26-N	lar-2026 , 17-J	ul-2026 , 19-Nov-2026	
Synopsis	The purpose of this Funding Opportunity to treat Substance Use Disorders (SUDs). mobile, web, or other software-based pla authorization of DTx can play an importan objective of this FOA is to move DTx to the FDA authorized, disseminated treatments and testing of new DTx or existing DTx de phases. The UG3 phase, for up to 2 years, end of the period. The UH3 phase is to pr UG3. UG3 projects that meet their milest UH3 phase. Investigators submitting to th	Advances in technology offer unpre- tiforms designed to deliver treatment nt role in increasing the availability eir next step in the development p s for SUDs. Applications may focus veloped for other indications. The is designed to support a project w ovide funding for up to 3 additional ones will be administratively considered.	ecedented opp ents that are sa of treatments rocess, with th on the pre-clin UG3/UH3 Coop ith specific mil I years followin dered by NIDA	ortunities to develop ife and effective for SU to patients with SUD. e ultimate goal of gen ical and/or clinical dev perative Agreement in estones to be accomp ng successful completi	clinical-grade JD. FDA The primary erating new, relopment volves 2 lished by the on of the
RFA-DA-25-035 Using Neuromo 125324 Pathophysiology Between Substa Clinical Trial Required)	odulation to Characterize the Continuum on nce Use and Mental Health Disorders (R01			.5-Jul-2024 Optional][LOI/Pre-App	Not ] Specified
Contact Telephone	John Fedota, Ph.D. 301-402-0812 john.fedota@nih.gov				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jul-2024 [Optional][LOI/Pre-App], 15-	-Aug-2024			
	Synopsis	This notice of funding opportunity (NOF effects of neuromodulation on brain circ disorder (MHD). Proposed studies are en pathophysiology related to SUD and MH neuromodulation in human participants assessed as part of the scientific and tec considered incomplete and will be witho and view the available PEDP guidance m	cuits and behaviors relevant to both xpected to provide a mechanistic pe D through the causal manipulation o . This NOFO requires a Plan for Enha hnical peer review evaluation. Appli- drawn. Applicants are strongly encod	substance use di rspective on the of relevant circuit ncing Diverse Pe cations that fail t	sorder (SUD) and i shared and unique t(s) via targeted rspectives (PEDP), o include a PEDP v	mental health e which will be vill be
109744		ases and Disorders Across the Lifespan: aining Award (NCD-LIFESPAN) (D43 Clinic	al National Institutes of Health/DHHS	PAR-22- 104 15-	Jul-2024	Not Specified
	Contact Name	Kathleen Michels, Ph.D.				
	Contact Telephone	301-496-1653				
	Contact Email	FIC-NCD@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jul-2024				
	Synopsis	This funding opportunity announcement Disorders Across the Lifespan: Fogarty Ir research training programs in low-and m Applications may be for collaborations b institutions if there is a previous track re LMIC institution. The proposed institution research capacity of the LMIC institution the lifespan, with the long-range goal of countries. Interdisciplinary research train main focus of research training covered	nternational Research Training Awar hiddle-income countries (LMICs, as d between institutions in the U.S and a cord of externally funded research a onal research training program is exp is, and to train in-country experts to developing and implementing evide ning that cuts across NCDs is encour	d (NCD-LIFESPAN lefined by the Wo n eligible LMIC of and/or research t bected to sustain develop and con ence-based interv aged. However, f	I) D43 program for orld Bank classificat r may involve just raining programs ably strengthen the duct research on ventions relevant to for more topical approximant to	r institutional ation system). LMIC by the lead e NCD NCDs across o their oplications, the

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding mount
	the participating NIH ICs, other than FIC, included as secondary and complementar of Trainees (D43) proposing to serve as th clinical trial; or proposing to gain research and career development.	ry focus areas. This Funding Opportune lead investigator of an independe	unity Announce ent clinical trial;	ment (FOA) allows ap or proposing a separ	pointment ate ancillary
	of Co-occurring conditions across the indromE (INCLUDE) Clinical Trial Readiness	National Institutes of Health/DHHS		-Jun-2024 otional][LOI/Pre-App]	275,000 USD
Contact Telephon Contact Ema Sponsor Websit Program UR	il <u>ryanl@mail.nih.gov</u> e L <u>Link to program URL</u>				
	.) 01-Jun-2024 [Optional][LOI/Pre-App], 01- The NIH INvestigation of Co-occurring con to improve health and quality-of-life for i invites researchers to submit applications in Down syndrome. This initiative seeks a efficient and effective movement of cand co-occurring conditions, and to increase t clinical outcome assessment measures, d defining the presentation and course of t of future clinical trials.	nditions across the Lifespan to Unden ndividuals with Down syndrome. Th s for support of clinical projects that pplications that are intended to faci lidate therapeutics or diagnostics to heir likelihood of success through d evelopment and testing of novel tria	is Funding Oppo address critical litate Down syn wards clinical tr evelopment and al methods and	ortunity Announceme needs for clinical tria drome research by e ials for Down syndroi d testing of biomarke recruitment strategie	ent (FOA) Il readiness nabling me and its rs and es, or by
	e Research Award for the INCLUDE onditions across the Lifespan to Understand linical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-OD- 22-009 01-	-Jul-2024	Not Specified
Contact Telephon	e Charlene Schramm, Ph.D. e 301-402-3793 il <u>schrammc@nih.gov</u>				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL)	Link to program URL				
	Synopsis	The NIH INvestigation of Co-occurring cor to improve health and quality-of-life for in soliciting Transformative Research Award groundbreaking, exceptionally innovative scientific paradigms, establish entirely new to Down syndrome. For the program to su	ndividuals with Down syndrome. The applications to support individual s , original, and/or unconventional re w and improved clinical approaches upport the best possible researchers search workforce. Individuals from co fill spectrum of eligible institutions in prtunity Announcement. Application rring conditions. No preliminary dat	is Funding Oppo cientists or grou search that has f , or develop tran s and research, a liverse backgrou n all geographic l ns are welcome i a are required. P	rtunity Announce ps of scientists pro- the potential to cr asformative techn applications are so nds, including the locations are stron n all topics relevant projects must cleant	ment (FOA) is oposing eate new ologies related ught which use from ngly nt to Down rly
110290		evelopment for Co-Occurring Conditions in Phased Awards for INCLUDE (R61/R33	National Institutes of Health/DHHS		Jun-2024 tional][LOI/Pre-Aj	Not op] Specified
	Contact Telephone	ryanl@mail.nih.gov				
	-	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2024 [Optional][LOI/Pre-App], 01-		rational Davids	dromE (INCLUDE	
	Synopsis	The NIH INvestigation of Co-occurring cor to improve health and quality-of-life for in encourages Exploratory/Developmental P trials to treat critical and co-occurring hea should be milestone-driven. The total pro years. This FOA provides support for up to	ndividuals with Down syndrome. Th hased Innovation (R61/R33) grant a alth conditions in individuals with Do ject period for an application submi	is Funding Oppo opplications to su own syndrome. T tted in response	rtunity Announce upport developme The proposed rese to this FOA may	ment (FOA) ent of clinical earch aims not exceed five

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		by possible transition to clinical trial sup exceed five years. This FOA requires mea		ough the total du	uration of the award	d may not
		Grants for Analysis, Curation, and/or ed Research Data for the INCLUDE Project	National Institutes of Health/DHHS		-Jun-2024 ptional][LOI/Pre-Ap	200,000 p] USD
	Contact Name	Huiqing Li, PhD				
	Contact Telephone	301-435-0554				
	Contact Email	Huiqing.Li@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2024 [Optional][LOI/Pre-App], 01	-Jul-2024			
	Synopsis	to improve health and quality-of-life for research projects focused on analyses of research, with an emphasis on elucidatir Development of approaches, tools, or al data sharing within the research commu	genomics other -omics, clinical and ng the underlying etiologies of risk a gorithms appropriate for analyzing o	phenotypic data nd resiliencies to lata relevant to l	asets related to Dov co-occurring healt Down syndrome an	vn syndrome h conditions.
110045	RFA-HG-23-017 Investigator-Ini	tiated Research in Genomics and Health	National Institutes of	RFA-HG- 08	-Jun-2024	2,500,000
IIGUZS	Equity (R01 Clinical Trial Optional		Health/DHHS	23-017 [O	ptional][LOI/Pre-Ap	p] USD
	Contact Name	Lucia Hindorff, Ph.D.				
	Contact Telephone	240-271-1509				
	Contact Email	hindorffl@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jun-2024 [Optional][LOI/Pre-App], 08	-Jul-2024 , 08-Jun-2025 [Optional][L	.OI/Pre-App], 08	-Jul-2025	
	Synopsis	The purpose of this initiative is to support goal of developing approaches, generati advance the equitable use of genomics t	ng and disseminating data, and impl	ementing metric	cs or interventions t	hat will

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding mount
	generalizable research in genomics and h enhancing diverse perspectives. Applicati including those from groups traditionally described in the NIH Notice of Interest in (NOFO) requires a Plan for Enhancing Div not be reviewed.	ions supporting New or Early Stage underrepresented in the biomedic Diversity (NOT-OD-20-031), are en	Investigators f al, behavioral, couraged. This	from diverse backgrour and clinical research w Notice of Funding Opp	ids, orkforce, as portunity
RFA-MH-25-140 Streamlining 122829 Living with HIV in Low- and Mide Optional)	MentalHhealth Interventions for Youth dle-Income Countries (R01 Clinical Trial	National Institutes of Health/DHHS		13-Jul-2024 [Optional][LOI/Pre-App	Not ] Specified
Contact Nam	ne Teri Senn, Ph.D.				
Contact Telephor	ne 301-605-4146				
Contact Ema	ail <u>teri.senn@nih.gov</u>				
Sponsor Websit	te				
Program Uf	RL Link to program URL				
Deadline Dates (AL	L) 13-Jul-2024 [Optional][LOI/Pre-App], 12-	Aug-2024			
Synops	There is a practical need to develop streat can be feasibly implemented and scaled use novel methods to streamline evidence to deliver while still leading to clinically m	up in low- and middle-income coun e-based mental health intervention	tries (LMICs). <sup>-</sup> ns for YLWH sc	The purpose of this init that they require fewe	ative is to
114127 RFA-OD-22-026 Pathway to In	dependence Award in Tobacco Regulatory	National Institutes of	RFA-OD-	13-May-2024	Not
Research (K99/R00 - Independe	nt Clinical Trial Required )	Health/DHHS	22-026	[Optional][LOI/Pre-App	] Specified
Contact Nam	ne Sergei Radaev, PhD				
Contact Telephor	1e 240-276-5630				
	all an analism da au Oralla anno				
Contact Ema	ail <u>sergei.radaev@nih.gov</u>				
Contact Ema Sponsor Websit					
Sponsor Websit					
Sponsor Websit Program UF	te	2-Jul-2024 , 11-Jan-2025 [Optional]	[LOI/Pre-App],	12-Mar-2025	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		strong cohort of new and talented indep evaluation of regulations on tobacco pro facilitate a timely transition of outstandin mentored, postdoctoral research positio provide independent research support d research careers. Research projects must Drug Administration (FDA) Center for Tol Control Act (FSPTCA), Public Law 111-31. through the CTP and the FSPTCA (P.L. 11 applicants proposing to serve as the lead separate ancillary study to an existing tri- independent clinical trial, or proposing to companion FOA (RFA-OD-22-025).	oduct manufacturing, distribution, an ng postdoctoral researchers with a r ons to independent, tenure-track or e luring this transition in order to help t address the research priorities rela bacco Products (CTP) as mandated b . The awards under this FOA will be a 1-31). This Funding Opportunity Ann d investigator of an independent clini al, as part of their research and care	d marketing. The esearch and/or equivalent facult awardees launce ted to the regul y the Family Sm administered by ouncement (FC ical trial, a clinice er development	nis program is design clinical doctorate of ty positions. This pro- ch competitive, inde- latory authority of the noking Prevention a v NIH using funds m DA) is designed spec- cal trial feasibility st t. Applicants not pl	ned to legree from rogram will ependent the Food and and Tobacco ade available cifically for tudy, or a anning an
11/11/6	RFA-OD-22-025 Pathway to Ind Research (K99/R00 - Independent	lependence Award in Tobacco Regulatory t Clinical Trial Not Allowed)	National Institutes of Health/DHHS		-May-2024 ptional][LOI/Pre-A	Not p] Specified
	Contact Name	Sergei Radaev, PhD				
	Contact Telephone	240-276-5630				
	Contact Email	l <u>sergei.radaev@nih.gov</u>				
	Sponsor Website	<u>د</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-May-2024 [Optional][LOI/Pre-App], 1				
	Synopsis	The purpose of the Pathway to Independ strong cohort of new and talented indep evaluation of regulations on tobacco pro facilitate a timely transition of outstandin mentored, postdoctoral research positio provide independent NIH research suppor research careers. Research projects must Drug Administration (FDA) Center for Tol Control Act (FSPTCA), Public Law 111-31. through the CTP and the FSPTCA (P.L. 11	endent investigators conducting res oduct manufacturing, distribution, an ng postdoctoral researchers with a r ons to independent, tenure-track or e ort during this transition in order to l t address the research priorities rela bacco Products (CTP) as mandated b . The awards under this FOA will be a	earch that will i d marketing. The search and/or quivalent facult nelp awardees l ted to the regul y the Family Sm administered by	nform the develop nis program is desig clinical doctorate of ty positions. This pr aunch competitive latory authority of noking Prevention a NIH using funds m	ment and gned to legree from rogram will , independent the Food and and Tobacco ade available

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	<sup>E</sup> unding Amount
		candidates proposing research that doe ancillary study to a clinical trial. Applicat mentor or co-mentor. Those proposing companion FOA (RFA-OD-22-026).	nts to this FOA are permitted to prop	ose research ex	perience in a clinical	trial led by a
11/11/5		earch Scientist Career Development Awar			-May-2024	Not
<u>ii4125</u>	in Tobacco Regulatory Research (	K01 - Independent Clinical Trial Required	) Health/DHHS	22-024 [O	ptional][LOI/Pre-App	] Specified
	Contact Name	Sergei Radaev, PhD				
	Contact Telephone	240-276-5630				
		<u>sergei.radaev@nih.gov</u>				
	Sponsor Website					
		Link to program URL				
	Deadline Dates (ALL)	13-May-2024 [Optional][LOI/Pre-App],		•••		
	Synopsis	The purpose of the Mentored Research provide support and protected time (th biomedical, behavioral, and social scien tobacco product manufacturing, distribu- must address the research priorities rela- Tobacco Products (CTP) as mandated by 31. The awards under this FOA will be a 111-31). This Funding Opportunity Anno- investigator of an independent clinical t part of their research and career develo- research experience in a clinical trial lec-	ree, four, or five years) for an intensi ce research that will inform the deve ution, and marketing and that will lea ated to the regulatory authority of the the Family Smoking Prevention and dministered by NIH using funds mad puncement (FOA) is designed specific rial, a clinical trial feasibility study, o pment. Applicants not planning an ir	ve, supervised ca lopment and evant ad to research in the Food and Drug Tobacco Contro the available throut cally for applican the separate anci- the pendent clini	areer development e aluation of regulation dependence. Resear g Administration (FD, I Act (FSPTCA), Publi- gh the CTP and the F ts proposing to serve llary study to an exis cal trial, or proposing	experience in ns on ch projects A) Center for c Law 111- ESPTCA (P.L. e as the lead ting trial, as g to gain
TIGHTS	Native American Research Center Optional)	rs for Health (NARCH) (S06 Clinical Trial	National Institutes of Health/DHHS	PAR-23- 166 06	-Jul-2024	6,500,000 USD
	Contact Name	Sheila A. Caldwell, PhD				
	Contact Telephone					
	Contact Email	caldwells@mail.nih.gov				
	Sponsor Website	2				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	The p	-2024 , 07-Aug-2024 , 08-Jul-2025 urpose of the Native American Res	, 07-Aug-2025 , 08-Jul-2026 , 07-Aug earch Centers for Health (NARCH) p	rogram is to fund			
	Synopsis		al colleges or universities, tribal heal nealth-related research, research ca		-		
122431	RFA-OD-24-006 Coordinating Center to Interventions that Address Social Deterr that Experience Health Disparities (U24,	ninants of Health in Populations	e National Institutes of Health/DHHS		-Jul-2024 ptional][LOI/Pre-App	7,000,000 ] USD	
	Contact Name Jennif	er Alvidrez, PhD					
	Contact Telephone 301-8	27-0071					
	Contact Email <mark>Jennif</mark>	er.alvidrez@nih.gov					
	Sponsor Website						
	Program URL Link to	program URL					
	Deadline Dates (ALL) 05-Jul	-2024 [Optional][LOI/Pre-App], 05-	Aug-2024				
	The purpose of this NOFO is to seek applications for a Coordinating Center (CC) for the Multi-Sectoral Preventive Interventions (MSPI) Research Network. Members of the Multi-Sectoral Preventive Interventions (MSPI) Research including the CC and separately funded research projects, will work collaboratively with the NIH to test prospecti sectoral preventive interventions that address social determinants of health in populations that experience healt The MSPI Research Network will include the CC funded under this Cooperative Agreement and up to 10 Research funded under the companion UG3/UH3 Phased Cooperative Agreement NOFO, PAR-24-053, Multi-sectoral preve interventions that address social determinants of health in populations that experience health disparities. The CC overarching support and guidance to the network in three domains: (1) administration, coordination, and commu methodology, data, and analytic support and consultation; and (3) community and other collaborator engagemen dissemination support. It is important that applicants for the CC also read the companion NOFO to understand the mission and structure of the research network.						
109253	RFA-NS-22-049 BRAIN Initiative Conne CONNECTS): Specialized Projects for Sca Not Allowed)	· · · · · · · · · · · · · · · · · · ·	National Institutes of al Health/DHHS		-Jun-2024 ptional][LOI/Pre-App	Not ) Specified	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Edmund Talley				
	Contact Telephone	301-496-1917				
	Contact Email	BRAIN-CONNECTS-Inquiries@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Jun-2024 [Optional][LOI/Pre-App], 13	-Jul-2024			
	Synopsis	generate comprehensive atlases of brain Projects using other species are also perr can be generalized across species. Applic integration, dissemination, and interpret precise, and more cost-effective generation develop distinct capabilities and compete companion FOAs, with aims of further de and potentially risky approaches. Funded Specialized Projects from this FOA, and C aimed at developing the capabilities to generation.	mitted, if their use is well justified an ations may address any aspect(s) of a ation of brain connectivity and assoc ion and interpretation of brain-wide encies that may be expected to comp eveloping and optimizing current tech projects will be integrated into the B comprehensive Centers from its comp	d the goal is tes data collection, iated data pipe wiring diagrams plement Compr nologies, or pr BRAIN CONNEC panion annound	st and validate app reconstruction, ar lines, to enable fas s. Proposals are en ehensive Centers s oposing entirely ne TS Network, consis cements, as a coord	roaches that alysis, iter, more couraged to olicited by the ew, disruptive sting of other dinated effort
F	RFA-OD-21-007 INvestigation of	Co-occurring conditions across the				
106670 -	Lifespan to Understand Down syn		National Institutes of		-Jun-2024	275,000
	Exploratory/Developmental Resea Allowed)	arch Grant Award (R21 Clinical Trial Not	Health/DHHS	21-007 [Oj	ptional][LOI/Pre-A	opj USD
	Contact Name	Melissa A. Parisi, M.D., Ph.D.				
	Contact Telephone					
	Contact Email	parisima@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2024 [Optional][LOI/Pre-App], 01	-Jul-2024			
	Synopsis	This Funding Opportunity Announcemen developmental research projects that ad	t (FOA) invites researchers to submit dress critical needs for Down syndro	applications fo me projects, as	r support of new e articulated in the	xploratory ar NCLUDE

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	(INvestigation of Co-occurring condition such projects could assess the feasibility to enhance health-related research. And methodology to explore a new scientific a particular area, or to the development a major impact on a field of biomedical,	of a novel area of investigation or a other example could include the uni area. These studies may involve co of novel techniques, agents, metho	new experimen que and innovati nsiderable risk bu	tal system that has t ve use of an existing ut may lead to a brea	he potential akthrough in
112126 RFA-TR-22-030 Pilot Projects Inv Associated with Rare Diseases (R0		National Institutes of Health/DHHS		-Jun-2024 ptional][LOI/Pre-App	100,000 ] USD
Contact Name	Karlie Sharma, Ph.D.				
Contact Telephone	301-451-4965				
Contact Email	DruggableGenome@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Jun-2024 [Optional][LOI/Pre-App], 15	5-Jul-2024			
Synopsis	The purpose of this funding opportunity understudied proteins associated with ra- eligible understudied protein(s). A list of have a known association with a rare dis associated with rare diseases and provid work to further the characterization of u	are diseases. Awards will support ge eligible proteins is provided and ar sease. This FOA is intended to jumps le applicants with sufficient funding	eneration of preli e members of dr start research on to perform basic	minary data and/or uggable protein fam understudied prote	tools around ilies that ins that are
122378 RFA-HG-23-032 Advancing Genc Optional)	omic Medicine Research (R01 Clinical Tria	al National Institutes of Health/DHHS	RFA-HG- 23-032 08	-Jul-2024	2,500,000 USD
Contact Name	Christine Chang, MPH				
Contact Telephone					
	changcq@mail.nih.gov				
Sponsor Website					
	Link to program URL				
-	08-Jul-2024 , 11-Feb-2025				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
,	Synopsis	This NOFO solicits proposals that stimulat implement the use and sharing of genom of racial/ethnic background or socioecond diverse teams working together and capit teams. There are many benefits that flow enhancing global competitiveness, contril advancing the likelihood that underserved To support the best science, the NIH enco perspectives include but are not limited to researchers from fields such as computat well as bioethics. Engagement from differ focused, minority-serving, community-ba heterogeneity. Investigators and teams of diverse backgrounds, including groups tra- workforce (see NOT-OD-20-031), such as disadvantaged backgrounds, and women. career investigators. This NOFO requires the scientific and technical peer review ev- will be withdrawn. Applicants are strongly guidance material.	ic information and technologies in omic status. Plan for Enhancing Di alizing on innovative ideas and dis from a diverse scientific workford outing to robust learning environn d populations participate in, and b ourages inclusivity in research. Exa o: Transdisciplinary research proj ional biology, physics, engineering ent types of institutions and orga sed). Individual applications and p omposed of researchers at different ditionally underrepresented in th underrepresented racial and ethn Opportunities to enhance the re a Plan for Enhancing Diverse Pers valuation. Applications that fail to	a clinical care prov verse Perspective stinct perspective ce, including: foste ments, improving for penefit from resea imples of structure ects and collabora g, mathematics, co nizations (e.g., resp partnerships that ent career stages. e biomedical, beh ic groups, those w search environme pectives (PEDP), w include a PEDP w	vided to all person s The NIH recogni s outperform hom ering scientific inne- the quality of the r rch, and enhancin es that promote d ations among neur omputer and data search-intensive, u enhance geograph Participation of in avioral, and clinica vith disabilities, the ent to benefit early vhich will be assess ill be considered in	s irrespective zes that ogeneous ovation, esearch, g public trust. verse oscientists and sciences, as ndergraduate- ic and regiona dividuals from a research ose from - and mid- sed as part of acomplete and
	RFA-HG-23-033 Advancing Gen Optional)	omic Medicine Research (R21 Clinical Trial	National Institutes of Health/DHHS	RFA-HG- 23-033 08-	Jul-2024	750,000 USD
	Contact Name	Christine Chang, MPH				
	Contact Telephone	240-552-1208				
	Contact Email	<u>changcq@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jul-2024 , 11-Feb-2025				
	Synopsis	This NOFO solicits proposals that stimulat implement the use and sharing of genom racial/ethnic background or socioeconom	ic information and technologies ir	-		

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding Mount
114124 RFA-OD-22-023 Mentored Resolution Allowed)	earch Scientist Career Development Award (K01 - Independent Clinical Trial Not	National Institutes of Health/DHHS		-May-2024 otional][LOI/Pre-App	Not ] Specified
Contact Name	e Sergei Radaev, PhD				
Contact Telephone	240-276-5630				
Contact Emai	l <u>sergei.radaev@nih.gov</u>				
Sponsor Website					
Program UR	Link to program URL				
Deadline Dates (ALL	) 13-May-2024 [Optional][LOI/Pre-App], 12	2-Jul-2024 , 11-Jan-2025 [Optional][L	OI/Pre-App], 12	2-Mar-2025	
	The purpose of the Mentored Research S provide support and protected time (thre biomedical, behavioral, and social science tobacco product manufacturing, distribut	ee, four, or five years) for an intensive e research that will inform the develo ion, and marketing and that will lead	e, supervised ca opment and eva d to research ind	areer development e aluation of regulation dependence. Resear	xperience in ns on
Synopsi	must address the research priorities relat Tobacco Products (CTP) as mandated by to 31. The awards under this FOA will be add 111-31). This Funding Opportunity Annou not involve leading an independent clinic Applicants to this FOA are permitted to p Those proposing a clinical trial or an ancil 22-024).	the Family Smoking Prevention and T ministered by NIH using funds made incement (FOA) is designed specifica al trial, a clinical trial feasibility study ropose research experience in a clini	obacco Control available throu Ily for candidate , or an ancillary cal trial led by a	Act (FSPTCA), Public gh the CTP and the F es proposing researc study to a clinical tr a mentor or co-ment	E Law 111- SPTCA (P.L. That does tial. or.
119046 RFA-HG-23-018Investigator-Ini	Tobacco Products (CTP) as mandated by to 31. The awards under this FOA will be add 111-31). This Funding Opportunity Annou not involve leading an independent clinic Applicants to this FOA are permitted to p Those proposing a clinical trial or an ancil 22-024). tiated Research in Genomics and Health	the Family Smoking Prevention and T ministered by NIH using funds made incement (FOA) is designed specifica al trial, a clinical trial feasibility study ropose research experience in a clini lary clinical trial as lead investigator, National Institutes of	obacco Control available throu Ily for candidate o, or an ancillary cal trial led by a should apply to RFA-HG- 08-	Act (FSPTCA), Public gh the CTP and the F es proposing researc y study to a clinical tr a mentor or co-ment o the companion FOA -Jun-2024	E Law 111- SPTCA (P.L. th that does tial. or. A (RFA-OD- 400,000
119046 RFA-HG-23-018Investigator-Ini Equity (R21 Clinical Trial Optional	Tobacco Products (CTP) as mandated by to 31. The awards under this FOA will be add 111-31). This Funding Opportunity Annou not involve leading an independent clinic Applicants to this FOA are permitted to p Those proposing a clinical trial or an ancil 22-024). tiated Research in Genomics and Health	the Family Smoking Prevention and T ministered by NIH using funds made incement (FOA) is designed specifica al trial, a clinical trial feasibility study ropose research experience in a clini lary clinical trial as lead investigator,	obacco Control available throu Ily for candidate o, or an ancillary cal trial led by a should apply to RFA-HG- 08-	Act (FSPTCA), Public gh the CTP and the F es proposing researc y study to a clinical tr a mentor or co-ment o the companion FOA	E Law 111- SPTCA (P.L. th that does tial. or. A (RFA-OD- 400,000
119046 RFA-HG-23-018Investigator-Ini Equity (R21 Clinical Trial Optional Contact Name	Tobacco Products (CTP) as mandated by to 31. The awards under this FOA will be add 111-31). This Funding Opportunity Annou not involve leading an independent clinic Applicants to this FOA are permitted to p Those proposing a clinical trial or an ancil 22-024). tiated Research in Genomics and Health I)	the Family Smoking Prevention and T ministered by NIH using funds made incement (FOA) is designed specifica al trial, a clinical trial feasibility study ropose research experience in a clini lary clinical trial as lead investigator, National Institutes of	obacco Control available throu Ily for candidate o, or an ancillary cal trial led by a should apply to RFA-HG- 08-	Act (FSPTCA), Public gh the CTP and the F es proposing researc y study to a clinical tr a mentor or co-ment o the companion FOA -Jun-2024	E Law 111- SPTCA (P.L. th that does tial. or. A (RFA-OD- 400,000
119046 RFA-HG-23-018Investigator-Ini Equity (R21 Clinical Trial Optiona Contact Name Contact Telephone	Tobacco Products (CTP) as mandated by to 31. The awards under this FOA will be add 111-31). This Funding Opportunity Annou not involve leading an independent clinic Applicants to this FOA are permitted to p Those proposing a clinical trial or an ancil 22-024). tiated Research in Genomics and Health I) Lucia Hindorff, Ph.D. 240-271-1509	the Family Smoking Prevention and T ministered by NIH using funds made incement (FOA) is designed specifica al trial, a clinical trial feasibility study ropose research experience in a clini lary clinical trial as lead investigator, National Institutes of	obacco Control available throu Ily for candidate o, or an ancillary cal trial led by a should apply to RFA-HG- 08-	Act (FSPTCA), Public gh the CTP and the F es proposing researc y study to a clinical tr a mentor or co-ment o the companion FOA -Jun-2024	E Law 111- SPTCA (P.L. th that does tial. or. A (RFA-OD- 400,000
119046 RFA-HG-23-018Investigator-Ini Equity (R21 Clinical Trial Optiona Contact Name Contact Telephone Contact Emai	Tobacco Products (CTP) as mandated by to 31. The awards under this FOA will be add 111-31). This Funding Opportunity Annou not involve leading an independent clinic Applicants to this FOA are permitted to p Those proposing a clinical trial or an ancil 22-024). tiated Research in Genomics and Health Lucia Hindorff, Ph.D. 240-271-1509 hindorffl@mail.nih.gov	the Family Smoking Prevention and T ministered by NIH using funds made incement (FOA) is designed specifica al trial, a clinical trial feasibility study ropose research experience in a clini lary clinical trial as lead investigator, National Institutes of	obacco Control available throu Ily for candidate o, or an ancillary cal trial led by a should apply to RFA-HG- 08-	Act (FSPTCA), Public gh the CTP and the F es proposing researc y study to a clinical tr a mentor or co-ment o the companion FOA -Jun-2024	E Law 111- SPTCA (P.L. th that does tial. or. A (RFA-OD- 400,000
119046       RFA-HG-23-018Investigator-InitEquity (R21 Clinical Trial Optional Contact Name Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website)	Tobacco Products (CTP) as mandated by to 31. The awards under this FOA will be add 111-31). This Funding Opportunity Annou not involve leading an independent clinic Applicants to this FOA are permitted to p Those proposing a clinical trial or an ancil 22-024). tiated Research in Genomics and Health 1) Lucia Hindorff, Ph.D. 240-271-1509 hindorffl@mail.nih.gov	the Family Smoking Prevention and T ministered by NIH using funds made incement (FOA) is designed specifica al trial, a clinical trial feasibility study ropose research experience in a clini lary clinical trial as lead investigator, National Institutes of	obacco Control available throu Ily for candidate o, or an ancillary cal trial led by a should apply to RFA-HG- 08-	Act (FSPTCA), Public gh the CTP and the F es proposing researc y study to a clinical tr a mentor or co-ment o the companion FOA -Jun-2024	E Law 111- SPTCA (P.L. th that does tial. or. A (RFA-OD- 400,000
119046 RFA-HG-23-018Investigator-Ini Equity (R21 Clinical Trial Optional Contact Name Contact Telephone Contact Emai Sponsor Website Program UR	Tobacco Products (CTP) as mandated by to 31. The awards under this FOA will be add 111-31). This Funding Opportunity Annou not involve leading an independent clinic Applicants to this FOA are permitted to p Those proposing a clinical trial or an ancil 22-024). tiated Research in Genomics and Health Lucia Hindorff, Ph.D. 240-271-1509 hindorffl@mail.nih.gov	the Family Smoking Prevention and T ministered by NIH using funds made incement (FOA) is designed specifica al trial, a clinical trial feasibility study ropose research experience in a clini lary clinical trial as lead investigator, National Institutes of Health/DHHS	obacco Control available throu lly for candidate , or an ancillary cal trial led by a should apply to RFA-HG- 08- 23-018 [Op	Act (FSPTCA), Public gh the CTP and the F es proposing researc y study to a clinical tr a mentor or co-ment o the companion FO/ -Jun-2024 otional][LOI/Pre-App	E Law 111- SPTCA (P.L. th that does tial. or. A (RFA-OD- 400,000

SPIN ID	Program Title	Sponsor Nam	ie	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	goal of developing appr advance the equitable u generalizable research i enhancing diverse persp be carried out in a short including pilot and feasi development of researc Stage Investigators from behavioral, and clinical encouraged. This Notice	oaches, generatin use of genomics to n genomics and h pectives. This R21 t period of time w bility studies; seco ch methodology; a n diverse backgrou research workford e of Funding Oppo	t investigator-initiated research in g g and disseminating data, and imple o improve health in U.S. populations ealth equity spanning across genom Notice of Funding Opportunity (NOF ith limited resources. The R21 grant ondary analysis of existing data; sma and development of new research te unds, including those from groups to ce, as described in the NIH Notice of rtunity (NOFO) requires a Plan for E EDP will not be reviewed.	ementing metr . Awardees wi hic research are TO) will suppor t mechanism su all, self-contair echnology. App raditionally und Interest in Div	ics or interventions Il conduct innovative eas and will incorpor t small research pro upports different typ ned research projects plications supporting derrepresented in the versity (NOT-OD-20-0	that will a and rate a plan for jects that can pes of projects s; New or Early be biomedical, D31), are
	Assessment of Climate at Institutic Allowed)	ons (ACt) Award (RC2 - C	<u>Clinical Trial Not</u>	National Institutes of Health/DHHS	PAR-24- 038	1-Jul-2024	1,250,000 USD
		H. Nelson Aguila, D.V.M	l.				
	Contact Telephone	240-276-6170					
	Contact Email	aguilah@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
			-	Pre-App], 01-Jul-2025 , 20-Jan-2026	-		
	Synopsis	assessments using valid retention, and advanced (see NIH Interest in Dive attitudes, and concerns should provide a founda	ated survey instrument of faculty, in ersity). The plans f , about, for examp ation for the deve	oportunity (NOFO) is to solicit applie iments and to develop action plans icluding those from groups underre for self-studies should lead to institu- ole, inequities, micro-aggressions, ir lopment of an action plan to enhan g, retention, and advancement of fa	for positive ch presented in b utional culture nstitutional rac ce diversity, ec	ange in the recruitm iomedical and behav change by identifyin ism, and bias. The se	ent, hiring, vioral researc g perception elf-studies
1 /10/11 -	Leveraging Extant Data to Underst Talking Children (R21 Clinical Trial		jectories of Late	National Institutes of Health/DHHS	PAR-24- 045	9-Jul-2024	275,000 USD
	Contact Name	Holly Storkel, PhD, CCC-	SLP				

Icahn School of Medicine at Mount Sinai

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	301-451-6842				
Contact Email	holly.storkel@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	19-Jul-2024 , 19-Nov-2024				
Synopsis	The National Institutes of Health (NIH) Ta better understand early language learnin understanding of the developmental traj shared data resources to aid in identifyin exploring potential underlying mechanism	g and delay. NIH TALK invites applic ectories of late talking children by le g patterns and predictors of develop	ations for resear everaging existin	ch projects that ai g data and creatin	m to further g open and
122019 Information and Practice Needs R Clinical Trial Not Allowed)	elevant to Late Talking Children (R21	National Institutes of Health/DHHS	PAR-24- 046 19-	Jul-2024	275,000 USD
Contact Name	Holly Storkel, PhD, CCC-SLP				
Contact Telephone	· · ·				
Contact Email	holly.storkel@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	19-Jul-2024 , 19-Nov-2024				
Synopsis	The National Institutes of Health (NIH) Ta better understand early language learnin understand the information and practice talking children and to determine whethe with rigorous qualitative research and div the-science information and practice to t	g and delay. NIH TALK invites applic needs of caregivers, professionals, er those needs are being effectively verse research teams are needed to	ations for resear and other invest met. Communit enrich our unde	ch projects that ai ed parties who su y engaged researc rstanding of how t	m to better oport late n combined
	vork (BPN): Biologic-based Drug Discovery f the Nervous System (UG3/UH3 Clinical	A National Institutes of Health/DHHS	PAR-21- 163 07-	May-2024	Not Specified

Contact Name Ann-Marie Broome, Ph.D. MBA

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
Contact Telephone	301-496-1779							
Contact Email	ann-marie.broome@nih.gov							
Sponsor Website								
Program URL	ink to program URL							
Deadline Dates (ALL)	07-May-2024 , 15-Jul-2024 , 19-Aug-2024							
Synopsis	(FOA) supports preclinical discovery and including, but not limited to, large biolog (i.e., oligonucleotide- and viral-based), ce therapies). Applicants will collaborate wi organizations (CROs) that specialize in m Biologics awardee institutions retain the	The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based thera discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity An FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biolog ncluding, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbion herapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contro organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical t Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-E contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidate in this program.						
110353 Cancer Epidemiology Cohorts: Bui Cohorts (U01 Clinical Trial Not Allo	ilding the Next Generation of Research owed)	National Institutes of Health/DHHS	PAR-22- 29 161	-Jul-2024	Not Specified			
Contact Name	Tram Kim Lam, Ph.D., MPH							
Contact Telephone	240-276-6970							
Contact Email	<u>lamt@nih.gov</u>							
Sponsor Website								
Program URL	Link to program URL							
Deadline Dates (ALL)	29-Jul-2024 , 28-Feb-2025							
Synopsis	Through this funding opportunity announ Epidemiology Cohorts: Building the Next seeks to support initiating and building the specific knowledge gaps in cancer etiolog initiate and build cancer epidemiology co in relation to cancer risks and outcomes understudied populations (e.g., racial/et	Generation of Research Cohorts" P. he next generation of population-ba gy and survivorship. Specifically, it w phorts that can address critical scien and (ii) achievement of diverse pop	AR. This funding ised cancer epid vill support meth tific gaps concer ulations in cohor	opportunity anno emiology cohorts t odological work ne rning (i) new or uni rts with the inclusio	uncement to address ecessary to que exposures on of			

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding Mount
		others) with substantial community enga	gement.			
124237		tigation of Co-occurring conditions across syndromE) Predoctoral to Postdoctoral Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-OD- 24-007 01	-Jul-2024	Not Specified
	Contact Telephone	Sujata Bardhan, M.S., Ph.D. 301-435-0471 <u>sujata.bardhan@nih.gov</u>				
	Program URL	Link to program URL 01-Jul-2024 , 01-Jul-2025 , 01-Jul-2026				
	Synopsis	The purpose of the INvestigation of Co-oc (INCLUDE) Predoctoral to Postdoctoral Fe broad variety of research fields to pursue students from disciplines including, but me and neurobiology are invited to apply to to INCLUDE Program Staff prior to initiating does not allow applicants to propose to le experience in a clinical trial led by a sponse	llow Transition award (F99/K00) is t postdoctoral training focused on D ot limited to, genetics, biochemistry his opportunity. Prospective applica plans for application submission. Th ead an independent clinical trial, but	o recruit excep own syndrome , data science, ants are strongl is Funding Opp	tional graduate stude related research. Gr maging, engineering y encouraged to cont ortunity Announcem	aduate , act the ent (FOA)
122370		ntions That Address Social Determinants o ence Health Disparities (UG3/UH3, Clinical	<sup>f</sup> National Institutes of Health/DHHS		-Jul-2024 ptional][LOI/Pre-App	Not ] Specified
	Contact Telephone Contact Email Sponsor Website Program URL	Jennifer Alvidrez, PhD 301-827-0071 Jennifer.alvidrez@nih.gov Link to program URL 05-Jul-2024 [Optional][LOI/Pre-App], 05-4	\ug_2024			
		The purpose of this NOFO is to support pu	-	toral preventive	e interventions that a	ddress socia

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Sectoral F Funded un approach are encour activities. Agreemen and capao will be ad	Preventive Interventions (MSPI) nder a cooperative agreement, es, methods, and data, working graged to review the Coordination This NOFO solicits bi-phasic res nt applications. Funding for the city to meet foundational milest ministratively considered by NII	at experience health disparities. The Research Network, which will also in projects participating in the MSPI Re closely with NIH Institutes, Offices a ng Center NOFO to fully understand earch projects proposed in UG3/UH UG3 phase (phase I) will be used to one targets specific to the work pro H and prioritized for transition to the d milestones for both the UG3 and U	nclude a Coordir esearch Networl and Centers. App the MSPI Resea I3 Phased Innova demonstrate su posed. A UG3 pr e UH3 award (ph	nating Center (RFA c will collaborate to plicants applying to rch Network struct ation Awards Coop fficient preparation roject that meets in	OD-24-006). o share o this NOFO cure and erative n, feasibility cs milestones
	Notice of Special Interest (NOSI): Disease and Alzheimer's Disease-			National Institutes of Health/DHHS	NOT-AG- 21-050 09-	Jul-2024	Not Specified
	Contact Name	Amelia Ka	arraker, Ph.D.				
	Contact Telephone	301-496-3	3131				
	Contact Email	<u>amelia.ka</u>	<u>rraker@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	09-Jul-202	24 , 12-Nov-2024				
	Synopsis	diagnosis, that exam AD/ADRD hormonal physical a status, ed functionir provider l that sepa	, and clinical presentation of Alz nine sex and gender differences as well as AD/ADRD caregiving- l, genetic, metabolic, comorbidit activity, substance use, social en lucational attainment, socioecon ng, socio-emotional functioning knowledge and attitudes about rately, or together, may drive of tudies that account for methodo	earch to clarify sex and gender differ heimer's disease (AD) and Alzheime in outcomes (e.g., clinical, functional related outcomes are also relevant ty-related), neuroscientific (e.g., neu gagement), social (e.g., history of m nomic and employment status), psyc and self-regulation, stress reactivity dementia) and healthcare system-le pserved differences by sex and gend plogical and measurement issues the	er's disease-relat al, well-being) ar . Broad areas of ural systems and altreatment or a chological (e.g., y, personality), h evel (e.g., access ler and/or may o	ed dementias (ADI nong people living interest include bio functions), behavio adversity, parentho depression, cognit ealthcare profession to care) factors an operate differently	RD). Studies with blogical (e.g., oral (e.g., bod, marital ive on (e.g., d processes by sex and

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Notice of Special Interest (NOSI):   Bisexual+ People	Research on the Health of Bisexual and	National Institutes of Health/DHHS	NOT-OD- 22-166 0	7-May-2024	Not Specified
	Contact Name	Christopher Barnhart, PhD				
	Contact Telephone	301-594-8983				
	Contact Email	christopher.barnhart@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Oct-2024 , 25-Oct-2024 , 12-Nov-202				4 , 05-Oct-2024
109112	Synopsis	well-being of people who identify as bise: potential to be attracted, romantically an time, not necessarily in the same way, an umbrella term that is intended to encomp sexually fluid, and queer. Health Disparities and Alzheimer's Disease	d/or sexually, to people of more that d not necessarily to the same degre bass non-monosexual identities, inc	an one sex or g e. "Bisexual+" luding but not	ender, not necessa or "bi+" in this NOS	ily at the same I is an
100115			Health/DHHS	21-033	9-Jul-2024	Specified
	Contact Name	Damali Martin, Ph.D.				
	Contact Telephone	301-402-8310				
	Contact Email	martinda@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
	Synopsis	This Notice of Special Interest (NOSI) enco AD/ADRD, using diverse cohorts of subject		nediators and	moderators of dispa	rities in
108050	Research on Current Topics in Alz	heimer's Disease and Its Related	National Institutes of	PAR-22-	9-Jul-2024	275,000
100020	Dementias (R21 Clinical Trial Option	onal)	Health/DHHS	094	5-JUI-2024	USD
	Contact Name	Sanoj K. Suneja, Ph.D				

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Contact Telephone	301-402-7710				
•	sanoj.suneja@nih.gov				
Sponsor Website					
	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
Synopsis	The purpose of this Funding Opportunity techniques, etc. to advance research on preliminary data with broader dissemina will be announced through a series of No	Alzheimer's disease (AD) and its tion to establish them for more g	related dementia general use in thi	s (ADRD) that need a	additional
108049 Research on Current Topics in Alz		National Institutes of	PAR-22-	)9-Jul-2024	Not
Dementias (R01 Clinical Trial Option	onal)	Health/DHHS	093	55 501 2024	Specified
Contact Name	Sanoj K. Suneja, Ph.D				
Contact Telephone	301-402-7710				
Contact Email	<u>sanoj.suneja@nih.gov</u>				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				
	The purpose of this Funding Opportunity in Alzheimer's disease (AD) and its relate be announced through a series of Notice	d dementias (ADRD). Further infe	ormation on the		
108374 Notice of Special Interest (NOSI): Disruption in Alzheimer's Disease	Sleep Disorders and Circadian Clock and other Dementias of Aging	National Institutes of Health/DHHS	NOT-AG- 21-051	09-Jul-2024	Not Specified
Contact Name	Miroslaw 'Mack' Mackiewicz, Ph.D.				
Contact Telephone	301-496-9350				
Contact Email	mirolsaw.mackiewicz@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	09-Jul-2024 , 12-Nov-2024				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding mount
	Synopsis	The aim of this NOSI is to advance basic circadian clock dysfunction in AD/ADRD progression of neurodegeneration.		•		
	Notice of Special Interest (NOSI): I Improve Health Outcomes	Research on Addressing Violence to	National Institutes of Health/DHHS	NOT-OD- 22-167	07-May-2024	Not Specified
	Contact Name	Dara R. Blachman, Ph.D.				
	Contact Telephone	301-496-8522				
	Contact Email	Dara.blachman-demner@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
		07-May-2024 , 05-Jun-2024 , 16-Jun-202 2025 , 05-Feb-2025 , 16-Feb-2025 , 07-N				, 07-Jan-
	Synopsis	The purpose of this Notice is to highlight violence-related screening and interven focused on addressing exposure to viole dating violence, elder mistreatment, per processes and outcomes.	tions into health care settings. This I ence - including but not limited to ch	Notice is to end ild maltreatme	courage intervention re ent, intimate partner vie	search plence/teer
124567	RFA-MD-2D-24-007 Technologie	es for Improving Minority Health and	National Institutes of	RFA-MD-	11-May-2024	Not
124307	Eliminating Health Disparities (R4:	1/R42- Clinical Trial Optional)	Health/DHHS	24-007	[Optional][LOI/Pre-App	Specified
	Contact Name	LCDR Michael Banyas, USPHS, MPA				
	Contact Telephone	240-619-9483				
	Contact Email	nimhdsbirsttr@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-May-2024 [Optional][LOI/Pre-App], 1 May-2025 [Optional][LOI/Pre-App], 10-J 2026 [Optional][LOI/Pre-App], 10-Jun-20	un-2025 , 07-Jul-2025 , 10-Nov-2025	5 [Optional][LC	0I/Pre-App], 09-Dec-202	
	Synonsis	This Funding Opportunity Announcemen	nt (FOA) invites eligible United State	s small busines	ss concerns (SBCs) to su	bmit Small

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Business Technology Transfer (STTR) gra commercialization with the aim of impro one or more NIH-defined populations th affordable, and culturally acceptable.	wing minority health and/or reducing the second sec	ng and ultimate	ely eliminating healt	n disparities in
114750	Trailblazer Award for New and Ea Optional)	rly Stage Investigators (R21 Clinical Trial	National Institutes of Health/DHHS	PAR-24- 022	)7-May-2024	400,000 USD
	Contact Name	Randy King, Ph.D.				
	Contact Telephone	301-451-0707				
	Contact Email	Randy.King@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 16-Jun-2024 , 16-Jul-2024 2025 , 07-May-2025 , 16-Jun-2025 , 16-Ju	• • • • • • • • • • • • • • • • • • • •			25 , 16-Mar-
	Synopsis	This Trailblazer Award is an opportunity (https://grants.nih.gov/policy/early-inve- integrate engineering and the physical so exploratory, developmental, proof of con- driven, or hypothesis-driven. Importantly preliminary data. A distinct feature for the if available, minimal preliminary data are independently produced and not yet pub- limited to one-half page, which may inclu- one figure will be considered noncomplia	stigators/index.htm) to pursue rese ciences with the life and/or biomed ncept, or high risk-high impact, and y, applicants must propose research nis FOA is that no preliminary data a e allowed. Preliminary data are defin plished in a peer-reviewed journal.A ude one figure. Applications includin	earch programs ical sciences. A may be techno n approaches fo are required, ex ned as material All preliminary o ng data more th	of high interest to t Trailblazer project r ology design-directed or which there are m spected, or encourag which the applicant data should be clear nan one-half page or	nay be d, discovery- inimal or no ged. However, : has y marked and
111641	Notice of Special Interest (NOSI):	Climate Change and Health	National Institutes of Health/DHHS	NOT-ES- 22-006	07-May-2024	Not Specified
	Contact Name	Claudia L. Thompson				
	Contact Telephone	984-287-3330				
	Contact Email	thompso1@niehs.nih.gov				
	Sponsor Website					

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2024 , 25-May-2024 , 05-Jun-202 2024 , 07-Sep-2024 , 25-Sep-2024 , 05-Oc Dec-2024 , 09-Dec-2024 , 07-Jan-2025 , 2 07-May-2025	ct-2024 , 12-Oct-2024 , 16-Oct-2024	, 21-Oct-2024 , 2	12-Nov-2024 , 15-N	Nov-2024,08-
	Synopsis	The National Institute of Environmental H National Institute of Minority Health and Health and Human Development (NICHD (NINR), National Heart Blood and Lung In leading an NIH-wide Climate Change and climate change across the lifespan; impro climate change impacts; and building hea increasing health equity. As a part of this on health and well-being over the life cou globally.	Health Disparities (NIMHD), Eunice ), National Institute of Mental Health stitute (NHBLI) and National Institut Health Initiative (CCHI) with the goa oving the health of people who are a oth resilience among individuals, cor CCHI, this NOSI encourages applicat	Kennedy Shriver n (NIMH), Nation e of Allergy and ls of: reducing t t increased risk nmunities, nation ions that address	r National Institute nal Institute of Nur Infectious Disease he health threats p from or disparately ons around the wo as the impact of cli	of Child sing Research (NIAID) is bosed by y affected by rld, thereby mate change
1/5/54	Feasibility Trials of the NIH Music- Disorders of Aging (R34 Clinical Tri	based Interventions Toolkit for Brain al Required)	National Institutes of Health/DHHS		May-2024 htional][LOI/Pre-Ap	450,000 pp] USD
	Contact Name	Sekai Chideya, M.D., M.PH				
	Contact Telephone	301-827-1916				
	Contact Email	<u>Sekai.Chideya@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
		21-May-2024 [Optional][LOI/Pre-App], 20 Nov-2024	0-Jun-2024 , 25-Jul-2024 , 22-Sep-20	24 [Optional][LC	)I/Pre-App], 21-Oc	t-2024 , 19-
	Synopsis	The purpose of this Notice of Funding Op Interventions Toolkit for Brain Disorders trials guided by the NIH Music-based Inte clinical trials will generate evidence supp pilot data to design a subsequent clinical interventions in the context of brain diso	of Aging (R34 Clinical Trial Required) erventions (MBI) Toolkit for research orting the validity of the NIH MBI To efficacy or effectiveness study (or p	" in order to sup on brain disord olkit's guiding p ragmatic clinical	oport proof-of-con ers of aging. These rinciples as well as trial) using music-	cept feasibility early phase the necessary based

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		disease-related dementias, Parkinson's di order to facilitate development of a comp		ed should addr	ess gaps in scientific	knowledge in
103723		vork (BPN): Biologic-based Drug Discovery the Nervous System (U44 Clinical Trial	National Institutes of Health/DHHS	PAR-21- 233 1	5-Jul-2024	Not Specified
	Contact Name	Ann-Marie Broome PhD MBA				
	Contact Telephone	301-496-1779				
	Contact Email	ann-marie.broome@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jul-2024 , 19-Aug-2024				
	Synopsis	The Blueprint Neurotherapeutics Network discovery and development, from lead op (FOA) supports preclinical discovery and con- including, but not limited to, large biologi (i.e., oligonucleotide- and viral-based), ce therapies). Applicants will collaborate wit organizations (CROs) that specialize in ma Biologics awardee institutions retain their contractors (and thereby control the pate in this program.	otimization through phase I clinical t development of potential therapeut c macromolecules, (e.g., proteins, a II therapies, and novel emerging the h NIH-funded consultants and can inufacturing, scaling, pharmacokine c assignment of IP rights and gain as	esting. This Fu tic Biotechnolo antibodies, and erapies (e.g., m augment their stics, toxicology ssignment of IP	nding Opportunity A gy Products and Biol peptides), gene-bas nicrobial and microbi project with NIH con y, and Phase I clinical rights from the BPN	nnouncement ogics ed therapies ome tract research testing. BPN- -Biologics
1/7378	<u>Global Infectious Disease Research</u> <u>Optional)</u>	n Training Program (D43 Clinical Trial	National Institutes of Health/DHHS		7-Jul-2024 Optional][LOI/Pre-Ap	Not p] Specified
	Contact Name	Barbara Sina Ph.D.				
	Contact Telephone	301-402-9467				
	Contact Email	<u>sinab@mail.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jul-2024 [Optional][LOI/Pre-App], 06-A	Aug-2024 , 07-Jul-2025 [Optional][L	OI/Pre-App], 0	6-Aug-2025 , 07-Jul-2	026

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	[Optional][LOI/Pre-App], 06-Aug-2026 This Funding Opportunity Announcement Research Training programs from low- ar propose a collaborative training program research (not including HIV/AIDS). FIC will threatening emerging infectious diseases HIV infected individuals or 4) infections of health importance in LMICs.Advanced sci technical area of basic, epidemiological, of training programs should incorporate did prepare individuals for sustainable career This Notice of Funding Opportunity (NOF of an independent clinical trial; or propose clinical trial led by another investigator, a	nd middle-income country (LMIC) and in that will strengthen the capacity of Il support research training program (s, 2) neglected tropical diseases, 3) in or microbiomes associated with non- ientific training related to preventio clinical, behavioral or social science dactic, mentored research and profe rs that will have significant impact o (O) allows appointment of Trainees ( sing a separate ancillary clinical trial)	d U.S. institution a LMIC institution is that focus on a fections that fro- communicable of n, treatment or health research ssional develope n the priority he D43) proposing c or proposing to	ns. The application on to conduct infe- 1) major endemic of equently occur as of disease conditions public health appro- may be supported ment skills comported to serve as the lea	should ctious disease or life- co-infections in of public oaches to any . Research nents to ds of LMICs. d investigator
122317 Blueprint Neurotherapeutics Network and Development for Disorders o Optional)	work (BPN): Small Molecule Drug Discover f the Nervous System (U44 Clinical Trial	National Institutes of Health/DHHS	PAR-24- 063 15-	-Jul-2024	Not Specified
Contact Name	Charles Cywin, PhD				
Contact Telephone	301-496-1779				
Contact Email	charles.cywin@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Jul-2024 , 18-Aug-2024 , 15-Jan-2025 18-Aug-2026	, 18-Apr-2025 , 15-Jul-2025 , 18-Aug	-2025 , 15-Jan-2	2026 , 17-Apr-2026	, 15-Jul-2026 ,
	The Blueprint Neurotherapeutics Networ advance their small molecule drug discov for conducting all studies that involve dis for all activities to be conducted in their of consultants and can augment their projec chemistry, pharmacokinetics, toxicology, Practices (GMP), and Phase I clinical testi	very and development projects into sease- or target-specific assays, mod own laboratories. In addition, applic ct with NIH contract research organi formulations development, chemic	the clinic. Partic els, and other re ants will collabo izations (CROs) t al synthesis inclu	ipants in the BPN a esearch tools and r prate with NIH-func that specialize in m uding under Good	are responsible eceive funding ded edicinal Manufacturing

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		Discovery phase the goal is to characteria structure activity relationships (SAR) and as metabolism, selectivity, toxicity, etc. A development candidate through Investig Projects can enter the program at the De and phase I clinical testing. BPN recipient assignment of IP rights from the BPN con negotiations) for drug candidates develo	structure property relationships (SF as projects enter or advance to the D ational New Drug (IND)-enabling to evelopment stage and progress in a s t Institutions retain their assignment stractors and consultants (and there	PR) including in Development sta xicology studies shorter period to t of intellectual	vitro and in vivo pr age the goal is to ac and phase I clinica o IND enabling toxi property (IP) rights	operties such dvance a single I testing. cology studies and gain
122315 🧧		work (BPN): Small Molecule Drug Discover the Nervous System (UG3/UH3 Clinical	Y National Institutes of Health/DHHS	PAR-24- 043 15	-Jul-2024	Not Specified
	Contact Name	Charles Cywin, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	<u>charles.cywin@nih.gov</u>				
	Sponsor Website	2				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jul-2024 , 18-Aug-2024 , 15-Jan-2025 18-Aug-2026	, 18-Apr-2025 , 15-Jul-2025 , 18-Au	g-2025 , 15-Jan-2	2026 , 17-Apr-2026	, 15-Jul-2026 ,
	Synopsis	The Blueprint Neurotherapeutics Networ advance their small molecule drug discov for conducting all studies that involve dis for all activities to be conducted in their consultants and can augment their proje chemistry, pharmacokinetics, toxicology, Practices (GMP), and Phase I clinical testi Discovery phase the goal is to characteriz structure activity relationships (SAR) and as metabolism, selectivity, toxicity, etc. A development candidate through Investig Projects can enter the program at the De and phase I clinical testing. BPN recipient	very and development projects into sease- or target-specific assays, mod own laboratories. In addition, applic ct with NIH contract research organ formulations development, chemic ing. Projects can enter either at the ze and optimize promising hit compo- structure property relationships (SF as projects enter or advance to the D ational New Drug (IND)-enabling to evelopment stage and progress in a	the clinic. Partic lels, and other re- cants will collabor izations (CROs) cal synthesis incl Discovery or the ounds using me PR) including in Development sta- xicology studies shorter period to	cipants in the BPN a esearch tools and r prate with NIH-fund that specialize in m uding under Good e Development stag dicinal chemistry to vitro and in vivo pr age the goal is to ad and phase I clinica o IND enabling toxi	re responsible eceive funding ded edicinal Manufacturing ge. In the establish operties such dvance a single l testing. cology studies

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding mount
REA-CA-24-023 Small Busin		assignment of IP rights from the BPN cont negotiations) for drug candidates develop	-	by control the p	atent prosecution an	d licensing
125494	RFA-CA-24-023 Small Business (R41/R42 Clinical Trial Not Allowe	Transition Grant For Early Career Scientists ed)	National Institutes of Health/DHHS	-	-Jul-2024 ptional][LOI/Pre-App]	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL	saroj.regmi@nih.gov Link to program URL	2024			
		21-Jul-2024 [Optional][LOI/Pre-App], 21-A Through this Notice of Funding Opportunit Institute (NHGRI), National Institute of Bio Health (NIMH) intend to support early-car supporting the transfer of technology from universities are drivers of technological inter- ideas into products that can benefit the U. laboratories, the NIH also supports innova programs. As technologies transition from the right team with the right expertise to t development. This NOFO seeks to address entrepreneurial mentoring support, and p	ty (NOFO), the National Cancer Inst medical Imaging and Bioengineerin eer academic scientists interested in nacademic laboratories into small hovation in the United States (U.S.) S. population. While most NIH func- tive technology development in U.S. academic discovery to small busine take the product into a small busine both challenges simultaneously by	ng (NIBIB), and N in transitioning businesses. Both , often working ding supports ba S. small busines esses, two commess, and funding	lational Institute of N to entrepreneurship n small businesses an together to advance asic research in unive ses through its SBIR a non challenges arise, for early-stage techr	Nental while also d innovative rsity ind STTR identifying nology
125676	Lasker Clinical Research Scholars	Program (Si2/R00 Clinical Trial Optional)	National Institutes of Health/DHHS		-Jul-2024 ptional][LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone	Charles R. Dearolf, Ph.D. 301-402-1225				

Contact Email LaskerScholar@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-Jul-2024 [Optional][LOI/Pre-App], 30-Aug-2024

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	This NOFO encourages applications for the research activities during the early stage a unique bridge between the NIH intramu phase, Lasker Scholars will receive appoir Research Program with independent rese NIH support for their research at an extra investigator within the intramural progra	careers of independent clinical rese ural and extramural research comm ntments for up to 5-7 years as tenu earch budgets. In the second phase amural research facility; or, the Sch	earchers. The pro- nunities and cont re-track investig , successful scho	ogram offers the o cains two phases. I ators within the NI lars will receive up	portunity for the first H Intramural to 3 years of
114765 Notice of Special Interest (NOSI): Research	Firearm Injury and Mortality Prevention	National Institutes of Health/DHHS	NOT-OD- 23-039 07	-May-2024	Not Specified
Contact Name	Dara R. Blachman, Ph.D.				
Contact Telephone					
Contact Emai	l <u>Dara.blachman-demner@nih.gov</u>				
Sponsor Website					
Program URI	-				
Deadline Dates (ALL	07-May-2024 , 05-Jun-2024 , 16-Jun-2024 2024 , 12-Nov-2024 , 07-Jan-2025 , 05-Fe Oct-2025 , 16-Oct-2025 , 07-Jan-2026 , 05	b-2025 , 16-Feb-2025 , 07-May-202	• • •	-	
Synopsis	The purpose of this Notice is to highlight the identification of those at risk of firear injury), the development, piloting, and te examination of approaches to improve th injury and mortality.	m injury (including self- and other- sting of innovative interventions to	directed, victims prevent firearm	and perpetrators, n injury and mortal	accidental ity, and the
113256 Notice of Special Interest (NOSI): Health-related Behavioral Interve	Development and Preliminary Testing of entions	Office of Behavioral and Social Sciences Research/NIH/DHHS	NOT-OD- 22-203 07	-May-2024	Not Specified
Contact Name	e William Elwood, PhD				
Contact Telephone	301-402-0116				
Contact Emai	l <u>william.elwood@nih.gov</u>				
Contact Emai Sponsor Website					

	Program Fitle	9	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	07-May-20 2024	024 , 13-May-2024 , 05-Jun-202	24 , 07-Jun-2024 , 16-Jun-2024 , 1	8-Jun-2024 , 09-J	ul-2024 , 07-Sep-20	24 , 13-Sep-
	Synopsis	methodica Office of Bi the system behavioral behavior cl underlying	I translation of foundational b ehavioral and Social Sciences F natic development of original h and social sciences research ( hange. This includes research	mote sustained health-related be ehavioral and social science disco Research (OBSSR) and participatin ealth-related behavioral interven bBSSR) findings that posit causal o chat focuses on use-inspired bBSS change, and systematic developm	veries into new o g ICOs are issuing tions that test hy or processual mee R, understanding	r improved interver this Notice to high potheses that draw chanisms of action of of mechanisms of a	ntions. The light interest in on basic of healthier action
1/46/5	A-OD-24-014 Botanical Dieta ams (RM1 Clinical Trial Require		ents Translational Research	Office of Dietary Supplements/NIH/DHHS		9-Jun-2024 )ptional][LOI/Pre-A	Not ppl Specified
	Contact Name		Sorkin, Ph.D.				
	Contact Telephone		nail aib anu				
	Contact Email Sponsor Website		nan.mn.gov				
	Program URL		gram LIRI				
	-		24 [Optional][LOI/Pre-App], 08	-lul-2024			
		The purpos chemically trials of the products a For examp the optima product sp provide a g for a trial o outcomes by the prod ingested pu	se of this Notice of Funding Op complex botanical products o e efficacy of exceptionally pror re often challenged by gaps in le, the molecular mechanism(s al product chemistry, for a give pecifications, stability testing an good test of the effect of that b of a product reputed to have m might be relevant might benef duct, and the health outcomes roduct will benefit from the av	portunity (NOFO) is to support tra- r natural products traditionally us nising dietary supplements for im- understanding that critically affects of action of a botanical dietary se n health outcome may not be known assessments of bioavailability a potanical on the health outcome (se any different health effects, or to it from deeper understanding of to expected from modulating those ailability of methods to assess bio s. Clinical trial design will benefit f	ed as dietary con proving resilience t the design and supplement migh own; in the absen and absorption ki assessed. Simila have effects whe the biological stru- targets. Interpre- pavailability of action	ponents, to inform e. Clinical efficacy tr /or interpretation o t not be well establ ce of such informat netics a clinical trial arly, the best outcor ere many different o icture(s) and/or sys tation of a clinical t cive constituents of	future clinical rials of such f a clinical trial. ished and thus ion to guide might not me measure quantitative tem(s) affected rial of an the product or

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		• •	ence the effect of the intervent	tics, background diet, epigenomics, ion tested. The forgoing are exampl	-		•
11////	RFA-OD-22-014Specialized Cen Differences (U54 Clinical Trial Opt		earch Excellence (SCORE) on Se	x Office of Research on Women's Health/NIH/DHHS		-Jul-2024 ptional][LOI/Pre-Ap	7,500,000 o] USD
	Contact Name	Rajeev K.	Agarwal, Ph.D.				
	Contact Telephone	301-451-7	7058				
	Contact Email	rajeev.ag	arwal@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	16-Jul-20	24 [Optional][LOI/Pre-App], 15-,	Aug-2024			
	Synopsis	(SCORE) o research	on Sex Differences. The Centers on sex differences. Each SCORE	ns and institutes seek applications for of Excellence will support interdisci institution should develop a researcy t to improving the health of women	plinary approacl ch agenda bridgi	nes to advance trans	lational

## National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
125520	National Science Foundation Re Program	search Traineeship Institutional Partner	ship Pilot (NRT-IPP)	National Science Foundation	24-566	22-Jul- 2024	4,500,000 USD
	Contact Name	Daniel Denecke					
	Contact Telephone	703-292-8072					
	Contact Email	ddenecke@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	22-Jul-2024					
	Synopsis	master's and doctoral degree program science, technology, engineering, and r for the existing NRT Program that will s certificate, or a track within an existing identified in this pilot. This will be acco Education (IHE) (lead institution), (b) ar in at least one of the focus areas define area(s). The overall purpose is to train collaborations among non-R1 institutio	mathematics (STEM) c support research and e master's or Ph.D. pro mplished through an e n non-lead IHE (an R1 ed for this pilot (see be the STEM workforce in	areers. This solicita education projects gram with high inc effective partnersh or non-R1) that ha elow), and (c) two n focus areas speci	ation describes a p that will result in lustry relevance in ip among: (a) a no s either an ongoir to three industry fied in this solicita	pilot for a po a new mastern at least one on-R1 Institu- ng or comple partners in t ation by stim	tential new track er's degree, e focus area ition of Higher ted NRT program he same focus ulating
124969	Dear Colleague Letter: Catalyzin Innovation in Science, the Enviro	ig Human-Centered Solutions through R onment and Society	esearch and	National Science Foundation	NSF 24- 074	01-Jul- 2024	100,000 USD
	Contact Name						
	Contact Telephone	703-292-5111					
	Contact Email	NSF_CRISES_Program@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jul-2024					
	Synopsis	This funding opportunity for planning p with support from NSF's directorates fo	proposals is led by NSF or Geosciences (GEO),	's Social, Behavior Biological Science	al and Economic S s (BIO), Engineerii	Sciences Dire ng (ENG), Te	ctorate (SBE) chnology,



#### National Science Foundation (NSF) Funding Opportunities

	Program Title	Sponsor Name	Sponsor	Deadline	Funding
SPINID			Number	Date	Amount

Innovation and Partnerships (TIP), and STEM Education (EDU), as well as the Office of International Science and Engineering (OISE) and the Office of Integrative Activities (OIA). By supporting research to understand the social and behavioral aspects of the rapidly changing world and how these challenges are affected by social, political, economic, and natural environments this DCL aims to advance understandings of fundamental and use-inspired research of people, organizations, and society, while revealing emerging opportunities to address challenges affecting individuals and communities to live healthy and productive lives. This announcement encourages multi-disciplinary teams led by social or behavioral scientists to develop research programs to advance scientific understanding of critical challenges facing social and environmental systems at local, regional, and global scales.



## **Other Federal Funding Opportunities**

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

n/a



SPIN ID Program Title	Sponsor Name	Sponsor Numb	oer Deadli	ne Date F	unding Amo
059477 Neuroimaging and CSF Biomar	ker Development Program	Alzheimer's Drug Discovery Fou	ndation	13-May-202 [LOI/Pre-Ap	
Contact Name	Meriel Owen, PhD, Associate Direc	tor Scientific Affairs		[-0.7.107.4	p] 001
Contact Telephone					
	mowen@alzdiscovery.org				
	Link to sponsor website				
	Link to program URL				
-	13-May-2024 [LOI/Pre-App], 22-Ju	I-2024 . 30-Sep-2024 [LOI/Pre-App]	. 09-Dec-2024		
Synopsis Applicant Types	Alzheimer's disease and related de advantage over other relevant bio	evelop and validate established bion ementias. This RFP prioritizes bioma markers, and a path to commerciali	rkers with a define	ed context of ι	
Synopsis Applicant Types	Alzheimer's disease and related de advantage over other relevant bio 600,000.00 maximum	mentias. This RFP prioritizes bioma	rkers with a define	ed context of ι	
Synopsis Applicant Types Funding Limit Limited Submission	Alzheimer's disease and related de advantage over other relevant bio 600,000.00 maximum No	mentias. This RFP prioritizes bioma	rkers with a define zation and/or clini	ed context of ι	se, a clear 4 5,000,0
Synopsis Applicant Types Funding Limit Limited Submission 061078 <u>Request For Proposal: Prevent</u>	Alzheimer's disease and related de advantage over other relevant bio 600,000.00 maximum No	ementias. This RFP prioritizes bioma markers, and a path to commerciali Alzheimer's Drug Discovery Four	rkers with a define zation and/or clini	ed context of u ical use. 13-May-202	se, a clear 4 5,000,0
Synopsis Applicant Types Funding Limit Limited Submission 061078 <u>Request For Proposal: Prevent</u>	Alzheimer's disease and related de advantage over other relevant bio 600,000.00 maximum No <u>ion Pipeline</u> Yuko Hara, PhD, Assistant Director	ementias. This RFP prioritizes bioma markers, and a path to commerciali Alzheimer's Drug Discovery Four	rkers with a define zation and/or clini	ed context of u ical use. 13-May-202	se, a clear 4 5,000,0
Synopsis Applicant Types Funding Limit Limited Submission 061078 <u>Request For Proposal: Prevent</u> Contact Name Contact Telephone	Alzheimer's disease and related de advantage over other relevant bio 600,000.00 maximum No <u>ion Pipeline</u> Yuko Hara, PhD, Assistant Director	ementias. This RFP prioritizes bioma markers, and a path to commerciali Alzheimer's Drug Discovery Four	rkers with a define zation and/or clini	ed context of u ical use. 13-May-202	se, a clear 4 5,000,0
Synopsis Applicant Types Funding Limit Limited Submission 061078 <u>Request For Proposal: Prevent</u> Contact Name Contact Telephone Contact Email	Alzheimer's disease and related de advantage over other relevant bio 600,000.00 maximum No <u>ion Pipeline</u> Yuko Hara, PhD, Assistant Director 212-901-7991	ementias. This RFP prioritizes bioma markers, and a path to commerciali Alzheimer's Drug Discovery Four	rkers with a define zation and/or clini	ed context of u ical use. 13-May-202	se, a clear 4 5,000,0
Synopsis Applicant Types Funding Limit Limited Submission 061078 <u>Request For Proposal: Prevent</u> Contact Name Contact Telephone Contact Email Sponsor Website	Alzheimer's disease and related de advantage over other relevant bio 600,000.00 maximum No ion Pipeline Yuko Hara, PhD, Assistant Director 212-901-7991 yhara@alzdiscovery.org	ementias. This RFP prioritizes bioma markers, and a path to commerciali Alzheimer's Drug Discovery Four	rkers with a define zation and/or clini	ed context of u ical use. 13-May-202	se, a clear 4 5,000,0



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date Fu	nding Amount
	Synopsis	The ADDF seeks to support studies research, and epidemiological stud cognitive decline.				
	Applicant Types					
	Funding Limit	5,000,000.00 see detail				
	Limited Submission	No				
033842 /	Accelerating Drug Discovery for	r Frontotemporal Degeneration	Alzheimer's Dru	g Discovery Foundation	13-May-2024 [LOI/Pre-App	
	Contact Name					
	Contact Telephone	212-901-8000				
	Contact Email	dniehoff@theaftd.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-May-2024 [LOI/Pre-App], 22-Jul	-2024			
	Synopsis	This is a request for proposals for f oligonucleotides, peptides, gene the				
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
055305 [	Drug Development RFP		Alzheimer's Dru	g Discovery Foundation	13-May-2024	5,000,000 USD
	Contact Name	Aaron Burstein, PharmD, Head of S	earch & Evaluation			
	Contact Telephone	212-901-8000				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Email	aburstein@alzdiscovery.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-May-2024 , 22-Jul-2024 , 30-Sep	2024			
	Synopsis	The Drug Development RFP support and early-phase clinical trials that te (AD) and related dementias. Both di opportunity prioritizes diverse drug emerging therapeutic areas for dem proposals will not be considered for	est promising pharr sease-modifying a mechanisms and r entia. For this reas	macological interventions nd symptomatic agents w nodes of action related to	and devices for Alz ill be considered. Th the biology of agin	heimer's disease his funding g and other
	Applicant Types					
	Funding Limit	5,000,000.00 maximum				
	Limited Submission	No				
083814	Every Heartbeat Matters Valve	Fellowship Program	American Associ	ation for Thoracic Surgery	01-Jul-20	15,000 USD
	Contact Name					
	Contact Telephone	978-252-2200				
	Contact Email	admin@aatsfoundation.org				
	Sponsor Website	Link to sponsor website				
	-	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	This fellowship's aim is to enhance h who treat individuals with limited a host institution for advanced VHD to daily practice.	ccess to healthcare	e. Surgeons may apply for	up to three months	s of study, visiting a



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Applicant Types					
Funding Limit	15,000.00 maximum				
Limited Submission	No				
083815 Honoring Our Cleveland Clinic	Mentors Program	American Assoc	iation for Thoracic Surgery	02-Jul-20	1,000 USD
Contact Name					
Contact Telephone					
Contact Email	admin@aatsfoundation.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	02-Jul-2024				
Synopsis	The AATS Foundation Honoring O residents in the chief/penultimate obtain a basic understanding of the their training, developing areas of applicants are invited to attend the \$1,000 stipend to help cover their attend an evening reception prece	e year of their trainin the steps necessary to expertise, and begin is valuable course (7 travel and hotel exp	ng to participate in a full-da o secure their first full-time nning their careers in an ac Fentative Date: September penses. Participants are als	ay program at the C position following cademic program. S 24, 2024) and will so welcome, but no	leveland Clinic to completion of uccessful be provided with a t obligated, to
Applicant Types					
Funding Limit	1,000.00 see detail				
Limited Submission	No				
083812 Denton A. Cooley Fellowship		American Assoc	iation for Thoracic Surgery	01-Jul-20	5,000 USD
Contact Name Contact Telephone					



SPIN ID	Program Title	S	Sponsor Name	Sponsor Number	Dea	adline Date	Funding Amount
	Contact Email	admin@aatsfoun	dation.org				
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program l	JRL				
	Deadline Dates (ALL)	01-Jul-2024					
	Synopsis	who are in the fir at the Texas Hear and awarded a gr	nal year of their residency, or t Institute (THI) and Baylor	n educational experience for or have recently completed St. Luke's Medical Center (E vel and living expenses. Add	their residen SLMC). Annu	icy, to spend fo ually, one recip	ur weeks studying ient is selected
	Applicant Types						
	Funding Limit	5,000.00 maximu	ım				
	Limited Submission	No					
083840 🥂	ATS Foundation Gardner Lect	<u>ureship</u>	Ameri	can Association for Thoracic	Surgery	01-Jul-20	24 10,000 US
	Contact Name						
	Contact Telephone						
	Contact Email	admin@aatsfoun	dation.org				
	Sponsor Website	Link to sponsor w	<u>vebsite</u>				
	Program URL	Link to program l	JRL				
	Deadline Dates (ALL)	01-Jul-2024					
	Synopsis	to honor his care will bring a promi Sponsored and ac	er as a nationally-recognize inent AATS member lecture	as been established by men d cardiac surgeon and leade r to an ACGME-approved ca undation, the lectureship pi s.	er in cardiova Irdiothoracic	ascular medicin surgery reside	e. This lectureship ncy institution.



SPIN ID Program Titl	le	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	,.	10,000.00 maximum				
Lim	nited Submission					
006566 <u>Research and</u>			American Assoc Gynecologists F	iation of Obstetricians and oundation	01-Jul-20	24 360,000 USD
	Contact Name	William Catherino, MD, F	PhD Chair, AAOGF Scholar Co	mmittee		
Со	ntact Telephone	301-295-3126				
	Contact Email	william.catherino@usuh	s.edu			
S	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
Dead	dline Dates (ALL)	01-Jul-2024				
	Synopsis	identify future academic development through th Department of Obstetric for a candidate of prover academic career. Researc	undation, the Foundation for physician leaders in the field e support of advanced scient s and Gynecology in the Unit n ability who exhibits significa ch training may focus on basi s and prevention, epidemiolo	of Obstetrics and Gynecole ific training. The Scholarshi ed States or Canada to pro- ant talent, original thought, c or translational research,	ogy and to stimulate p Award is to be use vide research trainin and evidence of de disease pathogene	e their scholarly ed in an academic ng and experience dication to an
	Applicant Types					
	Funding Limit	120,000.00 per year				
Lim	nited Submission	No				
	Memorial Awarc	I for Outstanding Service	to the American Colleg	ge of Physicians	01-Jul-20	24 Not Specified



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Contact Name					
Contact Telephone	800-523-1546				
Contact Email	awards@acponline.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Jul-2024				
Synopsis	The Alfred Stengel Memorial Award outstanding service to the America			llege of Physicians is	bestowed for
Applicant Types					
Funding Limit	0.00 see detail				
Limited Submission	No				
016284 Harriet P. Dustan Award for Sci	ience as Related to Medicine	American Colleg	e of Physicians	01-Jul-202	24 Not Specified
Contact Name					
Contact Telephone	800-523-1546				
Contact Email	awards@acponline.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Jul-2024				
Synopsis	The Harriet P. Dustan Award for Sci related to medicine. Scientists of ar physical, or social, shall be eligible f	ny country and in a		-	
Applicant Types					



SPIN ID Program Title	:	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	0.00 see detail				
Limited Submission	NO				
048481 Pathway to Stop Diabetes - Init	iator Award (INI)	American Di	abetes Association, Inc.	17-Jul-20	)24 Not Specified
Contact Name					
Contact Telephone	800-342-2383				
Contact Email	pathway@diabe	tes.org			
Sponsor Website	Link to sponsor v	<u>website</u>			
Program URL	Link to program	<u>URL</u>			
Deadline Dates (ALL)	17-Jul-2024				
Synopsis	research, and to transformative suf from mentored t to support early talented and pro programs and ma to support partic diabetes with an ('moving the nee	Stop Diabetes Program intends to accelerate their research progres cience. The Initiator Award is a tw training to independent research f career researchers who have disti- omising research investigators with aking seminal contributions in dia cularly innovative and transformate emphasis on the investigator's pe- cedle') to improve the lives of peop uring late stages of mentored train	s by providing the necessary is co-phased award designed to faculty. The Pathway to Stop I inguished themselves during the hahigh likelihood of establish betes research. These award cional ideas that have the pot otential to significantly transfe le with diabetes. These award	resources and suppor support the transiti Diabetes® Initiator a their research traini hing successful, inde Is are highly compet ential to have an ex orm diabetes throug ds provide salary an	ort for conducting on of scientists award is designed ng as exceptionally ependent research itive and intended ceptional impact in gh research d research support
Applicant Types					
Funding Limit	0.00 see detail				
Limited Submission	Yes				



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount
048482 <u>F</u>	Pathway to Stop Diabetes - Acc	celerator Award (ACE)	American Diabete	es Association, Inc.	17-Jul-202	24 1,625,000 USD
	Contact Name					
	Contact Telephone	800-342-2383				
	Contact Email	pathway@diabetes.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	17-Jul-2024				
		The Pathway to Stop Diabete	as Accelerator Award is des	signed to support exce	ntional, independent e	arlv-career
	Synopsis	researchers who have distin	guished themselves as proi ainable diabetes research p	mising investigators an programs. Awards will p	d are in the beginning	stages of
	Synopsis Applicant Types	researchers who have disting establishing successful, susta to \$325,000/year (including	guished themselves as proi ainable diabetes research p	mising investigators an programs. Awards will p	d are in the beginning	stages of
	Applicant Types	researchers who have disting establishing successful, susta to \$325,000/year (including	guished themselves as proi ainable diabetes research p	mising investigators an programs. Awards will p	d are in the beginning	stages of
	Applicant Types	researchers who have disting establishing successful, susta to \$325,000/year (including 325,000.00 per year	guished themselves as proi ainable diabetes research p	mising investigators an programs. Awards will p	d are in the beginning	stages of
084040 []	Applicant Types Funding Limit	researchers who have disting establishing successful, susta to \$325,000/year (including 325,000.00 per year	guished themselves as prom ainable diabetes research p 30% indirect costs) for a to	mising investigators an programs. Awards will p	d are in the beginning	stages of search support up
084040 []	Applicant Types Funding Limit Limited Submission Information Systems Award	researchers who have disting establishing successful, susta to \$325,000/year (including 325,000.00 per year	guished themselves as prop ainable diabetes research p 30% indirect costs) for a to American Institut Astronautics	mising investigators an programs. Awards will p tal of \$1,625,000.	d are in the beginning provide five years of re	stages of search support up
084040 1	Applicant Types Funding Limit Limited Submission Information Systems Award	researchers who have disting establishing successful, susta to \$325,000/year (including 325,000.00 per year Yes Patricia A. Carr, manager, Al	guished themselves as prop ainable diabetes research p 30% indirect costs) for a to American Institut Astronautics	mising investigators an programs. Awards will p tal of \$1,625,000.	d are in the beginning provide five years of re	stages of search support up
084040 []	Applicant Types Funding Limit Limited Submission Information Systems Award Contact Name Contact Telephone	researchers who have disting establishing successful, susta to \$325,000/year (including 325,000.00 per year Yes Patricia A. Carr, manager, Al	guished themselves as prop ainable diabetes research p 30% indirect costs) for a to American Institut Astronautics	mising investigators an programs. Awards will p tal of \$1,625,000.	d are in the beginning provide five years of re	stages of search support up
084040 [	Applicant Types Funding Limit Limited Submission Information Systems Award Contact Name Contact Telephone Contact Email	researchers who have disting establishing successful, susta to \$325,000/year (including 325,000.00 per year Yes Patricia A. Carr, manager, Al 703-264-7623	guished themselves as prop ainable diabetes research p 30% indirect costs) for a to American Institut Astronautics	mising investigators an programs. Awards will p tal of \$1,625,000.	d are in the beginning provide five years of re	stages of search support up
084040 <u>I</u>	Applicant Types Funding Limit Limited Submission Information Systems Award Contact Name Contact Telephone Contact Email Sponsor Website	researchers who have disting establishing successful, susta to \$325,000/year (including 325,000.00 per year Yes Patricia A. Carr, manager, Al 703-264-7623 <u>awards@aiaa.org</u>	guished themselves as prop ainable diabetes research p 30% indirect costs) for a to American Institut Astronautics	mising investigators an programs. Awards will p tal of \$1,625,000.	d are in the beginning provide five years of re	stages of search support up



SPIN ID	Program Title	Sponsor Name	е	Sponsor Number	Deadline Date	Funding Amount
	Synopsis Applicant Types Funding Limit Limited Submission	aeronautics computer and sen	rd is presented for tech ising aspects of informa	nical and/or management tion technology and sciend	contributions in spa ce.	ce and
001181	Joan F. Giambalvo Fund for the	e Advancement of Women	American Medic	cal Association Foundation	15-Jul-202	24 10,000 USD
	Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types	312-464-4200 wps@ama-assn.org Link to sponsor website Link to program URL 15-Jul-2024 The Joan F. Giambalvo Fund for research advancing the study of address the issues affecting wo	of women in the medica	al profession and strengthe		••
038894	Resident and Fellow Fast-Track	<u>« Grants</u>	American Societ	ry for Surgery of the Hand	24-May-2 [Optional]	5 000 0 00
	Contact Name Contact Telephone Contact Email					



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadlin	e Date Fund	ing Amount
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	24-May-2024 [Optional], 01-Jul-	2024 [LOI/Pre-App], 1	2-Aug-2024			
Synopsis	This research opportunity is des innovative projects related to ha the traditional AFSH basic science	and surgery. The scope	e of the project is smalle			
Applicant Types						
Funding Limit	5,000.00 maximum					
Limited Submission	Yes					
116448 Rheumatoid Arthritis Research	Request for Proposals (RFP)	Arthritis Founda	tion	RFP- RA- 2023	21-May-2024 [LOI/Pre-App]	Not Specified
Contact Name	Kristen Mueller					
Contact Telephone	800-283-7800					
Contact Email	kmueller@arthritis.org					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	21-May-2024 [LOI/Pre-App], 17-	-Jul-2024				
Synopsis	This Request for Proposals (RFP) RA, including from pre-RA to clir define risk factors/biomarkers o disease onset and progression. T slow disease progression.	nical RA, and progress f disease progression,	ion to more severe disea pathogenic mechanisms	se. Competers, and approved	titive projects sh oaches to prever	ould aim to nt or slow RA
Applicant Types						



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amoun
Funding Limit Limited Submission	0.00 see detail				
079141 Exceptional Project Grants		Breast Cancer Al	liance, Inc.	19-Jul-20	24 250,000 USD
Contact Name					
Contact Telephone	203-861-0014				
Contact Email	researchgrants@breastcancerallia	ance.org			
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	19-Jul-2024				
Synopsis	Breast Cancer Alliance invites clin docs, whose current proposal is for recognizes creative, unique and ir contiguous United States. This is a	ocused on breast can movative research a	icer, to apply for an Except nd is open to applicants a	tional Project Grant	. This award
Applicant Types					
Funding Limit	125,000.00 per year				
Limited Submission	Yes				
059797 Young Investigator Grant Progr	am	Breast Cancer Al	liance, Inc.	19-Jul-20	24 125,000 USD
Contact Name					
Contact Telephone	203-861-0014				

Contact Email researchgrants@breastcanceralliance.org

Sponsor Website Link to sponsor website



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Fundi	ing Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	19-Jul-2024				
Synopsis	Breast Cancer Alliance invites clinical doctors and including post docs, whose current proposal is foc Investigator Grant. This is a two-year grant for a to	used on breast cancer, to app			
Applicant Types	·				
Funding Limit	125,000.00 see detail				
Limited Submission	Yes				
062091 Macular Degeneration Researce	<u>ch Program - Postdoctoral Fellowship</u> BrightFocus	Foundation	25-Jul-20 [LOI/Pre	-	200,000 USD
Contact Name					
Contact Telephone					
Contact Email	researchgrants@brightfocus.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	25-Jul-2024 [LOI/Pre-App], 05-Dec-2024				
Synopsis	This Macular Degeneration Research Fellowship is final stages of mentored training. The award provi studies in an established laboratory focused on re- new clinical treatment of macular degeneration. T on some aspect of research that will have an impa- also serve as the basis for the applicant's own inde- year for two years.	des salary support for a youn search contributing to unders he specific research proposed ct on understanding or treati	g scientist to condu standing the biologi d in the application ng macular degener	ict posto cal caus should ration a	doctoral ses and/or be focused and should
Applicant Types					



SPIN ID	Program Title	Sponsor Name	Sponsor N	umber De	eadline Date Fun	ding Amount
	Funding Limit Limited Submission	100,000.00 per year No				
104567	Macular Degeneration Researc	h Program - New Investigator Grant	BrightFocus Foundation		25-Jul-2024 [LOI/Pre-App]	450,000 USD
	Sponsor Website Program URL	800-437-2423 <u>researchgrants@brightfocus.org</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 25-Jul-2024 [LOI/Pre-App], 05-Dec-2				
	Synopsis	BrightFocus provides research funds prevention, and treatment of age-re support investigators during their ea on the causes and/or treatment of p	elated macular degeneration. T arly years as an independent in	The New Investiga	ntor Grant Program is	intended to
	Applicant Types					
	Funding Limit	150,000.00 per year				
	Limited Submission	No				
104563	Macular Degeneration Researc Grants	h Program - Innovative Research	BrightFocus Foundation		25-Jul-2024 [LOI/Pre-App]	600,000 USD
	Contact Name					
	Contact Telephone	800-437-2423				
	Contact Email	researchgrants@brightfocus.org				
	Sponsor Website	Link to sponsor website				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amo	unt		
	Program URL	Link to program URL							
	Deadline Dates (ALL)	25-Jul-2024 [LOI/Pre-App], 05-De	c-2024						
	BrightFocus provides research funds for researchers pursuing pioneering research leading to greater understanding, Synopsis prevention, and treatment of age-related macular degeneration. The Innovative Research Grants program is intende to provide support for high-risk/high-gain age-related macular degeneration research.								
	Applicant Types								
	Funding Limit	200,000.00 per year							
	Limited Submission	No							
113471	Texas New Technologies Comp Development Research	any Awards for Product	Cancer Prevent of Texas	ion and Research Institute	e 25-Jul-2	.024 Not Specifie	ed		
	Contact Name								
	Contact Telephone	512-463-3190							
	Contact Email	cprit@cprit.state.tx.us							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	25-Jul-2024							
	Synopsis	Funding available through this RF, technologies for the detection, di fund new and emerging technolog Development Research RFAs. Pro production of radionuclides or the quality of the samples used for ca appropriate justification, compan	agnosis, prognosis, gy projects that do i posals may include, eir precursors, mani incer research or cli	monitoring, or treatment not easily fit into any of th but are not limited to, bio ufacture of cell-based the nical care, and biomanufa	of cancer. CPRIT cre three other CPRIT oinformatics, artifici rapies, processes to cturing of therapeu	eated this RFA to Product al intelligence, improve the tics. With	)		



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline	Date Fund	ing Amount
	concept, product validation, design	n, production, manu	facturing and developme	nt, and clin	ical studies der	nonstrating
Applicant Type Funding Limi Limited Submission	t 0.00 not provided					
059521 Grants Program		Conservation, Fc	ood and Health Foundation	า	01-Jul-2024 [LOI/Pre-App]	Not Specified
Contact Name	Prentice Zinn					
Contact Telephone	617-391-3091					
Contact Emai	I <u>pzinn@gmafoundations.com</u>					
Sponsor Website	<u>Link to sponsor website</u>					
Program UR	Link to program URL					
Deadline Dates (ALL	) 01-Jul-2024 [LOI/Pre-App], 01-Sep-	2024				
Synopsi	The Conservation, Food and Health promote public health in Africa, Asi projects and applied research that environment and human life; advar agricultural, and health sciences; de the field. The Foundation prefers to Foundation funds applied research ongoing support for programs that seed money to help promising proj major foundation funding in the fut	ia, the Caribbean, La generate local or re nce local leadership evelop the capacity o support projects t , pilot projects, new are already well un ects, organizations,	atin America, and the Mid egional solutions to proble and promote professiona of local organizations and hat address under-funded initiatives, training, and t derway. An important go	dle East. T ms affectir I developn I coalitions I issues and echnical as al for the F	he Foundation ng the quality o nent in the con ; and address c d geographic ar ssistance, rathe Foundation is to	supports f the servation, hallenges in eas. The er than o provide
Applicant Type	S					



SPIN ID Program	n Title	Sponsor Name	Sponsor N	Number	Deadline Date	Funding Am	iount
	Funding Limit Limited Submission	0.00 see detail Yes					
037505		issertation Award Mathematics, ring and Social Sciences	Council of Graduate Schoo	ls	03-Jul-202	2,000	) USD
	Contact Telephone	e Anna M. Naranjo e 202-223-3791 e anaranjo@cgs.nche.edu					
	•	Link to sponsor website Link to program URL					
	Deadline Dates (ALL) Synopsis	The CGS/ProQuest Distinguished D	ssertations representing origi awards are given annually in t	nal work that m wo different br	akes an unusually sig oad areas (mathema	gnificant itics, physica	
	-	2,000.00 see detail					
001440 <u>Career Dev</u>	Limited Submission velopment Awards		Crohn's & Colitis Foundatio	on of America	06-May-20 [LOI/Pre-A	-	)00
	Contact Name Contact Telephone	N'Dea Johnson 800-932-2423					

Contact Email training\_awards@crohnscolitisfoundation.org

Sponsor Website Link to sponsor website



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Fundi	ing Amount
	Program URL	Link to program URL					
	Deadline Dates (ALL)	06-May-2024 [LOI/Pre-App], 19-Jul-2024					
	Synopsis	Career Development Awards are mentor research potential to prepare for a caree bowel disease (IBD).			•		
	Applicant Types						
	Funding Limit	60,000.00 per year					
	Limited Submission	No					
000055	Research Fellowship Awards	Cro	hn's & Colitis	Foundation of America	06-May- [LOI/Pre-		210,000 USD
	Contact Name	N'Dea Johnson					
	Contact Telephone	646-943-7501					
	Contact Email	training_awards@crohnscolitisfoundatio	n.org				
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	06-May-2024 [LOI/Pre-App], 19-Jul-2024					
	Synopsis	Research Fellowship Awards are intended skills related to basic research investigati ulcerative colitis.	••	•	•		•
	Applicant Types						
	Funding Limit	70,000.00 per year					
	Limited Submission	No					



SPIN ID Program Title	Spo	onsor Name	Sponsor Number	Deadline Date	Fund	ing Amount
000628 Senior Research Awards		Crohn's a	& Colitis Foundation of America	08-May-2 [LOI/Pre- <i>A</i>		390,000 USD
Contact Name	Saleha Hossain					
Contact Telephone	800-932-2423					
Contact Email	SRA@crohnscolitisf	oundation.org				
Sponsor Website	Link to sponsor web	<u>osite</u>				
Program URL	Link to program UR	<u>L</u>				
Deadline Dates (ALL)	08-May-2024 [LOI/F	Pre-App], 19-Jul-2024				
Synopsis			le established researchers with finer sources such as the National			preliminary
Applicant Types						
Funding Limit	130,000.00 per year	r				
Limited Submission	No					
063869 Litwin IBD Pioneers Initiative		Crohn's a	& Colitis Foundation of America	06-May-2 [LOI/Pre-A		130,000 USD
Contact Name	Saleha Hossain					
Contact Telephone						
Contact Email	litwinprogram@cro	hnscolitisfoundation.org				
Sponsor Website	Link to sponsor web	<u>osite</u>				
Program URL	Link to program UR	L				
Deadline Dates (ALL)	06-May-2024 [LOI/F	Pre-App], 19-Jul-2024				
Synopsis			ovative clinical and translational ar future. The program encourag			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Applicant Type:	identification of clinically relevant subsets innovative pilot research so that scientists Pioneers supports researchers who are ex improvements, including novel, out-of-the relevant focus. Additionally, the program as countries outside the United States.	s can test their initial ideas and genera ploring all possible opportunities for c e-box ideas, and funds innovative and	te preliminary data liagnostic and thera pioneering ideas th	Litwin IBD peutic at have a clinically
	t 130,000.00 see detail			
Limited Submission	n Yes			
083322 Crohn's & Colitis Foundation/I Award	NASPGHAN IBD Young Investigator Crob	nn's & Colitis Foundation of America	05-May-2 [LOI/Pre-	
Contact Name	2			
Contact Telephone				
Contact Emai	grant@crohnscolitisfoundation.org			
Sponsor Website	Link to sponsor website			
Program UR	Link to program URL			
Deadline Dates (ALL	) 20-Jul-2024			
Synopsis	This three-year grant, in partnership with available to research fellows or junior fact epidemiological, or basic scientific researc in their submission for either a Crohn's & they want their award to be considered for Award.	ulty. Applications must propose origina th related to pediatric inflammatory be Colitis Foundation Career Developmen	al clinical, translatio owel disease. Applic nt or Research Fello	nal, cants must indicate wship Award, if
Applicant Type	s			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	Funding Limit Limited Submission	0.00 see detail No			
112617	CureSearch Young Investigator Cancer Drug Development	International Award in Pediatric	CureSearch for Children's Cancer	22-Jul-2024	225,000 USD
	Sponsor Website	+1-240-235-2215 researchgrants@curesearch.org Link to sponsor website Link to program URL			
	Synopsis	pediatric oncology. The 2024 Youn young investigators in pediatric on	upports the recruitment of promising early- g Investigator Program is designed to provid cology drug development. The award is inte and are transitioning to a full-time academic	le support and training fo nded for investigators w	or exceptional
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	No			
092281	Damon Runyon-Rachleff Innov	ation Award	Damon Runyon Cancer Research Foundation	08-Jul-2024	400,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	awards@damonrunyon.org			
	Sponsor Website	Link to sponsor website			



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jul-2024				
	Synopsis	exceptionally creative thi understanding of and/or for two years, \$200,000 to four years total for \$80	leff Innovation Award is desi nkers with "high-risk/high-re approaches to the preventio per year (\$400,000 total) with 00,000). Stage 2 support for y their proposed research dur	ward" ideas that have the n, diagnosis or treatment n the opportunity for up to years three and four will be	potential to signific of cancer. The Stage two additional yea granted to those a	cantly impact our e 1 award will be ırs of funding (up
	Applicant Types					
	Funding Limit	200,000.00 per year				
	Limited Submission	No				
121027	Type 1 Diabetes Research Gran	t Program	Diabetes Resear	ch Connection	15-Jul-20	75,000 USD
	Contact Name					
	Contact Telephone	844-484-3372				
	Contact Email	research@diabetesresea	rchconnection.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jul-2024 , 15-Oct-2024	4			
	Synopsis		onnection gives early-career a as of cure and care, including		to perform innovati	ive type 1 diabetes
	Applicant Types					
	Funding Limit	75,000.00 maximum				
	Limited Submission	No				



SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amou
089070 <u>Myelodysplastic Syndrom</u>	es (MDS) Research F	Fund Dresne	r (Vera and Joseph) Foundation	08-Jul-20	24 Not Specifie
Contact N	Jame				
Contact Telep	hone				
Contact	Email <u>info@dresner</u>	foundation.org			
Sponsor We	bsite Link to sponso	or website			
Program	URL Link to progra	<u>m URL</u>			
Deadline Dates	(ALL) 08-Jul-2024				
Syn	opsis as MDS/myeld idiopathic cyto	oproliferative neoplasms (MPN	t of Myelodysplastic Syndromes ( ) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi h Fund (MDSRF).	cute myeloid leukem	ia following MD
Syn Applicant <sup>-</sup>	opsis as MDS/myeld idiopathic cyto the foundation	oproliferative neoplasms (MPN openia of undetermined signifi	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi	cute myeloid leukem	ia following MD
Applicant <sup>-</sup>	opsis as MDS/myeld idiopathic cyto the foundation	oproliferative neoplasms (MPN openia of undetermined signifi n established the MDS Researc	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi	cute myeloid leukem	ia following MD
Applicant <sup>-</sup>	opsis idiopathic cyto the foundation Types Limit 0.00 see detai	oproliferative neoplasms (MPN openia of undetermined signifi n established the MDS Researc	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi	cute myeloid leukem	ia following MD
Applicant <sup>-</sup> Funding	opsis idiopathic cyto the foundation Types Limit 0.00 see detai	oproliferative neoplasms (MPN openia of undetermined signifi n established the MDS Researc	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi	cute myeloid leukem	ia following MD potential (CHIF
Applicant <sup>-</sup> Funding Limited Submi 004329 <u>Grants Program</u>	opsis idiopathic cyto the foundation Types Limit 0.00 see detai	oproliferative neoplasms (MPN openia of undetermined signifi n established the MDS Researc il Drown	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi h Fund (MDSRF).	cute myeloid leukem esis of indeterminate	ia following MD potential (CHIF
Applicant <sup>-</sup> Funding Limited Submi 004329 <u>Grants Program</u> Contact N	opsis idiopathic cyto the foundation ypes Limit 0.00 see detai ssion No	oproliferative neoplasms (MPN openia of undetermined signifi n established the MDS Researc il Drown	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi h Fund (MDSRF).	cute myeloid leukem esis of indeterminate	ia following MD potential (CHIF
Applicant <sup>–</sup> Funding Limited Submi 004329 <u>Grants Program</u> Contact N Contact Telep	as MDS/myeld idiopathic cyto the foundation Types Limit 0.00 see detai ssion No	oproliferative neoplasms (MPN openia of undetermined signifi n established the MDS Researc il Drown	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi h Fund (MDSRF).	cute myeloid leukem esis of indeterminate	ia following MD potential (CHIF
Applicant <sup>-</sup> Funding Limited Submi 004329 <u>Grants Program</u> Contact N Contact Telep Contact	as MDS/myeld idiopathic cyto the foundation Types Limit 0.00 see detai ssion No Jame Alyssa Santino hone 310-277-4488	oproliferative neoplasms (MPN openia of undetermined signifi n established the MDS Researc il Drown o, Program Officer	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi h Fund (MDSRF).	cute myeloid leukem esis of indeterminate	ia following MD potential (CHIF
Applicant <sup>-</sup> Funding Limited Submi 004329 <u>Grants Program</u> Contact N Contact Telep Contact Sponsor We	as MDS/myeld idiopathic cyto the foundation Types Limit 0.00 see detai ssion No No No Alame Alyssa Santino hone 310-277-4488 Email alyssa@jdrow	oproliferative neoplasms (MPN openia of undetermined signifi n established the MDS Researc il Drown o, Program Officer	) overlap syndromes, secondary a cance (ICUS), or clonal hematopoi h Fund (MDSRF).	cute myeloid leukem esis of indeterminate	ia following MD potential (CHIF



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Fund	ing Amount
	Synopsis	The Joseph Drown Foundation prov medical and scientific research; arts state of California, are eligible. The does not make multi-year commitm take a two-year hiatus.	and humanities; a Foundation makes	nd special projects. Tax-e grants for both operating	exempt organization support and progra	s, prim am sup	narily in the port, but
	Applicant Types						
	Funding Limit	0.00 not provided					
	Limited Submission	No					
084903 <u>T</u>	rauma Research Scholarship		Eastern Associat Trauma Foundat	ion for the Surgery of ion	13-May-2 [LOI/Pre-		40,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	managementoffice@east.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	13-May-2024 [LOI/Pre-App], 22-Jul-	2024				
	Synopsis	The intent of the Trauma Research substance to have potential for furt science, clinical, epidemiology, injur	her funding source	es as initial studies are pro	duced and publishe	d (e.g.	basic
	Applicant Types						
	Funding Limit	40,000.00 maximum					
	Limited Submission	No					
006050 <u>R</u>	esearch Grant Awards		EMDR Research	Foundation	01-Jul-20	24	40,000 USD



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding A	Amount
	Contact Name							
	Contact Telephone	630-296-4399						
	Contact Email	info@emdrfour	idation.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Jul-2024						
	Synopsis	Grant awards o research on EM		ilable for post-o	loctoral students, universi	ty faculty or clinicia	in conducti	ng
	Applicant Types							
	Funding Limit	40,000.00 maxi	mum					
	Limited Submission	No						
006686 🤇	Cardiovascular Disease Fellows	hip Program		Emory Universit	у	15-Jul-20	)24 No Spe	ot ecified
	Contact Name	Lesia Waker, Pr	ogram Coordinator					
	Contact Telephone	404-712-1504						
	Contact Email	waker@emory.	<u>edu</u>					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	15-Jul-2024						
	Synopsis	and systematic understanding	instruction in the scier of the entire spectrum	ice and art of ca of cardiovascula	s to train leaders in cardio rdiovascular disease. The ar pathophysiology, from t ows receive excellent trai	training program er he molecular and c	nphasizes ellular leve	el to



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
		bedside diagnosis to incorporation evidence-based and guideline-or		-	utic management, wit	h an emphasis on		
	Applicant Types							
	Funding Limit	0.00 not provided						
	Limited Submission	No						
103754	High Impact Research Grant		Eye Bank Associ	ation of America	31-Jul-20	024 50,000 USD		
	Contact Name	Stacey Gardner						
	Contact Telephone	202-775-4999						
	Contact Email	Stacey@restoresight.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL	Link to program URL					
	Deadline Dates (ALL)	31-Jul-2024						
	Synopsis	The Eye Bank Association of Ame and knowledge in sight restoration focused on the topic, "Developm	on, eye banking and o	cornea transplantation.	In 2024, EBAA seeks to	o fund research		
	Applicant Types							
	Funding Limit	50,000.00 maximum						
	Limited Submission	No						
057307	Research Grants		Fibrolamellar Ca	ancer Foundation	01-Jul-20	024 Not Specified		
	Contact Name	Payal Ray						
	Contact Telephone	203-340-7800						

Contact Email pray@fibrofoundation.org



Sponsor Website Program URL       Link to sponsor website Program URL         Deadline Dates (ALL)       01-Jul-2024, 01-Nov-2024         The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC), FLC, also known as fibrolamellar hepatocellular carcinoma (FL-HCC), is an aggressive liver cancer that tends to strike teens and young adults. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the Synopsis understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals. The FCF believes that collaboration engaging the best talent across institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers.         Applicant Types Funding Limit d Submission 058675       Foundation for Food and Agriculture Research       31-Jul-2024       1,000,000 USD         Ostact Name Sponsor Webste Link to sponsor website Program URL Link to program URL Deadline Dates (ALL)       20-624-0700       1,000,000 USD         Contact Telephone Sponsor Webste Link to program URL Deadline Dates (ALL)       31-Jul-2024       1,000,000 USD	SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
Program URL       Link to program URL         Deadline Dates (ALL)       01-Jul-2024, 01-Nov-2024         The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC). FLC, also known as fibrolamellar hepatocellular carcinoma (FLC), is an aggressive liver cancer that tends to strike teens and young adults. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards an ovel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the believes that collaboration engaging the best talent across institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers.         Applicant Types       Foundation for Food and Agriculture       31-Jul-2024       1,000,000         058675       Seeding Solutions Research Grants       Foundation for Food and Agriculture       31-Jul-2024       1,000,000         USD       Contact Name       Ryan Comella       Contact Telephone       202-624-0700       1,000,000         Contact Telephone       202-624-0700       Contact Telephone       202-624-0700       1,000,000       USD         Contact Email       romella@foundationfar.org       Sp			1						
Deadline Dates (ALL)       01-Jul-2024, 01-Nov-2024         The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC). FLC, also known as fibrolamellar hepatocellular carcinoma (FL-HCC), is an aggressive liver cancer that tends to strike teens and young adults. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals. The FCF believes that collaboration engaging the best talent across institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers.       Applicant Types         Seeding Solutions Research Grants       Foundation for Food and Agriculture Research       31-Jul-2024       1,000,000 USD         Contact Name       Ryan Comella       202-624-0700       Contact Elephone       202-624-0700       5         Sponsor Website       Link to pporgram URL       Link to program URL       Link to program URL       Link to program URL									
The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC). FLC, also known as fibrolamellar hepatocellular carcinoma (FL-HCC), is an aggressive liver cancer that tends to strike teens and young adults. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the support innovative and particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals. The FCF believes that collaboration engaging the best talent across institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers.         Applicant Types       Funding Limit         Funding Limit       0.00 see detail         Limited Submission       No         058675       Seeding Solutions Research Grants       Foundation for Food and Agriculture Research       31-Jul-2024       1,000,000 USD         Contact Name       Ryan Comella       Contact Trelephone       202-624-0700       USD       USD         Contact Email       rcomella@foundationfar.org       Sponsor Website       Link to program URL       Link to program URL       Link to program URL		Program URL							
understanding and curative treatments for fibrolamellar carcinoma (FLC). FLC, also known as fibrolamellar hepatocellular carcinoma (FL-HCC), is an aggressive liver cancer that tends to strike teens and young adults. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals. The FCF believes that collaboration engaging the best talent across institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers. Applicant Types Funding Limit 0.00 see detail Limited Submission No 058675 Seeding Solutions Research Grants Foundation for Food and Agriculture Contact Telephone 202-624-0700 Contact Telephone 202-624-0700 Contact Email Sponsor Website Program URL Link to sponsor website Program URL		Deadline Dates (ALL)	01-Jul-2024 , 01-Nov-2024						
Funding Limit       0.00 see detail         Limited Submission       No         058675       Seeding Solutions Research Grants         Contact Name       Ryan Comella         Contact Telephone       202-624-0700         Contact Email       rcomella@foundationfar.org         Sponsor Website       Link to sponsor website         Program URL       Link to program URL		Synopsis	understanding and curative treatme hepatocellular carcinoma (FL-HCC), research must focus specifically on l understanding, diagnosis, epidemio path towards a novel therapy or clir accept grant applications to support believes that collaboration engaging	ents for fibrolamel is an aggressive liv FLC. Studies should logy, or treatment nical trials with the innovative and pu g the best talent ag	lar carcinoma (FLC). FLC, ver cancer that tends to s d be intended to advance of FLC. Of particular inte ultimate goal of achievir comising research project cross institutions, togethe	also known as fibrola trike teens and youn knowledge relevant rest are applications ng a cure for FLC. The ts towards the listed	amellar g adults. The to the showing a clear Foundation will goals. The FCF		
Limited Submission       No         058675       Seeding Solutions Research Grants       Foundation for Food and Agriculture Research       31-Jul-2024       1,000,000 USD         Contact Name       Ryan Comella       202-624-0700       202-624-0700       1,000,000         Contact Email       rcomella@foundationfar.org       1,000,000       1,000,000         Sponsor Website       Link to sponsor website       1,000,000       1,000,000         Program URL       Link to program URL       1,000,000       1,000,000		Applicant Types							
058675 Seeding Solutions Research Grants       Foundation for Food and Agriculture Research       31-Jul-2024       1,000,000 USD         Contact Name Contact Telephone       Ryan Comella       202-624-0700       1,000,000 USD         Contact Email       comella@foundationfar.org       Link to sponsor website       1,000,000 USD         Program URL       Link to program URL       Link to program URL       1,000,000 USD		Funding Limit	0.00 see detail						
OS8675     Seeding Solutions Research Grants     Research     31-Jul-2024     USD       Contact Name     Ryan Comella     202-624-0700     202-624-0700     202-624-0700       Contact Email     rcomella@foundationfar.org     Ink to sponsor website     Ink to sponsor website       Program URL     Link to program URL     Link to program URL		Limited Submission	No						
Contact Telephone 202-624-0700 Contact Email <u>rcomella@foundationfar.org</u> Sponsor Website <u>Link to sponsor website</u> Program URL <u>Link to program URL</u>	058675	Seeding Solutions Research Gra	ants		Food and Agriculture	31-Jul-20	14		
Contact Email <u>rcomella@foundationfar.org</u> Sponsor Website <u>Link to sponsor website</u> Program URL <u>Link to program URL</u>		Contact Name	Ryan Comella						
Sponsor Website Link to sponsor website Program URL Link to program URL		Contact Telephone	202-624-0700						
Program URL Link to program URL		Contact Email	rcomella@foundationfar.org						
		Sponsor Website	Link to sponsor website						
Deadline Dates (ALL) 31-Jul-2024		Program URL	Link to program URL						
		Deadline Dates (ALL)	31-Jul-2024						



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	The Foundation for Food & Agriculture F research to benefit farmers, consumers, applications, prioritizing those projects t	and the environment. FFAR seeks to aw	vard approximately	ten meritorious
Applicant Types	1,000,000.00 maximum	nat emphasize a commitment to cross-s	sector partnerships.	
054948 Moffat Geriatric Research Gran	<u></u> Fo	undation for Physical Therapy Research	31-Jul-20	40,000 USD
Sponsor Website Program URL Deadline Dates (ALL) Synopsis	1-800-875-1378 info@foundation4pt.org Link to sponsor website Link to program URL	s of physical therapist examinations and iorities identified in the APTA 2023 Rese	l/or interventions ir	n geriatric
Applicant Types Funding Limit Limited Submission	40,000.00 maximum			
062339 Foundation Research Grant	Fo	undation for Physical Therapy Research	31-Jul-20	24 40,000 USD
Contact Name Contact Telephone				



SPIN ID Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
Contact Email	info@foundation4pt.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	31-Jul-2024				
Synopsis	The Foundation for Physical T effectiveness of physical ther or more priority area(s) of the \$40,000 for a period of either	apist interventions, with APTA 2023 Research A	nin any discipline relevant t	o physical therapy, a	and addresses one
Applicant Types					
Funding Limit	40,000.00 maximum				
Limited Submission	No				
030560 Therapeutic Pipeline Program		Fox (Michael J.) Research	Foundation for Parkinson	s 16-May-2	2,000,000 USD
Contact Name					
Contact Telephone	212-509-0995				
Contact Email	grants@michaeljfox.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	16-May-2024 , 18-Jul-2024				
Synopsis	The Pre-clinical Therapeutics clinical testing of approaches to benefit therapeutics with c daily symptoms.	addressing unmet need	s of people with Parkinson	's disease (PD). The	program is set up
Applicant Types					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	Inding Amount
	Funding Limit Limited Submission	2,000,000.00 see detail No			
076215	Shaffer Grant		Glaucoma Research Foundation	15-Jul-2024	55,000 USD
	Sponsor Website Program URL Deadline Dates (ALL) Synopsis Applicant Types	415-986-3162 <u>research@glaucoma.org</u> <u>Link to sponsor website</u> <u>Link to program URL</u> 15-Jul-2024 The Glaucoma Research Foundation s based on their strategic research goa	supports new high-impact clinical, epic ls.	demiological and laboratory	research
058140	Limited Submission Harvard Medical School Fellow Primary Care	shin in General Medicine and	Harvard Medical School	08-Jul-2024	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website	617-754-1426 GIMFellowship@bidmc.harvard.edu Link to sponsor website Link to program URL			



Synopsis       The Harvard Medical School Fel prepare talented physicians for         Applicant Types       0.00 not provided         Limited Submission       No         120996       HESI THRIVE Grants         Contact Name       Contact Name	lowship in General Medicine and Primary Care careers in academic medicine. Health and Environmental Sciences Institute (HESI)	e offers 2-year academic f 24-Jul-2024	fellowships to
Applicant Types Funding Limit 0.00 not provided Limited Submission No 120996 <u>HESI THRIVE Grants</u>	Health and Environmental Sciences		
Funding Limit 0.00 not provided Limited Submission No 120996 <u>HESI THRIVE Grants</u>		24-Jul-2024	
Limited Submission No 120996 HESI THRIVE Grants		24-Jul-2024	
120996 HESI THRIVE Grants		24-Jul-2024	50.000 USD
		24-Jul-2024	50.000 USD
Contact Name			
Contact Telephone 202-659-8404			
Contact Email <u>hesiprize@hesiglobal.org</u>			
Sponsor Website Link to sponsor website			
Program URL Link to program URL			
Deadline Dates (ALL) 24-Jul-2024			
and how adverse effects may or approaches to avoid or lessen to networks, THRIVE will enhance funding entities might elect to i program is designed to provide	science, clinical, and translational research the ccur in patients who have received cancer trea hese effects. By providing researchers with bo the visibility of the patient need, the value of ncorporate these research streams into future seed funding to investigators for the testing o long-term funding by the National Institutes o	atment and supports the opth seed funding and acce the research, and the rea e funding priorities. The T of initial hypotheses and c	development of ss to critical sons that larger HRIVE grant ollecting of
Applicant Types			
Funding Limit 50,000.00 maximum			
Limited Submission No			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
125279 Distinguished Professorship	Ηε	elmholtz Association	31-Jul-202	A Not Specified
Contact Name				
Contact Telephone	+49 30 206 329-0			
Contact Email	ebp_hdp@helmholtz.de			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	31-Jul-2024			
	The Helmholtz Association is intensifying Distinguished Professorships. A fundame			
Synopsis	yet employed at the Helmholtz Center. (that is, at the time the application is sul prerequisite for the funding is that the r at the partner university (so-called "Rufe meeting.	The funding program targets outstan bmitted) conducting research at insti nominated candidate has not receive	ding female scientists w itutions abroad. Anothe d an offer for the profes	ho are currently r important sorship position
Synopsis Applicant Types	yet employed at the Helmholtz Center. (that is, at the time the application is sul prerequisite for the funding is that the r at the partner university (so-called "Rufe meeting.	The funding program targets outstan bmitted) conducting research at insti nominated candidate has not receive	ding female scientists w itutions abroad. Anothe d an offer for the profes	ho are currently r important sorship position
Applicant Types	yet employed at the Helmholtz Center. (that is, at the time the application is sul prerequisite for the funding is that the r at the partner university (so-called "Rufe meeting.	The funding program targets outstan bmitted) conducting research at insti nominated candidate has not receive	ding female scientists w itutions abroad. Anothe d an offer for the profes	ho are currently r important sorship position
Applicant Types	yet employed at the Helmholtz Center. (that is, at the time the application is sul prerequisite for the funding is that the r at the partner university (so-called "Rufe meeting. 0.00 see detail	The funding program targets outstan bmitted) conducting research at insti nominated candidate has not receive	ding female scientists w itutions abroad. Anothe d an offer for the profes	ho are currently r important sorship position
Applicant Types Funding Limit	yet employed at the Helmholtz Center. (that is, at the time the application is sul prerequisite for the funding is that the r at the partner university (so-called "Rufe meeting. 0.00 see detail No	The funding program targets outstan bmitted) conducting research at insti nominated candidate has not receive	ding female scientists w itutions abroad. Anothe d an offer for the profes	ho are currently r important sorship position ship selection
Applicant Types Funding Limit Limited Submission	yet employed at the Helmholtz Center. (that is, at the time the application is sul prerequisite for the funding is that the r at the partner university (so-called "Rufe meeting. 0.00 see detail No He So	The funding program targets outstan bmitted) conducting research at insti- nominated candidate has not receive erteilung") until after the Helmholtz emostasis & Thrombosis Research	ding female scientists w itutions abroad. Another d an offer for the profes Distinguished Professors	ho are currently r important sorship position ship selection 100,000
Applicant Types Funding Limit Limited Submission 057292 <u>HTRS/ATHN DREAM Award</u>	yet employed at the Helmholtz Center. (that is, at the time the application is sul prerequisite for the funding is that the r at the partner university (so-called "Rufe meeting. 0.00 see detail No He So	The funding program targets outstan bmitted) conducting research at insti- nominated candidate has not receive erteilung") until after the Helmholtz emostasis & Thrombosis Research	ding female scientists w itutions abroad. Another d an offer for the profes Distinguished Professors	ho are currently r important sorship position ship selection 100,000
Applicant Types Funding Limit Limited Submission 057292 <u>HTRS/ATHN DREAM Award</u> Contact Name Contact Telephone	yet employed at the Helmholtz Center. (that is, at the time the application is sul prerequisite for the funding is that the r at the partner university (so-called "Rufe meeting. 0.00 see detail No He So	The funding program targets outstan bmitted) conducting research at insti- nominated candidate has not receive erteilung") until after the Helmholtz emostasis & Thrombosis Research	ding female scientists w itutions abroad. Another d an offer for the profes Distinguished Professors	ho are currently r important sorship position ship selection 100,000



SPIN ID Program Title	Spons	or Name	Sponsor Number	Deadline Date	Funding Amount	
Program URI	Link to program URL					
Deadline Dates (ALL)	01-Jul-2024					
Synopsis		M Award enables young inves tment centers to conduct res				
Applicant Types	;					
Funding Limit	100,000.00 maximum					
Limited Submissior	No					
081163 SWOG/Hope Impact Award		Hope Foundat	ion for Cancer Research	01-Jul-202	250,000 24 USD	
Contact Name	Johanna Horn, Preside	nt & CEO				
Contact Telephone	734-998-7150					
Contact Emai	jo@thehopefoundatio	n.org				
Sponsor Website	Link to sponsor websit	<u>e</u>				
Program URI	Link to program URL					
Deadline Dates (ALL)	01-Jul-2024 , 01-Sep-2	024				
Synopsis	The SWOG/Hope Foundation Impact Award is a funding program that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to future clinical trials in SWOG and the National Clinical Trials					
Applicant Types	;					
Funding Limit	250,000.00 maximum					



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
Limited Submission	No			
033209 HD Human Biology Project Fell	owship	Huntington's Disease Society of America, Inc.	05-Jul-2024	4 180,000 USD
Contact Name				
Contact Telephone	212-242-1968 x219			
Contact Emai	lfox@hdsa.org			
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			
Deadline Dates (ALL)				
Deadline Dates (ALL) Synopsis	The HD Human Biology Project provide understanding the biology of Huntingt from them should have the potential t for HD. The HD Human Biology Projec two years) for new clinical or translatio	es support for investigator-initiated resea con's disease (HD) in humans. The researce to directly impact the lives of patients or the trellowships are provided as "seed moni- onal research projects that are directly re- n be used to attract funding from other s	ch projects and observa help guide future drug ies" (up to \$90,000 per lated to understanding	ations resulting development r year for up to
	The HD Human Biology Project provide understanding the biology of Huntingt from them should have the potential t for HD. The HD Human Biology Projec two years) for new clinical or translatio disease in the hope that the results ca	con's disease (HD) in humans. The researce to directly impact the lives of patients or t Fellowships are provided as "seed mon onal research projects that are directly re	ch projects and observa help guide future drug ies" (up to \$90,000 per lated to understanding	ations resulting development r year for up to
Synopsis Applicant Types	The HD Human Biology Project provide understanding the biology of Huntingt from them should have the potential t for HD. The HD Human Biology Projec two years) for new clinical or translatio disease in the hope that the results ca	con's disease (HD) in humans. The researce to directly impact the lives of patients or t Fellowships are provided as "seed mon onal research projects that are directly re	ch projects and observa help guide future drug ies" (up to \$90,000 per lated to understanding	ations resulting development r year for up to
Synopsis Applicant Types	The HD Human Biology Project provide understanding the biology of Huntingt from them should have the potential t for HD. The HD Human Biology Projec two years) for new clinical or translatio disease in the hope that the results ca	con's disease (HD) in humans. The researce to directly impact the lives of patients or t Fellowships are provided as "seed mon onal research projects that are directly re	ch projects and observa help guide future drug ies" (up to \$90,000 per lated to understanding	ations resulting development r year for up to
Synopsis Applicant Types Funding Limit	The HD Human Biology Project provide understanding the biology of Huntingt from them should have the potential t for HD. The HD Human Biology Project two years) for new clinical or translatio disease in the hope that the results ca 90,000.00 per year No	con's disease (HD) in humans. The researce to directly impact the lives of patients or t Fellowships are provided as "seed mon onal research projects that are directly re	ch projects and observa help guide future drug ies" (up to \$90,000 per lated to understanding	ations resulting development r year for up to g Huntington's
Synopsis Applicant Types Funding Limit Limited Submission	The HD Human Biology Project provide understanding the biology of Huntingt from them should have the potential t for HD. The HD Human Biology Projec two years) for new clinical or translatio disease in the hope that the results ca 90,000.00 per year No	con's disease (HD) in humans. The researce to directly impact the lives of patients or it Fellowships are provided as "seed moni- onal research projects that are directly re- n be used to attract funding from other s	ch projects and observa help guide future drug ies" (up to \$90,000 per elated to understanding ources.	ations resulting development r year for up to g Huntington's
Synopsis Applicant Types Funding Limit Limited Submission 010629 IEEE Medal for Innovations in I	The HD Human Biology Project provide understanding the biology of Huntingt from them should have the potential t for HD. The HD Human Biology Project two years) for new clinical or translation disease in the hope that the results ca 90,000.00 per year No Healthcare Technology	con's disease (HD) in humans. The researce to directly impact the lives of patients or it Fellowships are provided as "seed moni- onal research projects that are directly re- n be used to attract funding from other s	ch projects and observa help guide future drug ies" (up to \$90,000 per elated to understanding ources.	ations resulting development r year for up to g Huntington's



SPIN ID	Program Title	Sponsor N	ame	Sponsor Number	Deadline Date	Funding Amou	ınt
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Jun-2024 , 01-Jul-2024					
	Synopsis	The IEEE Medal for Innovat and applications benefiting criteria are considered: imp contributions; leadership in publications or patents or o certificate, and cash honor	healthcare, medicine, an bact on the profession and accomplishing worthwhi other evidence; and qualit	d the health sciences. In th I/or society; succession of le goal(s); previous honors	ne evaluation proces significant technica ;; other achievemen	s, the following or other ts as evidenced b	
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
020632 <u>E</u>	lectron Devices Society PhD Si	tudent Fellowship	Institute of Elec Engineers (IEEE	ctrical and Electronics	15-Jul-20	024 5,000 U	SD
	Contact Name	Stacy Lehotzky					
	Contact Telephone	732-562-6635					
	Contact Email	<u>s.lehotzky@ieee.org</u>					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Jul-2024					
	Synopsis	The EDS PhD Student Fellor and research within the Ele			recognize, and supp	oort PhD level stu	udy
	Applicant Types						
	Funding Limit	5,000.00 see detail					



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Limited Submission	No			
019720 Roy Ellis Patient Benefit Award		titute of Physics and Engineering in edicine (IPEM)	31-Jul-20	24 375 USD
Contact Name				
Contact Telephone	01904 610821			
Contact Email	marie@ipem.ac.uk			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	31-Jul-2024			
Synopsis	The Roy Ellis Patient Benefit Award is aw patients. This may be directly, for examp information leaflet or providing advice o and a certificate.	le, designing a bespoke device or indir	ectly, for example, p	roducing an
Applicant Types				
Funding Limit	300.00 see detail			
Limited Submission	No			
019819 Innovation Gold Medal		titute of Physics and Engineering in edicine (IPEM)	31-Jul-20	24 625 USD
Contact Name				
Contact Telephone	01904 610821			
Contact Emai	office@ipem.ac.uk			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	31-Jul-2024				
	Synopsis	IPEM awards the Innovation of outstanding level of contribut practice; related to physics and the second se	tion to the advancement	of healthcare innovation		
	Applicant Types					
	Funding Limit	500.00 see detail				
	Limited Submission	No				
000405 🤇	Christianson Fellowship		InterExchange F	oundation	15-Jul-20	24 10,000 USD
	Contact Name					
	Contact Telephone	212-924-0446				
	Contact Email	grants@interexchange.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jul-2024 , 15-Oct-2024 , 1	5-Mar-2025			
	Synopsis	The InterExchange Foundation meaningful projects abroad. money to support motivated abroad. The volunteer project	Funding is available for in young Americans who ar	npactful service projects re committed to perform	abroad with up to \$1 meaningful service p	0,000 in grant projects
	Applicant Types					
	Funding Limit	10,000.00 maximum				
	Limited Submission	No				
019752	Educational Support Grant Prop	gram	International Em	nbryo Transfer Society	01-Jul-20	24 Not Specified



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
Contact Name	2			
Contact Telephone	217-398-4697			
Contact Email	iets@assochq.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Jul-2024			
Synopsis	The purpose of this program is to stimulate de the IETS Foundation; and to encourage use of the development, application and research in transfer, genetic enhancement of animals, en products arising from embryo biotechnology.	electronic technologies to deliv embryo-related technologies, i	er educational informat ncluding but not limited	ion regarding to, nuclear
Applicant Types	;			
Funding Limit	0.00 not provided			
Limited Submission	No			
022521 Grants Program	Internat	tional Foundation	31-May-20	24 50,000 USD
Contact Name	2			
Contact Telephone	2			
Contact Email	info@intlfoundation.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	31-May-2024 , 31-Jul-2024 [LOI/Pre-App], 31-	Oct-2024		
Synopsis	The International Foundation's grants suppor believe address the most pressing needs in th	t the specific types of programs he world today. Eligible organiza	in specific geographic r tions must have substan	egions, that we tial experience



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		in implementing projects with measu Environment Health	urable results in one or more of the follow	ing categories: Agric	ulture Education
	Applicant Types				
	Funding Limit	50,000.00 maximum			
	Limited Submission	Yes			
020749	Primary Grants		International Mechanical Diagnosis and Therapy Research Foundation	01-Jul-20	50,000 USI
	Contact Name				
	Contact Telephone				
	Contact Email	info@imdtrf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2024			
	Synopsis	Diagnosis and Therapy (MDT) which quality of care for patients with mus	ications to further research into the usefu could include basic and clinical sciences w culoskeletal conditions. New or experience a peer-review process and only the highes ested.	ith the ultimate aim ed investigators are	of improving the encouraged to
	Applicant Types				
	Funding Limit	50,000.00 maximum			
	Limited Submission	No			
017755 🤇	G.G. Stokes Award in Optical Po	olarization	International Society for Optics and Photonics (SPIE)	01-Jul-20	024 2,000 USD



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone	360-676-3290				
	Contact Email	awards@SPIE.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2024 , 15-Jul-2024				
	Synopsis	The SPIE George W. Goddard Av achievement in optical or photo reconnaissance or surveillance. technology, instrumentation, or	nic technology or instr The award is for the in	rumentation for earth or p vention and development	lanetary or astrono	mical science,
	Applicant Types					
	Funding Limit	2,000.00 maximum				
	Limited Submission	No				
017118 🤇	George W. Goddard Award in S	pace and Airborne Optics	International Soc Photonics (SPIE)	ciety for Optics and	01-Jul-20	24 2,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	awards@spie.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2024 , 15-Jul-2024				
	Synopsis	The SPIE George W. Goddard Av achievement in optical or photo	vard in Space and Airb nic technology or instr	orne Optics is presented i rumentation for earth or p	n recognition of exc lanetary or astrono	eptional mical science,



SPIN ID Program Title	Sponsor Name	Spons	sor Number	Deadline Date	Funding Am	ount
	reconnaissance, or surveillance. Th			•	r technique,	
	technology, instrumentation, or sy	stem. The award carries a	n honorarium of \$2	2,000.		
Applicant Types						
•	2,000.00 maximum					
Limited Submission	No					
023519 Britton Chance Biomedical Opt	tics Award	International Society for Photonics (SPIE)	or Optics and	15-Jul-20 [LOI/Pre-/	2 000	) USD
Contact Name						
Contact Telephone	360-676-3290					
Contact Email	awards@spie.org					
Sponsor Website	Link to sponsor website					
Program URL	Link to program URL					
Deadline Dates (ALL)	15-Jul-2024 [LOI/Pre-App]					
Synopsis	The Britton Chance Biomedical Op contributions to the field of biome					
Applicant Types	5					
Funding Limit	2,000.00 maximum					
Limited Submission	n No					
093725 Research Fellowships		Internationales Forsch Kulturwissenschaften	ungszentrum	07-Jul-20	24 9,951	USD
Contact Name						
Contact Telephone	+43 1 504 11 26 2606					
Contact Email	fellows@ifk.ac.at					



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Sponsor Website	Link to sponsor website				
	L <u>Link to program URL</u>				
Deadline Dates (ALL	) 07-Jul-2024				
Synopsi	الجلام IFK Research Fellowships provide su at IFK in Vienna.	upport for post-doo	ctoral scholars early in thei	ir careers for one ac	ademic semester
Applicant Type	s				
Funding Limi	t 2,325.00 per month				
Limited Submission	n No				
093722 Senior Fellowships	Internationales I Kulturwissensch	Forschungszentrum aften	07-Jul-202	24 9,951 USD	
Contact Name	e				
Contact Telephone	e +43-1-504 11 26				
Contact Ema	il <u>fellows@ifk.ac.at</u>				
Sponsor Website	e <u>Link to sponsor website</u>				
Program UR	L <u>Link to program URL</u>				
Deadline Dates (ALL	) 07-Jul-2024				
Synopsi	The IFK's Senior Fellowships are des careers.	signed to support e	excellent scholars, who are	well advanced in th	eir academic
Applicant Type	s				
Funding Limi	t 2,325.00 per month				
Limited Submission	n No				
115605 Healthy Eating Research (HER)	) Call for Proposals	Johnson (Robert	Wood) Foundation	10-Jul-202	275,000 24 USD



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
	Contact Name					
	Contact Telephone	800-578-8636				
	Contact Email	<u>healthyeating@duke.edu</u>				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jul-2024				
	Synopsis	As part of its commitment to seeks ideas that advance hea improving diet quality and nu nutrition insecurity. HER's mi strategies that promote healt Awards are up to a maximum	Ith, equity, and wellbeing trition for all Americans, ssion is to support and di hy eating among childrer	. Healthy Eating Research addressing nutrition dispa sseminate research on po	(HER) supports this rities, and reducing licy, systems, and e	s goal through g food and nvironmental
	Applicant Types					
	Funding Limit	275,000.00 maximum				
	Limited Submission	No				
111756	Waite-Griffin SBMA Fellowship		Kennedy's Disea	se Association	03-Jul-20	24 Not Specified
	Contact Name					
	Contact Telephone	559-658-5950				
	Contact Email	info@kennedysdisease.org				
	Sponsor Website	Link to sponsor website				

Program URL Link to program URL

Deadline Dates (ALL) 03-Jul-2024



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	Synopsis	The fellowship will provide a one-ye patient care.	ear stipend for a junior PhD or MD interested	d in a career in SBMA re	search and/or
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
077770	Emerging Leader Award		Mark Foundation for Cancer Research	22-Jul-2024	750,000 USD
	Contact Name				
	Contact Telephone	646-866-5950			
	Contact Email	info@themarkfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Jul-2024			
		• •	der Awards support innovative cancer resea to outstanding early career investigators to s research portfolio.	-	
	Applicant Types				
	Funding Limit	250,000.00 per year			
	Limited Submission	Yes			
068239	Grants Program - Healthcare In	itiatives	McGowan (William G.) Charitable Fund, Inc.	01-Jul-2024 [LOI/Pre-Apj	Not ] Specified
	Contact Name				
	Contact Telephone	312-761-9503			



SPIN ID Program Title	Sponsor Name	2	Sponsor Number	Deadline Date	Funding Amount
Contact Email	info@williamgmcgowanfund.or	rg			
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Jul-2024 [LOI/Pre-App], 01-/	Aug-2024			
Synopsis	The McGowan Charitable Fund mobility out of poverty and fun may not have other care optior	nds programs that seek			· ·
Applicant Types	3				
Funding Limit	t 0.00 not provided				
Limited Submission	ΙΝΟ				
017361 Thoracic Pathology Fellowship		Memorial Sloan	-Kettering Cancer Center	31-Jul-2	024 Not Specified
Contact Name	Angelica Angel and Sheila Vazq	uez			
Contact Telephone	212-639-7456				
Contact Email	l <u>pthfellows@mskcc.org</u>				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	i 31-Jul-2024				
Synopsis	The Department of Pathology a Pathology Fellowship Training F Education (ACGME). A second o should have completed training Board of Pathology prior to app	Program. A clinical yea optional research year g in anatomic patholog	r is accredited by the Accr focuses on the molecular y and be certified (or eligi	editation Council fo biology of thoracic	or Graduate Medical disease. All fellows
Applicant Types	<b>;</b>				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	Funding Limit Limited Submission	0.00 not provided No			
016997	Department of Pathology - Der	matopathology Fellowship M	emorial Sloan-Kettering Cancer Center	01-Jul-2024	Not Specified
	Contact Name	Angelica Angel and Sheila Vazquez			
	Contact Telephone	212-639-7456			
	Contact Email	pthfellows@mskcc.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2024			
	Synopsis	The Department of Pathology offers a o accredited fellowship program in derma	•	ted a residency in Derr	• •
	Synopsis	Pathology Departments of the New York	•		rmatology and
	Applicant Types	Pathology Departments of the New York	•		rmatology and
	Applicant Types	Pathology Departments of the New York	•		rmatology and
	Applicant Types	Pathology Departments of the New York	•		rmatology and
061229	Applicant Types Funding Limit	Anatomic Pathology, or Anatomic and C Pathology Departments of the New York 0.00 not provided No	•		rmatology and
061229	Applicant Types Funding Limit Limited Submission	Anatomic Pathology, or Anatomic and C Pathology Departments of the New York 0.00 not provided No <u>MISP) HPV</u> M	k Presbyterian Hospital, Weill Medical Sc	hool of Cornell Univers	rmatology and sity.
061229	Applicant Types Funding Limit Limited Submission Investigator Studies Program (I	Anatomic Pathology, or Anatomic and C Pathology Departments of the New York 0.00 not provided No <u>MISP) HPV</u> M	k Presbyterian Hospital, Weill Medical Sc	hool of Cornell Univers	rmatology and sity.
061229	Applicant Types Funding Limit Limited Submission Investigator Studies Program (I Contact Name Contact Telephone	Anatomic Pathology, or Anatomic and C Pathology Departments of the New York 0.00 not provided No <u>MISP) HPV</u> M	k Presbyterian Hospital, Weill Medical Sc	hool of Cornell Univers	rmatology and sity.



SPIN ID Program Title		Sponsor Name	Sponsor N	Number	Deadline Date	Funding Amount
Program URL	Link to program	<u>URL</u>				
Deadline Dates (ALL)	15-Jul-2024					
Synopsis	through the pro implemented, a reviewed public	nvestigator Studies Program ovision of drug/vaccine and/ and sponsored by external ir cations. Effective April 2024, protocols within the curren	or total/partial fundir vestigators. Results v the Merck Investigat	ng, high-quality vill be generated or Studies Progr	research that is init d and properly disse ram Review Commi	iated, designed, eminated in peer-
Applicant Types	5					
Funding Limit	0.00 not provid	ed				
Limited Submission	No					
110991 Spotlight Research Grant		Natio	nal Eczema Associatio	on	31-Jul-20	60,000 USE
Contact Name	2					
Contact Telephone	415-499-3474					
Contact Emai	grants@nationa	aleczema.org				
Sponsor Website	Link to sponsor	<u>website</u>				
Program URL	Link to program	<u>I URL</u>				
Deadline Dates (ALL)	31-Jul-2024					
Synopsis	Eczema Associa	esearch Grant is intended to tion's advancement of its ov ned on an annual basis; topi	verall research priorit	ies for eczema.	The availability of tl	his grant category
Applicant Types	5					
Funding Limit	60,000.00 maxi	mum				
Limited Submission	No					



SPIN ID	Program Title	:	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
_						
082432	Engagement Research Grants		Na	tional Eczema Association	31-Jul-2024	5,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	grants@national	leczema.org			
	Sponsor Website	Link to sponsor w	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	31-Jul-2024				
	Synopsis			active research experience and capaci ratory pilot research or secondary and		na investigators
	Applicant Types					
	Funding Limit	5,000.00 maximi	um			
	Limited Submission	No				
120683	Tier III Research Grant		Na	tional MPS Society, Inc.	15-May-20	24 25,000 USD
	Contact Name	Matthew Ellinwo	bod			
	Contact Telephone	919-806-0101				
	Contact Email	matthew@mpss	ociety.org			
	Sponsor Website	Link to sponsor w	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	15-May-2024 , 1	5-Jul-2024 [LOI/Pre-App	], 15-Sep-2024		
	Synopsis	best possible MP	PS and ML research appli	evised research grants program to eno cations through building out a predict or these revisions to provide predicta	table yet flexible progra	m of research



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amo	unt
	Applicant Types	flexibility to the Society through family.	which to meet the go	als of improved lives and o	outcomes to those in	the MPS and	ML
		25,000.00 maximum					
	Limited Submission	Yes					
120673 <u>T</u>	ier I Research Grant	·	National MPS Sc	ociety, Inc.	15-May-20	024 Not Specifie	ed
	Contact Name	Matthew Ellinwood					
	Contact Telephone	919-806-0101					
	Contact Email	matthew@mpssociety.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-May-2024 , 15-Jul-2024 [LOI/	/Pre-App], 15-Sep-202	4			
	Synopsis	The National MPS Society is initi best possible MPS and ML resea calls and grant mechanisms. The flexibility to the Society through family.	arch applications throu e goal is for these revis	igh building out a predicta sions to provide predictabi	ble yet flexible progr lity to the research c	am of researc	ch Id
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	Yes					
120678 1	ior II Rosparch Grant: Posparch	h or Clinical Scientist Fellow-Initia	atod National MDS Sc		15-May-2(	Not	

120678 <u>Tier II Research Grant: Research or Clinical Scientist Fellow-Initiated</u> National MPS Society, Inc.

15-May-2024 Specified



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Matthew Ellinwood				
	Contact Telephone	919-806-0101				
	Contact Email	matthew@mpssociety.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2024 , 15-Jul-2024 [LOI/Pi	re-App], 15-Sep-202	4 , 15-Nov-2024 [LOI/Pre-	App]	
	Synopsis	The National MPS Society is initiat best possible MPS and ML researc calls and grant mechanisms. The g flexibility to the Society through w family.	h applications throu oal is for these revis	gh building out a predictations to provide predictab	able yet flexible progr ility to the research o	am of research ommunity and
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	Yes				
002886 [	Mentor-Based Postdoctoral Fe	llowship In Rehabilitation Research	National Multipl	e Sclerosis Society	24-Jul-202 [LOI/Pre-/	
	Contact Name	Kathleen Zackowski, PhD, OTR Ser	nior Director, Patient	Management, Care and	Rehabilitation Resear	ch
	Contact Telephone	212-986-3240				
	Contact Email	kathleen.zackowski@nmss.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	24-Jul-2024 [LOI/Pre-App], 31-Jul-	2024			
	Synopsis	As part of its overarching goals of MS Society welcomes applications	stopping MS progre for support of men	ssion, restoring function, tors and institutions that	and ending MS forev provide training of po	er, the National ostdoctoral



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		fellows in MS research related to reha which is responsible for the recruitmen rehabilitation research applied to MS a researcher in MS or a related field. The medicine, physical, occupational, or sp The research training may focus on fur individuals with MS.	nt, selection, and and similar disor e mentor and fel eech therapy, p	d training of postdoctoral ders. The mentor should llow may come from a va sychology, rehabilitation	l fellows to pursue a be an established a riety of different fie engineering, nursing	i career in nd active Ids including g, or other fields.
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				
078566	Research Grants Program	1	National Rosacea	a Society	01-Jul-20	024 15,000 USD
	Contact Name					
	Contact Telephone	847-382-8971				
	Contact Email	info@rosacea.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2024				
	Synopsis	The Society awards grants of up to \$15 of rosacea is unknown, high priority is action, cell biology and potential gene	given to researc	ch in such areas as the pat	thogenesis, progress	sion, mechanism of
	Applicant Types					
	Funding Limit	15,000.00 see detail				
	Limited Submission	No				



SPIN ID Program Title		Sponsor Name	Sponsor Nu	mber	Deadline Date	Fund	ing Amount
060162 Psychosocial Research Gr	rants	Ne	eilsen (Craig H.) Foundation	1	11-Jul-20	024	Not Specified
Contact	Name Constanza Svidle	er					
Contact Teler	ohone 818-925-1245						
Contact	Email constanza@chn	foundation.org					
Sponsor W	ebsite Link to sponsor	<u>website</u>					
Program	n URL Link to program	URL					
Deadline Dates	(ALL) 11-Jul-2024						
					and scientific resea	arcn to	Improve
	the quality of life nopsis data to inform a living with SCI. T participation, he	e for those affected by a and disseminate best pra This research explores th	dedicated to supporting bo and living with spinal cord in actices that produce better he interrelation of behaviora and support systems in com	njury. The goa outcomes, im al, social and <sub>l</sub>	I of the portfolio is proving quality of I osychological facto	s to dev life for	velop sound people
Applicant	the quality of life nopsis data to inform a living with SCI. T participation, he	e for those affected by a and disseminate best pra This research explores th	and living with spinal cord in actices that produce better he interrelation of behaviora	njury. The goa outcomes, im al, social and <sub>l</sub>	I of the portfolio is proving quality of I osychological facto	s to dev life for	velop sound people
Applicant Funding	the quality of life oppsis data to inform a living with SCI. T participation, he timit 0.00 see detail	e for those affected by a and disseminate best pra This research explores th	and living with spinal cord in actices that produce better he interrelation of behaviora	njury. The goa outcomes, im al, social and <sub>l</sub>	I of the portfolio is proving quality of I osychological facto	s to dev life for	velop sound people
Applicant	the quality of life oppsis data to inform a living with SCI. T participation, he timit 0.00 see detail	e for those affected by a and disseminate best pra This research explores th	and living with spinal cord in actices that produce better he interrelation of behaviora	njury. The goa outcomes, im al, social and <sub>l</sub>	I of the portfolio is proving quality of I osychological facto	s to dev life for	velop sound people
Applicant Funding	the quality of life data to inform a living with SCI. T participation, he Limit 0.00 see detail ission No	e for those affected by a and disseminate best pra This research explores th ealth practice, lifestyle, a Award for Disorders	and living with spinal cord in actices that produce better he interrelation of behaviora	njury. The goa outcomes, im al, social and j imunity and c	I of the portfolio is proving quality of I osychological facto	to dev life for ors that	velop sound people
Applicant Funding Limited Subm	the quality of life oppsis data to inform a living with SCI. T participation, he tission No AstraZeneca Research A tinal Tract	e for those affected by a and disseminate best pra This research explores th ealth practice, lifestyle, a Award for Disorders	and living with spinal cord in actices that produce better he interrelation of behaviora and support systems in com orth American Society for P astoenterology, Hepatology	njury. The goa outcomes, im al, social and j imunity and c	I of the portfolio is proving quality of l osychological facto linical settings.	to dev life for ors that	velop sound people influence 150,000
Applicant Funding Limited Subm 099009 NASPGHAN Foundation// of the Upper Gastrointes Contact	the quality of life oppsis data to inform a living with SCI. T participation, he tission No AstraZeneca Research A tinal Tract	e for those affected by a and disseminate best pra This research explores th ealth practice, lifestyle, a Award for Disorders	and living with spinal cord in actices that produce better he interrelation of behaviora and support systems in com orth American Society for P astoenterology, Hepatology	njury. The goa outcomes, im al, social and j imunity and c	I of the portfolio is proving quality of l osychological facto linical settings.	to dev life for ors that	velop sound people influence 150,000
Applicant Funding Limited Subm 099009 NASPGHAN Foundation/A of the Upper Gastrointes Contact Contact Telep	the quality of life data to inform a living with SCI. T participation, he timit 0.00 see detail ission No AstraZeneca Research A tinal Tract	Award for Disorders	and living with spinal cord in actices that produce better he interrelation of behaviora and support systems in com orth American Society for P astoenterology, Hepatology	njury. The goa outcomes, im al, social and j imunity and c	I of the portfolio is proving quality of l osychological facto linical settings.	to dev life for ors that	velop sound people influence 150,000
Applicant Funding Limited Subm 099009 NASPGHAN Foundation/A of the Upper Gastrointes Contact Contact Telep Contact	the quality of life data to inform a living with SCI. T participation, he s Limit 0.00 see detail ission No AstraZeneca Research A tinal Tract Name phone 215-641-9800	e for those affected by a and disseminate best pra This research explores th ealth practice, lifestyle, a Award for Disorders Ga Nu	and living with spinal cord in actices that produce better he interrelation of behaviora and support systems in com orth American Society for P astoenterology, Hepatology	njury. The goa outcomes, im al, social and j imunity and c	I of the portfolio is proving quality of l osychological facto linical settings.	to dev life for ors that	velop sound people influence 150,000



125375       Young Investigator Development Award       Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024         Contact Name       Contact Telephone       215-641-9800         Contact Email       naspghan@naspghan.org       Ink to sponsor website         Sponsor Website       Link to sponsor website         Program URL       Link to program URL         Deadline Dates (ALL)       01-Jul-2024         The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Aw         support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in d per year for up to two years of support.	SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Image: Synopsis       The NASPGHAN Foundation/AstraZeneca Research Award for Disorders of the Upper Gastrointestinal Tract provide \$75,000 annually for two years (total \$150,000) for studies focused on the epidemiology, pathogenerity astrointestinal tract in children.         Applicant Types       Funding Limit       75,000.00 per year         Limited Submission       No         125375       NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Avard       North American Society for Pediatric Gastoenterology, Hepatology and O1-Jul-2024       1         125375       Contact Name Contact Telephone       215-641-9800       Nutrition Foundation       01-Jul-2024       1         Contact Telephone       Link to sponsor website       Link to program URL       Deadline Dates (ALL)       01-Jul-2024       1         Deadline Dates (ALL)       01-Jul-2024       The NASPGHAN Foundation/Celiac Disease Foundation (Celiac Disease Foundation Celiac Disease Foundation for Point Pornising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in dire years for up to two years of support.							
Synopsis       provide \$75,000 annually for two years (total \$150,000) for studies focused on the epidemiology, pathogeneric natural history, genetics, diagnosis and management of peptic disorders and other diseases of the upper gastrointestinal tract in children.         Applicant Types       Funding Limit         Funding Limit       75,000.00 per year         Limited Submission       No         125375       NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award       North American Society for Pediatric Gastoenterology, Hepatology and 01-Jul-2024 Nutrition Foundation         Contact Name       Contact Telephone       215-641-9800         Contact Telephone       215-641-9800       Nutrition Foundation         Sponsor Website       Program URL       Link to sponsor website         Program URL       Deadline Dates (ALL)       01-Jul-2024         Synopsis       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award         Synopsis       regram URL         Deadline Dates (ALL)       01-Jul-2024         The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in diper year for up to two years of support.		Deadline Dates (ALL)	01-Jul-2024				
Image: Limited Submission       75,000.00 per year         Limited Submission       No         125375       NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award       North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024       1         Contact Name Contact Telephone       215-641-9800       North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024       1         Program URL Deadline Dates (ALL)       In aspghan@naspghan.org Sponsor Website       Link to program URL Deadline Dates (ALL)       01-Jul-2024         The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in d per year for up to two years of support.		Synopsis	provide \$75,000 annually for two yea natural history, genetics, diagnosis a	ars (total \$150,00	0) for studies focused o	n the epidemiology, <sub>I</sub>	oathogenesis,
Limited Submission       No         125375       NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award       North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024       1         Contact Name Contact Telephone       215-641-9800       North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024       1         Sponsor Website       Link to sponsor website       Link to sponsor website       1         Deadline Dates (ALL)       01-Jul-2024       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award         Synopsis       Synopsis       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award         Synopsis       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award         Synopsis       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award         Synopsis       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award         Synopsis       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award         Synopsis       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award		Applicant Types					
125375       NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award       North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024       1         125375       Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)       215-641-9800       1       1         1       Interview of the term of the term of the term of t		Funding Limit	75,000.00 per year				
125375       NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Award       Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024       Intervention         125375       Contact Name Contact Telephone       215-641-9800       Intervention       Intervention         Contact Telephone       Contact Email       naspghan@naspghan.org       Link to sponsor website       Intervention         Program URL       Deadline Dates (ALL)       01-Jul-2024       The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Aw support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in d per year for up to two years of support.		Limited Submission	No				
Contact Telephone215-641-9800Contact Emailnaspghan@naspghan.orgSponsor WebsiteLink to sponsor websiteProgram URLLink to program URLDeadline Dates (ALL)01-Jul-2024SynopsisThe NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Aw support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in d per year for up to two years of support.	1/54/5			Gastoenterology	, Hepatology and	01-Jul-2	024 150,000 USD
Contact Emailnaspghan@naspghan.orgSponsor WebsiteLink to sponsor websiteProgram URLLink to program URLDeadline Dates (ALL)01-Jul-2024SynopsisThe NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Aw support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in d per year for up to two years of support.		Contact Name					
Sponsor Website Program URL Deadline Dates (ALL)Link to sponsor website Link to program URL 01-Jul-2024SynopsisThe NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Aw support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in di per year for up to two years of support.		Contact Telephone	215-641-9800				
Program URLLink to program URLDeadline Dates (ALL)01-Jul-2024SynopsisThe NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Aw support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in di per year for up to two years of support.		Contact Email	naspghan@naspghan.org				
Deadline Dates (ALL) 01-Jul-2024 The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Aw support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in d per year for up to two years of support.		Sponsor Website	Link to sponsor website				
The NASPGHAN Foundation/Celiac Disease Foundation Celiac Research Young Investigator Development Aw support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in disper year for up to two years of support.		Program URL	Link to program URL				
Synopsis support promising researchers in the early stages of their career, fostering their potential to contribute sign to independent basic, translational, or clinical research in pediatric celiac disease. The award is \$75,000 in diper year for up to two years of support.		Deadline Dates (ALL)	01-Jul-2024				
		Synopsis	support promising researchers in the to independent basic, translational, o	e early stages of th or clinical researc	neir career, fostering the	eir potential to contri	bute significantly
Applicant Types		Applicant Types					
Funding Limit 75,000.00 per year		Funding Limit	75,000.00 per year				
Limited Submission No		Limited Submission	No				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	NASPGHAN Foundation/Alcrest Pediatric Pancreatic Disease an	ta Research Award for the Study of d Malabsorption	North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation	01-Jul-20	024 150,000 USD
	Contact Name				
	Contact Telephone	215-641-9800			
	Contact Email	naspghan@naspghan.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2024			
		The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp	sta Research Award for the Study of Pediatric port meritorious research focused on pancrea direct costs per year for up to two years of su	atic disease or malab	
		The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp children. The award is \$75,000 in	ort meritorious research focused on pancrea	atic disease or malab	
	Synopsis Applicant Types	The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp children. The award is \$75,000 in	ort meritorious research focused on pancrea	atic disease or malab	
	Synopsis Applicant Types	The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp children. The award is \$75,000 in 75,000.00 per year	ort meritorious research focused on pancrea	atic disease or malab	
099011 <u>I</u>	Synopsis Applicant Types Funding Limit	The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp children. The award is \$75,000 in 75,000.00 per year No	ort meritorious research focused on pancrea	atic disease or malab	sorption in
099011 <u>I</u>	Synopsis Applicant Types Funding Limit Limited Submission	The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp children. The award is \$75,000 in 75,000.00 per year No <u>tions in Clinical Care Grant</u>	oort meritorious research focused on pancrea direct costs per year for up to two years of su North American Society for Pediatric Gastoenterology, Hepatology and	atic disease or malab upport.	sorption in
099011 [	Synopsis Applicant Types Funding Limit Limited Submission <u>NASPGHAN Foundation Innova</u>	The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp children. The award is \$75,000 in 75,000.00 per year No <u>tions in Clinical Care Grant</u>	oort meritorious research focused on pancrea direct costs per year for up to two years of su North American Society for Pediatric Gastoenterology, Hepatology and	atic disease or malab upport.	sorption in
099011 <u>I</u>	Synopsis Applicant Types Funding Limit Limited Submission <u>NASPGHAN Foundation Innova</u> Contact Name Contact Telephone	The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp children. The award is \$75,000 in 75,000.00 per year No <u>tions in Clinical Care Grant</u>	oort meritorious research focused on pancrea direct costs per year for up to two years of su North American Society for Pediatric Gastoenterology, Hepatology and	atic disease or malab upport.	sorption in
099011 <u>I</u>	Synopsis Applicant Types Funding Limit Limited Submission <u>NASPGHAN Foundation Innova</u> Contact Name Contact Telephone Contact Email	The NASPGHAN Foundation/Alcre Malabsorption is awarded to supp children. The award is \$75,000 in 75,000.00 per year No tions in Clinical Care Grant 215-641-9800	oort meritorious research focused on pancrea direct costs per year for up to two years of su North American Society for Pediatric Gastoenterology, Hepatology and	atic disease or malab upport.	sorption in



Deadline Dates (ALL)       01-Jul-2024         The NASPGHAN Foundation Innovations in Clinical Care Grant is offered to encourage and support the development of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases by the clinically focuse bediatic gastroenterologist. The Foundation will award up to two grants, each ranging from \$2,000 to \$5,000 to \$5,000 for a one-year period.         Applicant Types       0.00 see detail         Limited Submission       No         NASPGHAN Foundation/OOL Medical Research Award For the Study North American Society for Pediatric Gastoenterology, Hepatology and 01-Jul-2024       150,000 USD         103653       of Disorders Associated with Carbohydrate Gastoenterology, Hepatology and O1-Jul-2024       150,000 USD         Contact Name Contact Thema Imaspghan@naspghan.org       Sponsor Website       Ink to sponsor website         Program URL       Deadline Dates (ALL)       01-Jul-2024       The NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Gastoenterology, Hepatology and 01-Jul-2024       150,000 USD         Version       215-641-9800       Version Study of Disorders Associated with Carbohydrate Program URL       Version Sponsor Website         Program URL       Deadline Dates (ALL)       01-Jul-2024       The NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.	SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Image: Synopsise       The NASPGHAN Foundation Innovations in Clinical Care Grant is offered to encourage and support the development of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases of the disease						
Synopsis       of innovative approaches to optimize the quality of care and health care delivery to children with digestive diseases by the clinically focused pediatric gastroenterologist. The Foundation will award up to two grants, each ranging from \$2,000 to \$5,000 for a one-year period.         Applicant Types       0.0 see detail         Limited Submission       0.0 see detail         Limited Submission       No         MASPGHAN Foundation/QOL Medical Research Award For the Study       North American Society for Pediatric         103653       of Disorders Associated with Carbohydrate       Gastoenterology, Hepatology and       01-Jul-2024       150,000         Using       Using Limit       Contact Name       E       E       E       E         Contact Telephone       215-641-9800       E       <	Deadline Dates (A	LL) 01-Jul-2024				
Funding Limit       0.00 see detail         Limited Submission       No         103653       MASPGHAN Foundation/QQL Medical Research Award For the Study       North American Society for Pediatric         Gastoenterology, Hepatology and       01-Jul-2024       150,000         Maldigestion/Malabsorption in Children       Nutrition Foundation       01-Jul-2024       150,000         Contact Name       Contact Telephone       215-641-9800       Vertice       Vertice       Vertice         Contact Telephone       Contact Email       naspghan@naspghan.org       Vertice       Vertice       Vertice       Vertice       Vertice         Program URL       Link to program URL       Deadline Dates (ALL)       01-Jul-2024       The NASPGHAN Foundation/QQL Medical Research Award For the Study of Disorders Associated with Carbohydrate       Synopsis         Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.         Applicant Types       Funding Limit       75,000.00 per year	Synop	of innovative a by the clinically	pproaches to optimize the / focused pediatric gastroe	quality of care and health care delive	ry to children with dig	gestive diseases
Limited Submission       No         103653       MASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Maldigestion/Malabsorption in Children       Noth American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024       150,000 USD         Contact Name Contact Telephone       215-641-9800       215-641-9800       215-641-9800         Contact Telephone       215-641-9800       215-641-9800       215-641-9800         Contact Telephone       Link to sponsor website       1101/2024       1101/2024         Program URL       Link to program URL       Deadline Dates (ALL)       01-Jul-2024         Deadline Dates (ALL)       01-Jul-2024       The NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Synopsis       Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.         Applicant Types Funding Limit       75,000.00 per year	Applicant Ty	bes				
NASPGHAN Foundation/QOL Medical Research Award For the Study       North American Society for Pediatric       150,000         103653       of Disorders Associated with Carbohydrate       Gastoenterology, Hepatology and       01-Jul-2024       150,000         Maldigestion/Malabsorption in Children       Nutrition Foundation       01-Jul-2024       150,000       USD         Contact Name       Contact Telephone       215-641-9800       1	Funding Li	mit 0.00 see detail				
103653       of Disorders Associated with Carbohydrate Maldigestion/Malabsorption in Children       Gastoenterology, Hepatology and Nutrition Foundation       01-Jul-2024       150,000 USD         Contact Name Contact Telephone       215-641-9800	Limited Submiss	ion No				
Contact Telephone215-641-9800Contact Emailnaspghan@naspghan.orgSponsor WebsiteLink to sponsor websiteProgram URLLink to program URLDeadline Dates (ALL)01-Jul-2024SynopsisThe NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.Applicant Types75,000.00 per year	103653 of Disorders Associated with	n Carbohydrate	Gas	toenterology, Hepatology and	01-Jul-202	//
Contact Emailnaspghan@naspghan.orgSponsor WebsiteLink to sponsor websiteProgram URLLink to program URLDeadline Dates (ALL)01-Jul-2024SynopsisThe NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.Applicant Types75,000.00 per year	Contact Na	me				
Sponsor WebsiteLink to sponsor websiteProgram URLLink to program URLDeadline Dates (ALL)01-Jul-2024SynopsisThe NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.Applicant Types Funding Limit75,000.00 per year	Contact Telepho	one 215-641-9800				
Program URLLink to program URLDeadline Dates (ALL)01-Jul-2024SynopsisThe NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.Applicant Types Funding Limit75,000.00 per year	Contact En	nail <u>naspghan@nas</u>	spghan.org			
Deadline Dates (ALL) 01-Jul-2024 The NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Synopsis Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary. Applicant Types Funding Limit 75,000.00 per year	Sponsor Web	site Link to sponsor	website			
SynopsisThe NASPGHAN Foundation/QOL Medical Research Award For the Study of Disorders Associated with Carbohydrate Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary.Applicant Types Funding Limit75,000.00 per year	Program L	JRL Link to program	n URL			
Synopsis Maldigestion/Malabsorption in Children will provide \$75,000 annually for two years (total \$150,000) for studies focused on disorders of carbohydrate (CHO) maldigestion/malabsorption in children, either primary or secondary. Applicant Types Funding Limit 75,000.00 per year	Deadline Dates (A	LL) 01-Jul-2024				
Funding Limit 75,000.00 per year	Synop	osis Maldigestion/N	Malabsorption in Children v	vill provide \$75,000 annually for two	years (total \$150,000)	) for studies
	Applicant Ty	bes				
	Funding Li	mit 75,000.00 per v	year			
Limited Submission NO	Limited Submiss	ion No				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
UXXXhX -	NASPGHAN Foundation/Georg	e Ferry Young Investigator	North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation	01-Jul-202	4 150,000 4 USD
	Contact Name				
	Contact Telephone	215-641-9800			
	Contact Email	naspghan@naspghan.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2024			
		The NASPGHAN Foundation/NA a meritorious clinical, quality im	SPGHAN George Ferry Young Investigator Deve provement, translational or basic science resea reas or nutritional disorders of children.	-	•••
		The NASPGHAN Foundation/NA a meritorious clinical, quality im gastrointestinal tract, liver, pane	provement, translational or basic science resea	-	•••
	Synopsis Applicant Types	The NASPGHAN Foundation/NA a meritorious clinical, quality im gastrointestinal tract, liver, pane	provement, translational or basic science resea	-	• •
	Synopsis Applicant Types	The NASPGHAN Foundation/NA a meritorious clinical, quality im gastrointestinal tract, liver, pand 75,000.00 per year	provement, translational or basic science resea	-	
099010	Synopsis Applicant Types Funding Limit	The NASPGHAN Foundation/NA a meritorious clinical, quality im gastrointestinal tract, liver, pand 75,000.00 per year No	provement, translational or basic science resea	-	diseases of the
099010	Synopsis Applicant Types Funding Limit Limited Submission	The NASPGHAN Foundation/NA a meritorious clinical, quality im gastrointestinal tract, liver, pand 75,000.00 per year No <u>Nutrition Research Grant</u>	provement, translational or basic science resea creas or nutritional disorders of children. North American Society for Pediatric Gastoenterology, Hepatology and	arch project related to	diseases of the
099010	Synopsis Applicant Types Funding Limit Limited Submission <u>NASPGHAN Foundation/CPNP</u>	The NASPGHAN Foundation/NA a meritorious clinical, quality im gastrointestinal tract, liver, pand 75,000.00 per year No <u>Nutrition Research Grant</u>	provement, translational or basic science resea creas or nutritional disorders of children. North American Society for Pediatric Gastoenterology, Hepatology and	arch project related to	diseases of the
099010	Synopsis Applicant Types Funding Limit Limited Submission <u>NASPGHAN Foundation/CPNP</u> Contact Name Contact Telephone	The NASPGHAN Foundation/NA a meritorious clinical, quality im gastrointestinal tract, liver, pand 75,000.00 per year No <u>Nutrition Research Grant</u>	provement, translational or basic science resea creas or nutritional disorders of children. North American Society for Pediatric Gastoenterology, Hepatology and	arch project related to	diseases of the
099010	Synopsis Applicant Types Funding Limit Limited Submission <u>NASPGHAN Foundation/CPNP</u> Contact Name Contact Telephone Contact Email	The NASPGHAN Foundation/NA a meritorious clinical, quality im gastrointestinal tract, liver, pand 75,000.00 per year No <u>Nutrition Research Grant</u> 215-641-9800	provement, translational or basic science resea creas or nutritional disorders of children. North American Society for Pediatric Gastoenterology, Hepatology and	arch project related to	diseases of the



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date	Func	ling Amount
Deadline Dates (ALL)	01-Jul-2024						
Synopsis	year award ava nutrition care o	lable to pediatric die	titians to support es of children with	rition Professionals (CPN research activities that h nutritional disorders. Th	nave the potential to	o advar	ice the
Applicant Types							
Funding Limit	0.00 see detail						
Limited Submission	No						
001986 NASPGHAN Foundation/APGN	N Susan Moyer N	lursing Research		Society for Pediatric y, Hepatology and ation	01-Jul-2	024	5,000 USD
Contact Name							
Contact Telephone	215-641-9800						
Contact Email	naspghan@nas	oghan.org					
Sponsor Website	Link to sponsor	<u>website</u>					
Program URL	Link to program	URL					
Deadline Dates (ALL)	01-Jul-2024						
Synopsis	activities that h hepatobiliary, p	ave the potential to a ancreatic or nutrition rsing care of families	advance nursing c nal disorders. Mo	erology, nutrition and he are of patients and famil nies are awarded in supp pediatric gastrointestina	ies of children with ort of a meritorious	gastroi resear	ntestinal, ch projects
Applicant Types							
Funding Limit	5,000.00 maxim	ium					



SPIN ID P	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No			
099007 <u>NA</u>	ASPGHAN Foundation Mid-Le	vel Career Award	North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation	01-Jul-20	24 100,000 USD
	Contact Name				
	Contact Telephone	215-641-9800			
	Contact Email	naspghan@naspghan.org			
	Sponsor Website	Link to sponsor website			
		_			
	Program URL	Link to program URL			
	Program URL Deadline Dates (ALL)				
	Deadline Dates (ALL)	01-Jul-2024 The NASPGHAN Foundation Mid-Lev	el Career Award is for NASPGHAN memb enterology, hepatology, and nutrition. T		
	Deadline Dates (ALL)	01-Jul-2024 The NASPGHAN Foundation Mid-Lev pursuing research in pediatric gastro			
	Deadline Dates (ALL) Synopsis Applicant Types	01-Jul-2024 The NASPGHAN Foundation Mid-Lev pursuing research in pediatric gastro			
	Deadline Dates (ALL) Synopsis Applicant Types	01-Jul-2024 The NASPGHAN Foundation Mid-Lev pursuing research in pediatric gastro costs per year for up to two years. 50,000.00 per year			
012623 <u>Clir</u>	Deadline Dates (ALL) Synopsis Applicant Types Funding Limit	01-Jul-2024 The NASPGHAN Foundation Mid-Lev pursuing research in pediatric gastro costs per year for up to two years. 50,000.00 per year			\$50,000 in direct
012623 <u>Clir</u>	Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission inical Applications Grants	01-Jul-2024 The NASPGHAN Foundation Mid-Lev pursuing research in pediatric gastro costs per year for up to two years. 50,000.00 per year	enterology, hepatology, and nutrition. T Paralyzed Veterans of America	he award will provide \$	\$50,000 in direct 200,000
012623 <u>Clir</u>	Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission inical Applications Grants	01-Jul-2024 The NASPGHAN Foundation Mid-Lev pursuing research in pediatric gastro costs per year for up to two years. 50,000.00 per year No Lindsay Perlman, Associate Director,	enterology, hepatology, and nutrition. T Paralyzed Veterans of America	he award will provide \$	\$50,000 in direct 
012623 <u>Clir</u>	Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission inical Applications Grants Contact Name Contact Telephone	01-Jul-2024 The NASPGHAN Foundation Mid-Lev pursuing research in pediatric gastro costs per year for up to two years. 50,000.00 per year No Lindsay Perlman, Associate Director,	enterology, hepatology, and nutrition. T Paralyzed Veterans of America	he award will provide \$	\$50,000 in direct 
012623 <u>Clir</u>	Deadline Dates (ALL) Synopsis Applicant Types Funding Limit Limited Submission inical Applications Grants Contact Name Contact Telephone Contact Email	01-Jul-2024 The NASPGHAN Foundation Mid-Lev pursuing research in pediatric gastro costs per year for up to two years. 50,000.00 per year No Lindsay Perlman, Associate Director, 202-416-7611	enterology, hepatology, and nutrition. T Paralyzed Veterans of America	he award will provide \$	\$50,000 in direct 200,000



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	01-Jul-2024				
	Synopsis	The Paralyzed Veterans of America the lives of those with spinal cord in applications, specifically clinical and and interventions to alleviate these	njury and disease (S I functional studies	CI/D). The Research For	undation grant funds cl	inical research
	Applicant Types					
	Funding Limit	200,000.00 maximum				
	Limited Submission	No				
001563 <u>B</u>	Basic Science Research Grants		Paralyzed Vetera	ns of America	01-Jul-202	4 200,000 USD
	Contact Name	Lindsay Perlman, Associate Director	r, Research & Educa	ition		
	Contact Telephone	202-416-7611				
	Contact Email	lindsayp@pva.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2024				
	Synopsis	Basic Science research grants fund I disease. The PVA Research Foundat	aboratory research ion will provide up	in the basic sciences re to \$200,000 for a durat	elated to spinal cord inj ion of two or three yea	ury or ars.
	Applicant Types					
	Funding Limit	200,000.00 see detail				
	Limited Submission	No				
001069 <mark>P</mark>	Postdoctoral Fellowships Progr	am	Paralyzed Vetera	ns of America	01-Jul-202	4 150,000 4 USD



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	Deadline Date	Funding Amount
	Contact Name	Lindsay Perlman, Associate D	irector, Research and Ed	ucation		
	Contact Telephone	202-416-7611				
	Contact Email	LindsayP@pva.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2024				
	Synopsis	Paralyzed Veterans of Americ design and development, inte are funded up to \$150,000 fo	ended to encourage trair	•		••
	Applicant Types					
	Funding Limit	150,000.00 maximum				
	Limited Submission	No				
001067	Design and Development/Assis	tive Technology Grants	Paralyzed Veter	ans of America	01-Jul-20	024 200,000 USD
	Contact Name	Lindsay Perlman, Associate D	irector, Research & Educ	ation		
	Contact Telephone	202-416-7611				
	Contact Email	lindsayp@pva.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2024				
	Synopsis	Paralyzed Veterans of Americ rehabilitative and assistive te	chnology/devices for pe	ople with SCI/D to impro	ve function, which al	so includes

improving the identification, selection and utilization of these devices. Grants are now funded up to \$200,000 for two or three years.



SPIN ID Program Title	Sponsor Name	Sponsor	r Number	Deadline Date	Funding Amount
Applicant Types Funding Limit Limited Submission	200,000.00 see detail				
Medical Education Grant: Loca102065to Increase Awareness & Under Cardiomyopathy (ATTR-CM)	I Level Educational Grants Program erstanding of Transthyretin Amyloid	Pfizer Pharmaceuticals		30-Jul-20	24 20,000 USD
Contact Name	Amanda Stein, Grant Officer				
Contact Telephone					
Contact Email	amanda.j.stein@pfizer.com				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	30-Jul-2024 , 15-Oct-2024				
Synopsis	Pfizer is issuing this Request for Propeducational activities focused on he for TTR Amyloidosis. Potential applicity professionals to increase awareness early patient identification through a considered for small local/community programs.	althcare professionals invo cants are encouraged to ide of heart failure patients at an evidence-based approac	lved in the treatm entify and address t risk for TTR Amy ch. Individual proj	nent of heart failure s the educational ne loidosis and enable ects requesting up t	patients at risk eds of healthcare appropriate and co \$10,000 will be
Applicant Types					
Funding Limit	20,000.00 maximum				
Limited Submission	No				
125705 Medical Education Grant: New Treatment Options in Metasta		Pfizer Pharmaceuticals		27-Jul-20	24 4,000,000 USD



SPIN ID Program Titl	le		Sponsor Name		Sponsor Number	Deadline Date	Fundi	ing Amount
		1						
	Contact Name	Jacqueline Wald	drop, Grant Officer					
Со	ntact Telephone							
	Contact Email	Jacqueline.Wald	drop@pfizer.com					
S	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>I URL</u>					
Dead	dline Dates (ALL)	27-Jul-2024						
	Synopsis	Breast Cancer ( focused on the and address the landscape of ER	mBC). This competitive g evolving treatment lands e educational needs of he +/HER2- mBC. Proposed	rant program s scape for patie ealthcare profe educational ac	nt support for continuing seeks to support indepen nts with ER+/HER2- mBC essionals related to novel ctivities should focus on i s – particularly in the pos	ident medical educa . Applicants are enco treatments in the e increasing the under	tion ac ourage volving standir	tivities d to identify g clinical ng of
	Applicant Types							
	Funding Limit	4,000,000.00 m	aximum					
Lim	nited Submission	No						
006942 Career Develo	pment Awards		Re	esearch to Prev	ent Blindness	15-Jun-2 [LOI/Pre		350,000 USD
	Contact Name	Pattie Moran, D	Director of Grants Admini	stration				
Со	ntact Telephone	646-892-9566						
	Contact Email	pmoran@rpbus	a.org					
S	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>I URL</u>					

Deadline Dates (ALL) 15-Jun-2024 [LOI/Pre-App], 01-Jul-2024



SPIN ID Program Title	Sponsor Name	Sponsor	Number	Deadline Date	unding Amount
Synopsis	The RPB Career Development Aw Candidates (MDs, PhDs, or MD/P to and including Assistant Profes within three years of the applicat granted the full \$350,000. Other	hDs) must have primary appoir sor. Candidate's first full-time c ion deadline. Awardees will be	ntments in ophtha ophthalmology face e required to expe	almology with acade culty appointment m end the award within	mic positions up ust have been four years if
Applicant Types					
Funding Limit	350,000.00 maximum				
Limited Submission	Yes				
070892 <u>RPB International Research Co</u>	llaborators Award	Research to Prevent Blind	ness	15-Jun-202 [LOI/Pre-A	75 000 1150
Contact Name	Pattie Moran				
Contact Telephone	646-892-9566				
Contact Email	pmoran@rpbusa.org				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	15-Jun-2024 [LOI/Pre-App], 01-Ju	ıl-2024			
The RPB International Research Collaborators Award promotes international collaborations through which collaborating researchers in the U.S. and outside the U.S. gain new knowledge and skills. These international collaborations have the potential to accelerate the development of treatments for blinding disorders, positively affecting large populations worldwide for years to come. This award of up to \$75,000 is available to researchers fr any institution of higher education in the United States. A three- to six-month stay in the other country is expected each researcher, with a minimum stay of three months.					
Applicant Types					
Funding Limit	75,000.00 maximum				



SPIN ID	Program Title	Sponsor Nam	e	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	Yes				
006943 <u>N</u>	Nedical Student Fellowships		Research to Pre	event Blindness	15-Jun-20 [LOI/Pre-/	20 000 1150
	Contact Name	Pattie Moran				
	Contact Telephone	646-892-9566				
	Contact Email	pmoran@rpbusa.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2024 [LOI/Pre-App], 01	-Jul-2024			
	Synopsis	The Medical Student Eye Rese medical school and devote tim ophthalmology. Research to F Ophthalmology & Otolaryngol specifically targeted to a stude allopathic medicine, will not h vision research.	ne to the pursuit of a re Prevent Blindness (RPB) ogy-Head and Neck Sur ent of osteopathic med	search project within an is partnering with the Ar gery Foundation (AOCOC icine. The remaining Fello	RPB-supported depart nerican Osteopathic C D-HNS) to offer one (1 Dwships, targeted to s	ment of olleges of award tudents of
	Applicant Types					
	Funding Limit	30,000.00 see detail				
	Limited Submission	Yes				
017724 <u>C</u>	hapman Medal		Royal Astronom	nical Society	31-Jul-202	24 Not Specified
	Contact Name					
	Contact Telephone	+44 (0)20 7734 4582				

Contact Telephone +44 (0)20 7734 4582



SPIN ID Program Title		Sponsor Name	Sponsor	Number	Deadline Date	Funding Amount	
Contact Ema	il <u>awards@ras.or</u>	<u>g.uk</u>					
Sponsor Websit	e Link to sponsor	<u>website</u>					
Program UR	L Link to program	to program URL					
Deadline Dates (ALI	) 31-Jul-2024						
Synops		Nedal is awarded for invest r solar-terrestrial physics.	igations of outstandi	ng merit in the so	cience of the Sun, s	pace and planetary	
Applicant Type	s						
Funding Lim	it 0.00 not provid	ed					
Limited Submissio	n No						
	-						

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
087954	Jacquot Research Establishm	ent Fellowship	Royal Australasian College of Physicians		09-Jul-2024	59,400 USD
	Contact Name					
	Contact Telephone					
	Contact Email					
	Sponsor Website	Link to sponsor we	<u>ebsite</u>			
	Program URL	Link to program U	RL			
	Deadline Dates (ALL)	09-Jul-2024				
	Synopsis	The Jacquot Resean nephrology resean	arch Establishment Fellowship provides \$90 rch for a nephrologist who has completed a	,000 in support to a research higher de	assist the establishm gree in an area of re	ent of a career in levance.
	Applicant Types					
	Funding Limit	90,000.00 maximu	ım			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
048368	Royal-Mach-Gaensslen Prize Research	for Mental Health	Royal's Institute of Mental	Health Research	15-Jul-2024	73,000 USD
	Contact Name					
	Contact Telephone	613-722-6521				
	Contact Email	research.awards	<u>@theroyal.ca</u>			
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	15-Jul-2024				
	Synopsis	outstanding rese provides funding institution in the pursue their rese	earch scientists in Canada with to exceptional researchers v field of mental health and w	ealth Research is awarded annu n a focus in the area of mental he who are affiliated with a Canadia ho are 45 years of age or younge award of \$100,000 is available	ealth. This annual na n academic or clinica er, to encourage the	ational Prize al research m to continue to
	Applicant Types					
	Funding Limit	100,000.00 maxi	mum			
	Limited Submission	No				
046418	Science & SciLifeLab Prize for	Young Scientists	Science		15-Jul-2024	30,000 USD
	Contact Name					
	Contact Telephone	202-326-6417				
	Contact Email	SciLifeLabPrize@	aaas.org			
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			



SPIN ID	Program Title	5	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program l	JRL			
	Deadline Dates (ALL)	15-Jul-2024				
		science research thesis research m Systems Biology a	iLifeLab Prize for Young Scientists is a for which they were awarded a docto nust be in one of the following catego approaches; Ecology and Environmen the other three category winners rec	oral degree in the previous pries: Cell and Molecular Bi nt; Molecular Medicine. Th	two years. The top ology; Genomics, P	pic of the entrant's roteomics, and
	Applicant Types					
	Funding Limit	30,000.00 maxim	ium			
	Limited Submission	Yes				
125145	Neuroscience Collaborations Conferences Awards	Courses and	Simons Foundation		23-May-2024 [LOI/Pre-App]	Not Specified
	Contact Name					
	Contact Telephone	646-654-0066				
	Contact Email	neurogrants@sin	nonsfoundation.org			
	Sponsor Website	Link to sponsor w	<u>vebsite</u>			
	Program URL	Link to program l	JRL			
	Deadline Dates (ALL)	23-May-2024 [LC	0I/Pre-App], 25-Jul-2024			
	Synopsis	courses or confer of their programs computational ne on healthy cognit	dation has issued a Request for Appli rences in fundamental neuroscience. s, the Simons Collaboration on the Gle euroscience, and/or the Simons Colla tive aging, will be prioritized. They es nized by people in regions of the wor	Courses and conferences to obal Brain (SCGB), with a for boration on Plasticity and pecially encourage application	that align with the s ocus on the fields o the Aging Brain (SC tions for courses ar	scientific missions of systems and PAB), with a focus and conferences



SPIN ID	Program Title	:	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
			been less numerous. The ferences Award RFA mov	Simons Foundation Neuroscie ing forward.	nce Collaborations intend	s to run a yearly
	Applicant Types					
	-	0.00 see detail				
	Limited Submission	No				
082669	Creating Equitable Pathways Education	to STEM Graduat	<sup>e</sup> Sloan (Alfred P.) Found	ation	01-Jul-2024 [LOI/Pre-App]	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	dei@sloan.org				
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	01-Jul-2024 [LOI,	/Pre-App]			
	Synopsis	(MSIs) and in the universities. The institutional path computer scienc statistics. The int and through STE	e establishment of partner Foundation's Creating Eq nways from MSIs to maste e, data science, Earth scie tent is to facilitate the cre M graduate education wit	ed P. Sloan Foundation is seeki rships between MSIs and gradu uitable Pathways to STEM Gra er's and doctoral degree progra nces, economics, engineering, ation and strengthening of dive th the recognition that student through prevailing institutional	uate programs at other co duate Education grants wi ams in astronomy, biology marine science, mathema erse, inclusive, and equita t pathways are too often d	lleges and ill support , chemistry, atics, physics, and ble pathways to lisrupted by
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
049628	Stanley Smith Horticultural Tr	ust Grants Smith (Stanley) Horticultu	ural Trust	14-Jun-2024 [LOI/Pre-App]	25,000 USD
	Contact Name				
	Contact Telephone	415-332-0166			
	Contact Email	grants@smithct.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Jun-2024 [LOI/Pre-App], 15-Jul-2024			
	Synopsis	The Stanley Smith Horticultural Trust suppor botanical gardens, arboreta, universities, and interests. The maximum grant awarded by t	d other charitable organizations	strongly-aligned with	its funding
	Applicant Types				
	Funding Limit	25,000.00 maximum			
	Limited Submission	Yes			
084126	Travel Scholarships	Society for Advancement Native Americans in Scier		12-Jul-2024	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	info@sacnas.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Jul-2024 , 14-Jul-2024			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Society for Advancement of Chicanos scholarships that include funded travel, lo the SACNAS National Diversity in STEM (N specialized programming to welcome and	odging, and registration for underg IDISTEM) Conference. Accepted av	raduate and graduate wardees will also have	students to attend
	Applicant Types				
	Funding Limit	0.00 not provided			
	Limited Submission	No			
063528	Christopher J. Marshall Award	d Society for Melanoma	Research	01-Jul-2024	5,000 USD
	Contact Name	Debra Marshall			
	Contact Telephone				
	Contact Email	debra@sswmeetings.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2024			
	Synopsis	The Christopher J. Marshall Award For Stu has made substantial published and origin previous two years. The award's focus on mentoring and training new generations of \$5,000, a commemorative plaque and sup	nal contribution to studies of signa students, fellows or new PIs is in l of cancer scientists. The award wil	I transduction and me keeping with Chris Mar I consist of an unrestric	anoma within the shall's dedication to ted honorarium of
	Applicant Types				
	Funding Limit	5,000.00 see detail			
	Limited Submission	No			
066849	Mentored Clinical Scientist Re Development Award (K08)	esearch Career Society for Vascular Su	irgery	12-Jun-2024	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Name							
	Contact Telephone	800-258-7188						
	Contact Email	svsfoundation@vascularsociety.org						
	Sponsor Website	Link to sponsor website						
	Program URL Link to program URL							
Deadline Dates (ALL) 12-Jun-2024 , 12-Jul-2024 , 12-Oct-2024 , 12-Nov-2024								
	Synopsis	e Mentored Clinical Scientist Research Career Development Award (K08) will prepare clinically trained individuals r careers that have a significant impact on the health-related research needs of the Nation. This program provides pport and protected time for an intensive, supervised research career development experience in the fields of pmedical, behavioral, or clinical research, including translational research.						
	Applicant Types							
	Funding Limit	50,000.00 per year						
	Limited Submission	No						
024280	SFIAR Award	Swiss Forum for Inte Research	ernational Agricultural	03-Jul-2024	Not Specified			
	Contact Name							
	Contact Telephone	+41(0)31 910 21 91						
	Contact Email	<u>info@sfiar.ch</u>						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	03-Jul-2024						
	Synopsis	The Swiss Forum for International Agric Swiss institution in agricultural research		ual Award for scienti	sts working for a			



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	0.00 see detai	I			
	Limited Submission	No				
123676	Pilot Award Program for Mye Syndrome Research	odysplastic	Taub (Henry and Marilyn) Fo	oundation	01-Jul-2024	100,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	mdsgrants@ta	aubfoundation.org			
	Sponsor Website	Link to sponse	or website			
	Program URL	<u>Link to progra</u>	m URL			
	Deadline Dates (ALL)	01-Jul-2024				
	Synopsis	of exploring u and conceptua that bring in n conceptually i Applicants mu	d Marilyn Taub Foundation (HMT ntested strategies and disruptive ally innovative ideas that can incl new concepts, technologies and st nnovative ideas specifically focus ist hold a PhD, MD, MD/PhD or en ic, medical or research institution	new ideas. These one-yea ude high-risk/high-reward rategies from other fields. ed on Myelodysplastic Syn quivalent degree and an in	r proof-of-concept studie projects and encourage Proposals must represe drome (MDS), exclusive dependent faculty appoi	es represent new collaborative efforts nt novel and of AML and MPN. ntment at a non-
	Applicant Types					
	Funding Limit	100,000.00 m	aximum			
	Limited Submission	No				
001193	E.W. Al Thrasher Awards		Thrasher Research Fund		16-Jul-2024 [LOI/Pre-App]	Not Specified



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Name							
	Contact Telephone	801-240-4753						
	Contact Email	MartinezAF@Th	nrasherResearch.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	LL) 16-Jul-2024 [LOI/Pre-App], 22-Oct-2024						
	Synopsis	The purpose of the E.W. "Al" Thrasher Awards is to improve children's health through medical research, with an s emphasis on projects that have the potential to translate into clinically meaningful results within a few years. The Fund awards grants two times per year, with no fixed number of awards given in each funding cycle or in each year.						
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
065154	Comprehensive Research Pro	gram Competitio	on United States Poultry an	d Egg Asso	ciation	02-Jul-2024	Not Specified	
	Contact Name	Dr. Denise Hear	ď					
	Contact Telephone	770-493-9401						
	Contact Email	research@uspo	ultry.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>I URL</u>					
	Deadline Dates (ALL)	02-Jul-2024						
The USPOULTRY industry research grants program encompasses all segments of broiler, turkey, and co operations. To date over \$36 million has been invested in the association's research program. One of U key strategic objectives is to increase the availability and constant improvement of the quality and safe products through comprehensive research.						of USPOULTRY's		



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
013748	Janet L. Norwood Award		University of Alabama at E	irmingham	12-Jul-2024	Not Specified
	Contact Name					
	Contact Telephone	205-934-4993				
	Contact Email	norwoodawd@	uab.edu			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	<u>ı URL</u>			
	Deadline Dates (ALL)	12-Jul-2024				
	Synopsis	woman in the s	ublic Health is pleased to pres tatistical sciences. The school ontribution of all women to th	wishes not only to recogniz	<b>.</b>	•
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
003397	Wellington Doctoral Scholars	<u>hips</u>	Victoria University of Well	ngton	01-Jul-2024	53,100 USD
	Contact Name					
	Contact Telephone	64 4 472 1000				
	Contact Email	pg-research@v	uw.ac.nz			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	<u>I URL</u>			

SPIN ID	Program Title	Sponsor Name	S	Sponsor Number	Deadline Date	Funding Amount		
		I						
	Deadline Dates (ALL)	01-Jul-2024 , 01-Nov-2024						
	Synopsis	These scholarships are intended to encourage and support doctoral study (PhD) at Victoria University of Wellington. To encourage postgraduate research Victoria University of Wellington offers scholarships to those about to begin their doctoral studies. These scholarships are awarded on academic merit and are open to New Zealand and international students in any discipline.						
	Applicant Types							
	Funding Limit	29,500.00 per year						
	Limited Submission	No						
024768	Collaborative Research Grant	zoos Victoria			05-Jul-2024	Not Specified		
	Contact Name	Dr Michael Magrath, Senior Research Mar	nager, Wildlife	e Conservation & Science	2			
	Contact Telephone	+61-3 9340 2752						
	Contact Email	research@zoo.org.au						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	res (ALL) 05-Jul-2024 , 06-Sep-2024 , 01-Nov-2024						
	Synopsis	Zoos Victoria invites members of the scientific community to propose future research projects that align with its priority research themes. Zoos Victoria welcomes collaborative research proposals. These could involve the use of Zoos Victoria resources, active collaboration with Zoos Victoria staff or independent research at one of Zoos Victor four zoos: Healesville Sanctuary, Kyabram Fauna Park, Melbourne Zoo and Werribee Open Range Zoo.						
	Applicant Types							
	Funding Limit	0.00 not applicable						
	Limited Submission	No						
		•						

